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ABSTRACT 
This Thesis is presented in two parts - 
Part one covers an investigation into the secondary and tertiary structure of the protein 
Xylanase found in Pseudomonasfluorescens subspecies cellulosa. 
Part two documents the Computer Aided Design of Novel Quinazoline Antifolates for 
the enzyme Thyrnidylate Synthase. 
Partone 
Mature Xylanase protein consists of two distinct regions -a cellulose binding domain 
and a catalytic region, A and B respectively. Computer modelling of tertiary structure 
from primary sequence and secondary turn information proved difficult in the absence 
of experimental X-ray crystal data. Consequently, a series of modified proteins based 
on the Xylanase were prepared by Recombinant DNA technology for extraction and 
purification. The modified proteins were to be used as a bench mark for quantitative 
and definitive calculation and detennination of the secondary structure of the xylanase. 
This was to provide an excellent reference point for theoretical modelling of tertiary 
structure. Part one of the Thesis documents Computer Modelling work and protein 
purification and extraction of the xylanase. 
Part two 
Thymidylate Synthase (TS) exists as dimer with a single active site in each subunit. It 
has been crystallised in two forms; a "reduced" (major), and "oxidised" (minor) 
form. The major form of TS contains dUMP covalently bound to cysteine in both 
active sites and in the presence of CB3717. One active site of the minor form contains 
dUMP non-covalently bound and in the presence of CB3717 while the other active site 
contains only inorganic phosphate and CB3717. The active site of TS is a large cavity 
that binds CB3717 into two possible confirmations. One is seen in the major form 
and one in the minor form. 
Part two of my research documents an investigation into enzyme/inhibitor interaction 
in TS and covers the Computer Aided Design of a series of inhibitors based on the 
knowledge of the TS active site. Several of these compounds have been put forward as 
target compounds for synthesis. 
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PART ONE 
PROTEIN MODELLING AND XYLANASE 
1.1 INTRODUCTION 
(i) 2ýý 
Xylan is one of the major components of hemicellulose, the compound that cements 
together the cellulose fibres which form the structure of plant cell walls. Xylan is 
found predominantly in grasses where it forms chains made up of 1-4 linked anhydro- 
D-xylose units variously substituted by L-arabinose and 4-0-methyl D-glucuronic 
acid (see Figure 1.1). 
Xylan can be hydrolysed by 3 classes of xylanase enzyme: the B-xylanases (endo-1.4- 
O-D-xylanohydrolase) B-xylosidases and a third enzyme xylobiase. 1 Endoxylanases 
hydrolyse the internal glycosidic links of xylan, while exoxylanases attack the external 
ends of xylan. These two enzymes break down xylan to xylobiose and xylose. The 
third enzyme xylobiase attacks the disaccharide xylobiose and breaks it down to the 
monosaccharide xylose. 
Xylose can be metabolised to fructose-6-phosphate within the rumen and to lactic acid 
within the silage clamp. Xylanase enzymes have been identified from several 
organisms: 
Ruminococcusflavefaciens has been found to contain a multifunctional enzyme which 
possesses xylanase, and endocellulase actiVity. 2 Similarly Cellulonwnas uda has been 
found to exhibit xylanase activity as well as glucanase activity. The xylanase enzyme 
was found to be cell bound and it degraded 8-xylobiose. 1 Pseudontonasfluorescens 
subsp. cellulosa contains 3 xylanase genes and 3 cellulase genes. 3 Bacillus circulans 
possesses 2 endo B-D-xylanases and 1 B-D-xylobiase. 4 
Such micro organisms are thought to utilise these multifunctional enzyme complexes 
to degrade both cellulose and hemicellulose and ultimately to break down plant cell 
walls into water soluble carbohydrate. 
(ii) Cloning Methodology 
Recombinant DNA technology has expanded as an industry in its own right over the 
last 20 years. Its applications are varied and widespread. Genes encoding for 
polypeptide sequences of interest i. e. proteins such as enzymes, are removed from the 
native chromosomal DNA and inserted into a suitable vehicle (Vector), so that the 
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gene can be replicated in a host cell - usually a bacterium. In this study, the gene of 
interest (XYLA) was taken from Pseudomonasfluorescens subsp. cellulosa and 
cloned into a strain of Ecoli (see Figure 1.2). 
The genes are manipulated using restriction endonucleases; (RE's) which recognise 
specific nucleotide sequences in double-stranded DNA and cleave the double strand at 
this site. 
For example, the RE BamH1* recognises the nucleotide sequence GATCC and 
cleaves the DNA to produce cohesive ends (see Figure 1.3)*. 
The gene of interest can be inserted into double-stranded DNA vectors by digestion of 
both vector and gene with suitable RE's so that cohesive ends formed can interact to 
form hydrogen bonds. The hybrid molecule is joined up by another enzyme - DNA 
ligase. 
DNA ligase seals the vector molecule and the gene together by replacing the 
phosphodiester bond between adjacent nucleotides (see Figure 1.3). Suitable DNA 
vectors include plasmids and bacteriophage which can be maintained autonomously in 
the host cell. The recombinant DNA molecule is introduced into the host cell by a 
process known as transformation whereby the living host cell takes up the foreign 
DNA molecule under suitable experimental conditions. 
After multiple cell divisions a clone of identical host cells is produced, every cell in 
this clone containing one or more copies of the gene. Cells harbouring the 
recombinant DNA molecule can be selected for by growth, complementation or 
antibody screening. 
tructure o Xylanase 
The catalytic mechanisms of Xylanase have been thoroughly elucidated. -" Limited 
information on the domains of the Xylanase has also been obtained: 
Xylanase protein consists of two distinct regions A and B. 
Region A is serine-rich (> 16% SER) and contains a cellulose binding domain. 
Region B contains the active region of the protein- Region A can be excised without 
the protein losing its activity (see Figure 1.4 and 1.5). 
The cellulose binding domain shares considerable homology with the P. fluorescens 
endoglucanase. A hypothetical model has been proposed for the mode of enzyme 
action and its possible tertiary structure (see Figure 1.6). 
The most likely mode of enzyme action involves region A attaching to the substrate, 
* Barn HI is the name of a commercially available restriction endonuclease 
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bringing region B into contact with the substrate, where the active sites cleaves the 13,1- 
4 bonds of the Xylan chain. 
(iv) Applicadons of Xylanase 
This enzyme found in Pseudonwnas and other micro organisms such as Cellunwnas 
is often part of a multifunctional enzyme suite. 9 These enzyme complexes degrade 
both cellulose and hemicellulose, ultimately breaking down plant cell walls to water 
soluble carbohydrate. Xylanase could, in theory, be used commercially as either a 
silage inoculant (by improving silage quality through lowering clamp pH quickly and 
liberating water soluble carbohydrates), or as a novel enzyme secreted by transgenic: 
livestock which aids forage digestion and breakdown. 
Recombinant DNA technology has advanced sufficiently so, that the gene encoding 
xylanase could be inserted into suitable plasmid DNA hosts. The gene could then be 
incorporated into animal cell lines and ultimately, the animal itself, With suitable 
expression sequences and a stable environment for the protein ( e. g. liver tissue 
harbouring the Xylanase gene ), the Xylanase could be expressed and have a positive in 
vivo effect on nutrient uptake in the duodenum. The host animal would be able to 
derive greater nutritional value from forage - as the plant cell walls were hydrolysed to 
carbohydrate by the novel enzyme. 
(v) Advantages of Computer Modelling 
Computer modelling of crystal structures gives a rapid indication of the effects of 
specific active site mutations. 10-11 It can give an insight into the exact nature of the way 
the enzyme binds to the substrate. Modelling can calculate the energetics of 
interactions such as substrate binding - in the case of Xylanase, modelling can help 
determine how the enzyme attaches to the substrate polymer chain, either by sequential 
breakage of 8,1-4 bonds or random attach/reattachment along the chain. 
(vi) Limitations of computer modelling 
With the X-ray crystal data of the Xylanase catalytic region from Reading Institute not 
forthcoming, detailed docking studies using modelling packages could not be 
performed. Crystallisation of such a large protein proved difficult 
(see Chapterl. 4(vi) ). 
Any tertiary structure predictions are limited by both the software and relatively small 
database size of elucidated structures12 - to date, there are homologous proteins 
9 
available from over 400 structures in the Brookhaven database. Consequently, efforts 
were moved towards production of purified xylanase protein. This would allow further 
biological experimentation (such as gel filtration and circular dichroism) in order to 
determine the tertiary protein structure of the xylanase. The number of chemical 
experiments that could be performed was dependent on the amount of pure Xylanase 
protein harvested. If the protein was difficult to obtain and purify ( 15 miffigrarnmes 
of 90% pure protein needed to perform a 2D NMR run - this was considered a large 
amount in synthesis terms ), then some experiments became unfeasible. 
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1.2 MATERIALS AND METHODS 
(i) Computer Modelling 
Using the molecular modelling package QUANTA v(3.0) and CHARMM13 version 
(21.2) as supplied by Molecular Simulations on Silicon Graphics 4D20 personal Iris 
workstations, the raw amino acid sequences of both the A and B region of the Xylanase 
were written into the sequence builder module of QUANTA's Protein Package 
subprogram. 
Using the standard amino acid residue topology file ( AMINORTF ), the sequence 
was read into QUANTA. 71be secondary conformation of Xylanase was then specified 
- residues taldng up either the right-handed alpha helix or parallel 8 sheet 
conformation. Ile secondary structure assignment routine then was implemented to 
add any available turn information ( algorithm used according to Gamier et A 14-1S, 
default of 1800 turn ). Hydrogen bonding was then calculated and the secondary 
structure of region A or B displayed on screen. 
The CHARMm program was then used to minimise the two regions (see Chapter 2.1 
for details). 
A specified 500 steps of the "steepest descents" algorithm was employed to perform a 
first minimisation on each region, the coordinates for each step being updated every 
minimisation cycle. This process was repeated until the r. m. s ( root mean square ) force 
was less than 0.100 kcal/mol (r. m. s force gives an overall indication of energetic 
stability between residues). 
No distance constraints were set out at this stage. The "Adopted-Basis Newton 
Raphson" algorithm16-17 was then applied to the minimised structures until the r. m. s. 
force was below 0.100 kcal/mol. The resultant energy of each region was displayed in 
Kcals/mol. 
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(ii) Xylanase harvesdng and purif icadon 
The table below indicates the plasmids and microbial strain used in this work: 
Exo1i strain Genotype of Phenotype Source 
JM83 araA (lac-pro)SmR Norrander 
thi 0 89 dlac ZMIS et al ( 1983 )18 
Plasmids 
pNM52 lac Iq TcR Gilbert et al 3 
pN23++ lac Iq TcR AmpR Gilbert et al 3 
B41 lac Iq TcR AmpR Gilbert et al 3 
All these materials were stored in cryo tubes at -700C. The E. Coli strain JM83 is a 
commerically available host bacterium and the plasmids have inherent antibiotic 
resistance to Tetracycline (TcR) and Ampicillin (AmpR). 
Gilson pipettes were used throughout in all transformations and reHgations. 
Sterilised pipette tips were used once, discarded to prevent reagent contamination and 
surgical gloves were worn when using enzyme to avoid contamination by exogenous 
DNA. 
11orough mixing was performed by vortex and cryo samples were spun by 
microcentrifuge. 
All enzymes, enzyme buffers and cell-free extracts were stored at -200C. 
(iii) Transformation and religa6on of JM83 containing pNM52 with the plasmids B41 
and pN23++ 
JM83 was grown up to competent status and transformed with either B41 or pN23++ 
plasmids (see Appendix 1.1). 
Transformations were plated out, incubated and observed. 
(iv) Determination of recombinants of pN23++ and B41 
Plating ensured only recombinants of pN23++ and B41 grew on media containing 
ampicillin and tetracycline ( pN23++ and B41 are resistant to these two antibiotics). 
Four colonies from E. coli harbouring pN23++ and four from E. coli harbouring B41 
were picked and inoculated into sterile universal bottles containing 10ml L-Broth, 
10OW Amp stock and 10ml TET stock. and 10 gl OAM IPTG. 
These stock cultures were grown overnight at 370C on an orbiting starter (100 revs). 
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(v) Extmcdon of periplasmic fracdon 
Cultures of JM83 harbouring pNM52 and transformed with recombinant pN23++ or 
B41 were grown to mid log phase (optical density of 0.4 at 550 nm) with final 
antibiotic concentrations of 100 gg/ml ampicillin and 15 gg/ml tetracycline. 
These cultures were then prepared for Xylanase assay by extraction of the cell 
periplasmic fraction (see Appendix 1.3). 
(vi) Xylanase as= 
a) Non IPTG induced cultures 
50 W of each periplasmic fraction was incubated with 1 ml 1.3%w/w xylan in PC 
buffer and 95 W PC buffer for 20 minutes at 370C. Samples were removed and 2ml of 
DNSA reagent (see Appendix 1.4) was added to terminate the reaction. Samples were 
then vortexed, placed on ice for 5 minutes and then incubated in a boiling water bath for 
20 minutes. 
Samples were then microfuged for 2 minutes and the extinction value of the 
supernatants were measured at 575 nm. 
HIM induced cultures 
Periplasmic fractions were obtained from cultures incubated with an additional I 
IPTG stock per ml of culture and assayed as described previously. 
C) Time course assays 
Ibis was performed to deter-mine the ideal time to harvest the Xylanase protein. 
Cultures were grown to mid log phase and then induced with IPTG stock (23 mg/ml) - 
IgI per 1 ml of culture. 
Samples were removed from the cultures at regular intervals and periplasmic fractions 
extracted and assayed for Xylanase content. 
(vii) Avicel binding to Xylanase 
To sterile universal bottles containing periplasmic fractions was added an equal volume 
of 5%w/v avicel pH 10.5 in 100 mM tris HCL pH 7.5. The universal bottles were 
placed horizontally in ice on a shaker for 1 hour to let the avicel bind to the xylanase. 
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Samples were then shaken vigorously to resuspend the avicel and then washed with 3x 
10ml IOOmM tris HCL pH 7.5 over a micro glass vacuum filter. 
The washings were collected and assayed for xylanase activity to ensure that all the 
xylanase protein was bound to the avicel. The avicel cake was retained and 
resuspended in I ml 10% SDS (Sodium dodecyl sulphate) and boiled for 10 minutes 
in sterile universal bottles. Samples were decanted into eppendorfs and microfuged for 
5 minutes and the supernatant retained for SDS-page mini gel electrophoresis. 
(viii) SDS - l2age mini gel electrophoresis 
SDS-Polyacrylamide gels are used to analyse translational products of genes i. e. 
proteins. Running a gel on periplasmic fraction samples gave an indication of the 
amount of protein present ( full form xylanase or truncated inactive form). 
SDS denatures the tertiary and secondary structure of the xylanase protein, leaving a 
polypeptide chain with a negative charge due to the SDS molecule binding to the chain. 
Denatured proteins can be separated by running them on a polyacrylamide gel with a 
voltage applied across the gel. The protein chains will migrate to the positive terminal 
through the gel matrix. 
The gel was poured between two glass plates held apart by 1.5 cm width spacers and 
sealed with a rubber tube gasket. Ile gel was run vertically with reservoir buffer tanks 
situated at both ends of plates. 
Preparation of stock solutions 
0 Acrylamide 30 grammes 
KNI-methylene bisacrylamide 0.6 grammes 
H20 (double distilled ) to 10 ml 
ii) Ammonium persulphate 10% 2.5 grammes 
H20 (double distilled) to 25 ml. 
N. B. Due to the fact that Acrylamide is a powerful neurotoxin in monomer form, 
mask and gloves were used in preparation of stock solutions 
Acrylamide stock 30% 8.35 ml 
0.75m tris/SDS pH 8.8 12.50 ml 
Ammonium persulphate 90 RI 
Double distilled water to 25 ml 
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tris/SDS preparation: 
Trizma base 71g 
Tris/HCL 47.2g 
SDS 2g 
adjusted to pH 8.8 with IM NaOH. 
This was made up to I litre with double distilled water. 
Plate prel2aration for pouring 
The glass plates were washed in warm detergent solution and rinsed with single then 
double distilled water. 'Me plates were then rinsed with ethanol and allowed to air-dry 
(note - care was taken to avoid contamination of the working surfaces of the plates ). 
The rubber tube gasket was gently placed at the base of one plate and the other plate 
laid flush on top to form a sandwich. The plate and gasket assembly was clamped with 
bulldog clips to form a fight seal around the gasket. 30 W of TEMED (IM) (NN, N', N' 
- tetramethylene diamine) was added to the running gel, mixed and poured into the 
space between the plates. Ile plates were filled up to three quarters depth and 
isobutanol was layered on the gel to prevent oxidation of the air-exposed surface as the 
gel set. TEMED catalyses the reaction between acrylamide and bis-acrylamide to form 
the gel polymer that sets in about 15 minutes. 
30% acrylamide stock 4 mls 
0.25M TrislSDS pH 6.8 7 mls 
TEMED 18 gl 
10 % ammonium persulphate 54 gl 
Double distilled water to 15 mls total volume (approximately 3.5 ml) was added. 
N. B. The stacIdng gel had to be used within 5 minutes after preparation before it set. 
tris/SDS preparation 
Tris/HCL 39.4g 
SDS 2g 
adjust to pH 6.8 
Double distilled. water was added to make the volume to 1 litre. 
When the running gel set, the isobutanol was poured off and the gel rinsed with double 
distilled water repeatedly. The stacking gel was poured between the glass plates over 
the running gel and a spacer comb was inserted flush with the top of the assembly to 
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form wells in the gel (see Figure 1.7). Once set, the comb was carefully removed, the 
wells rinsed with double distilled water and the rubber gasket and clamps removed with 
care. Ile gel sandwiched between the glass plates was then slotted into an 
electrophoresis tank. Upper and lower reservoir tanks were filled with reservoir buffer. 
Reservoir electrode buffer 
Tris 15.15g 
Glycine 72g 
SDS 5g 
adjust to pH 8.3 
This was made up to 5 litres volume with double distilled. water. 
Sample preparation for the gel 
Sample (Periplasmic fraction or SDS fraction) 20 gI 
Loading buffer 1041 
Bromophenol blue 2 gl 
Samples were mixed and boiled for 2 minutes then loaded into the wells 
(approximately 20 W per well). 
Protein Standard Molecular wei P-ht(Dalton) 
alpha-lactalburnin 14200 
trypsin inhibitor 20100 
trypsinogen 24000 
carbonic anhydrase 29000 
glyceraldehyde-3-phosphate 
dehydrogenase 36000 
egg albumin 45000 
bovine albumin 66000 
Protein standards were mixed and boiled as before and loaded into wells at either end 
of the gel ( 20 [d total volume per well ). The gel was run at 25 mA for 30 minutes 
until the samples ran through the stacking gel. The current was then increased to 40 
mA for a further 120 minutes approximately. The gel was then removed from the 
plates and stained with Coomassie blue for 30 minutes. The gel was then de-stained 
with three washings of a 10% acetic/40% methanol mixture. The gel was then fixed in 
cellophane and heat-dried under vacuum. The presence of the xylanase was 
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elucidated by comparison of banding pattems from pN23 or B41 cultures with 
standards of known molecular weight. 
Periplasmic Fracdon 
ne Periplasmic fmction (total protein fmction) was analysed by SDS-page mini gel. 
20 gl of each SDS fraction (see Chapter 1.2 (vii)) was prepared for the SDS -page 
mini gel. Running of a mini gel using SDS fractions from avicel samples indicated 
how much (if any) of the xylanase bound directly to the avicel from 1.2(vi). 
(ix) Large scale harvesting of xylanase protein. 
4x0.5 litres of B41 and pN23 cultures were grown overnight for harvesting the 
following day. Periplasmic samples were prepared from these cultures for 
determination of the optimum amount of avicel necessary to bind B41 or pN23 
xylanase forms. 5 ml samples of periplasm were mixed with varying amounts of avicel 
(see Chapter 1.2. (vi)). 
avicel stocVml B41 Wriplasni/ml p N23 pcriWasm/ml 
1 5 5 
3 5 5 
5 5 5 
7 5 5 
10 5 5 
15 5 5 
20 5 5 
SDS-page mini gel electrophoresis was performed on the SDS extracts. The intensity 
of the banding on the gel was directly proportional to the amount of protein that had 
bound to the avicel (see Figures 1.10 to 1.17). 
Time course preparation of periplasmic fractions from cultures was also performed to 
determine the optimum time to harvest the cells. 
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(x) Guanidine extraction 
Once the optimum amount of avicel necessary for xylanase binding had been 
determined, the periplasmic fractions could then be treated with guanidine 
hydrochloride. Guanidine does not denature protein - unlike SDS, so the xylanase 
enzyme retains its structure and activity. Periplasmic fractions from pN23 and B41 
cultures were prepared as described previously and bound to the optimum amount of 
avicel. 
Each avicel/periplasmic mixture was then resuspended in I ml 6M guanidine 
hydrochloride after washing with three times 10 ml lOOmM tris pH 7.5. After one 
hour the mixture was spun down by microcentrifuge and the supernatant retained. 
Guanidine had stripped the xylanase protein from the avicel over this time. 5 litres of 
100 mM tris pH 7.5 (60.55g of trizma base in 5 litres; of double distilled water) was 
prepared, placed in a coldroorn at 40C and mixed continuously using a magnetic stirrer. 
6 inch portions of narrow dialysis tubing were boiled in double distilled water for 5 
minutes. The dialysis tubes were then clamped at one end and each I ml sample of 
guanidine hydrochloride (containing the xylanase protein) was placed in separate 
dialysis tubes by Gilson pipette. The open end of each dialysis tube was then clamped, 
ensuring that any air bubbles were expelled from the tube. Each clamped dialysis tube 
was placed in the 5 litres of tris buffer and left to dialyse overnight. The 6M guanidine 
inside the dialysis tubing passed into the 5 litres of IOOmM tris by osmosis, leaving the 
protein behind inside the tubing. 
(xi) SDS-page mini gel analysis of dialysed protein extract 
Protein extracts from dialysis ( see Chapter 1.2 (x)) were examined as before using 
SDS-page mini gels. 
(xii) Xylanase assays on dialysed protein extracts 
Xylanase assays were performed on the dialysed protein extracts as before 
(see Chapter 1.2 (vi)). 
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(xiii) Transformation of B41 and pN23 into JM83 without the regulation of pNM52 
As the level of protein extraction was found to be quantitatively low, the plasmids were 
transformed into JM83 without the regulatory multicopy pNM52 plasmids ( see 
Appendix 1.1). 
5 ml L-Broth 
50 pI Ampicillin stock 
a wire loop of JM83 E. coli 
Starter cultures were grown up overnight at 370C and 100 r. p. m. on an orbiting shaker. 
RerinUon 
20 pl competent JM83 cells 
10 pI plasmid (either B41 or pN23) 
(see Appendix 1.1) 
Transformants were plated out onto blue xylan agar (blue xylan stock 60 mg per 100 
ml L-Broth) and grown overnight at 370C. White colonies or "spots" indicated 
recombinants containing functional xylanase genes (the XYLA gene degrades xylan 
and the blue dye to a colourless product). 
Putative colonies were picked and inoculated into 500 ml L-Broth under previous 
standard conditions. Cells were harvested as before and the periplasms were bound to 
avicel. The avicel was then resuspended in 10 % SDS as before. Banding patterns and 
corresponding banding intensities were examined. 
&ligation 
200 W competent JM83 cells 
10 gl plasmids (either B41 or pN23++) ( see Appendix 1.1) 
Transformants were plated out onto blue xylan agar (xylan stock 60 mg/100 ml L- 
Broth/blue) guanidine hydrochloride 6M. The avicel and guanidine mixtures were 
spun down, the supernatant retained (first wash) and the avicel resuspended in I ml 
guanidine. This was repeated a further 2 times to obtain 4 washes of guanidine 
hydrochloride. 
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Each avicel pellet was then washed in 3x 10 ml tris pH 7.5 1 OOmM and resuspended 
in 1 ml 10% SDS - no protein should be left bound to the avicel. Samples were 
dialysed in 5 ml 100mM tris pH 7.5 as before. The protein samples were recovered 
from the dialysis tubing and prepared for SDS- page mini gel analysis. 
(xiv) Cellulose column extracdon of xylanase 
The Guanidine extraction of xylanase proved difficult. Cellulose columns were 
prepared to allow the xylanase contained in the periplasmic: fractions to bind to the 
cellulose. 
5% w/v cellulose HL and 5% w/v cellulose HBS were prepared in IOOmM tris pH 7.5 
and autoclaved. 
Mini columns of cellulose were prepared. Each column consisted of a plastic cylinder 4 
inches long with an open neck and glass filter at a tapered base. 
5 mls of each periplasm was added slowly to each column. Ibe cellulose binding 
domain of B41 and pN23 xylanase proteins bound to the granular cellulose in the 
column while the filtrate passed through unbound. The filtrate was assayed for 
xylanase activity - it should be negligible, if the xylanase bound successfully to the 
column. 
Once the periplasm had run through each column, the cellulose was washed with 4x5 
ml tris pH 7.5 100mM. Ile columns were then removed and resuspended in 1 ml 
10% SDS. 
Samples were boiled for 10 minutes, spun down and the supernatant retained for SDS- 
page mini gel analysis. Protein assays were performed on the tris, washes of the 
cellulose columns. 
(xv) Protein assay of cellulose columns 
The reagent for the protein assay detects the presence of polypeptide. The reaction 
mixture turns blue if protein is present or brown if there is no protein in the sample. 
1 ml of Coomassie G-250 reagent was added to 0.1 ml of each tris wash (Bradford 
Method 1976). Further cellulose columns were prepared and samples fully hydrated by 
2x 500k centrifuge spins for 10 mins and resuspended in 100 mM tris pH 7.5. 
Cellulose columns were finally washed and resuspended in 10ml IOOmM NaCl rather 
than 10% SDS. Ile salt eluted protein samples from the cellulose columns were then 
dialysed in 41 lOOmM tris pH 7.8 and an SDS page mini gel performed on the 
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recovered protein from dialysis. 
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1.3 RESULTS 
(i) Computer Modelling 
Initial computer modelling of secondary structure proved limited. Application of 
turn information and extensive minimisation of A and B regions of xylanase 
resulted in very linear three dimensional structures (see Figures 1.8 and 1.9). 
Although no homologous structures were available for comparison the two 
regions had begun to adopt some form of linear and spherical gross structure. 
(ii) Cloning 
The plasmids B41 and pN23 were successfully cloned into IM83 under the 
regulatory control of JM83. Bacteria that contained the B41 or pN23 plasmid 
were able to grow on media containing Ampicillin (Amp). Bacteria containing 
pNM52 as well as the xylanase containing plasmid were able to grow on media 
containing Tetracycline (TETOand Ampicillin. Hence bacterial colonies that 
were present on agar containing Amp and = were those colonies that were 
picked for use in all xylanase cloning work 
(iii) Periplasmic extraction 
Periplasmic fractions of Exo1i (JM83) containing the B41 or pN23++ plasmid 
under pNM52 regulatory control were prepared and subjected to SDS gel 
electrophoresis. A strong banding pattern was observed at 42 kD molecular 
weight for both b4l and pN23 samples. Banding was observed at 60 kD for 
pN23 only (see Figure 1.10). 
(iv) Xylanase asmyj 
In order to make representative measurements of the xylanase activity 
of pN23++ and B41, xylanase assays were performed on either the periplasmic 
fractions or "sucrose wash" of Exo1i in the mid log or stationary phase of their 
growth over various incubation periods. The basis of the assay is as follows: 
The periplasmic fmction when incubated with blue xylan substrate (soluble in 
water), will cleave the blue xylan, releasing a blue dye, remazol brilliant blue, at 
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Figure 1.8 
24 
Figure 1.9 
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a rate proportional to the activity of the xylanase enzyme present. The reaction 
is stopped by addition of 2 volumes of DNSA reagent which terminate the 
reaction. Samples are assayed colorimetrically; the more dye liberated, the 
greater is the activity of xylanase in the periplasmic fraction (see Appendix 1.4). 
(v) Avicel bindin 
SDS fractions from avicel pellets were prepared and subjected to SDS-page mini 
gel electrophoresis. Ilis gel indicated qualitatively the amount of xylanase 
protein bound to the avicel from 1.2(vii). Again, banding was observed at the 42 
kD for the B41 samples and 60 kD for the pN23 samples. A fainter band was 
observed at 42 kD in pN23 (see Figure 1.11). 
Using varying amounts of avicel to bind to the xylanase (see I (viii) ), SDS 
fractions were prepared for SDS-page mini gel electrophoresis. From the 
banding patterns observed, the ideal amount of avicel needed to bind the 
maximal amount of xylanase was determined (see Figure 1.12 and 1.13). 
From the gels, 5 ml of avicel was the optimum amount to bind 5 ml B41 
periplasm and 3 ml avicel to bind pN23 periplasm. 
(vi) Quanidine extraction and protein dialyaja 
SDS-page mini gels on dialysed guanidine extracts were prepared. From 
examination of the gels, almost negligible amounts of xylanase were 
successfully extracted (see Figure 1.14). 
Xylanase assays on these extracts did indicate some xylanase activity. 
(vii) Cloning without pNM52 regulation 
As levels of protein extraction were quantitatively low, the B41 and pN23++ 
plasmids were transformed into Ecoli (JM83) without pNM52 regulation. 
SDS-page mini gels were prepared as before. Much stronger banding patterns 
were observed at 60 kD and 42 kD, indicating quantitatively that more xylanase 
was present in this periplasmic fraction (see Figure 1.15). 
(viii) Further Xylanase assays 
Further assays were performed on the new periplasmic fractions of E. coli 
expressing the B41 or pN23++ plasmids without pNM52 regulation. 
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(ix) Cellulose column extraction 
The SDS-page mini gels results gave very faint banding patterns for cellulose 
bound fractions (see Figure 1.16). 
(x) 
-Protein assaya 
Protein assays were performed on the cellulose washes to determine if all 
unbound protein had been flushed from the cellulose column. 
cellulose HL cellulose HBS 
plasmids B41 pN23 
I 
control B41 N23 2 control 
I st wash blue brow- brown blue _b mwn brown 
2nd to 5th 
wash all solutions were brown after subsequent washes 
Repeated SDS-page mini gels on cellulose extracts revealed no bands 
whatsoever ( See figure 1.17 ). 
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Figure 1.11 
66kD 
45kD 
36kD 
29kD 
24kD 
20kD 
ow 
1.5 3.0 4.5 6.0 ov 1.5 3.0 4.5 6.0 ov 
(incubation times in hours) 
/ 
ov=overnight 
Protein 
Standard B41 pN23++ 
29 
Figure 1.12 
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Figure 1.14 
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Figure 1.15 
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Figure 1.16 
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Figure 1.17 
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1.4 DISCUSSION 
(i) Cloning of Xylanase 
Once the XYLA gene had been successfully cloned into the JM83 Exo1i 
(see Chapter l(viii)a ) there are many factors which affect the level of 
transcription and translation of the gene (see Figure 1.20). 
The rate limiting step of gene translation depends on the binding affinity of RNA 
polymerase to the promoter sequence. 19 The DNA fragment encoding the 
XYLANASE protein is expressed in very low levels in native Pseudomonas. 
This is due to a weak promoter sequence in the native chromosomal DNA. To 
overcome low expression, XYLA was inserted into vectors under the control of 
an adapted Lac operon. The Lac operon has one of the strongest naturally 
occurring promoter sequences, the Lac p sequence. 20 This strong promoter 
increased the level of expression of the XYLA gene and ultimately protein 
synthesis. 3 However the lacP gene must be controlled in its function. 
Unregulated gene expression places too great an energy demand on host RcoU 
and cell death results. To overcome this lethal hyper-expression, the multicopy 
plasmid pNM52 was initially transformed into E. coli to regulate the XYLA 
expression. pNM52 has a plasmid copy number of about 30 in E. coli and 
contains the Lac Iq gene which synthesises repressor protein. 21 
Normal E. coli strains contain only 10 molecules of repressor protein per cell, 
but E. coli transformed with pNM52 have 1000 molecules of repressor i. e. 300. 
Ecoli IM83 can harbour plasmid vectors up to a maximum copy number of 
300. Therefore, in this work transformation of recombinant plasmids into JM83 
Ecoli with pNM52 gave 100% suppression of XYLA gene expression. 
To activate host cell production of Xylanase, IPTG was used to induce gene 
expression through inactivation of the repressor protein. This IPTG activation 
was used to allow host bacterial cell numbers to reach maximal level before 
protein expression was initiated. 
(ii) Xylanase A&uya 
This assay method gave a qualitative indication of the amount of enzyme activity 
present in the samples analysed. In cases of raw periplasmic fraction, 
considerable activity was indicated by the deep blue colouration of samples. n 
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Assays on samples that had undergone various methods of protein extraction did 
not display such marked relative activity. Several methods of protein extraction 
involved temporary denaturation of protein (such as the guanidine method) and 
the subsequent refolding of the secondary structure to form an active protein. It 
was clearly the case that much of the original active enzyme was unable to 
reform into the correct tertiary structure and hence maintain activity. 
(iii) Extraction Techniques 
Periplasmic extraction breaks open E. coli cells in two stages. Initial 
resuspension of a bacterial pellet in sucrose and EDTA partially breaks down 
the bacterial cell wall - in effect, the cell "leaks" small fragments of protein 
through holes in the bacterial cell wall. Vigorous resuspension and 
centrifugation completely breaks down the bacterial cells, releasing cell proteins 
(the periplasmic: fraction). 'Mý periplasmic fraction contains the raw protein 
contents of the bacterium. In this work, the periplasmic fraction contained the 
xylanase protein expressed by B41 and pN23. 
This extraction technique for obtaining "raw" protein was successful in that 
activity of samples were maintained. The xylanase enzyme was not subjected to 
any chemical attack in this technique and as such, maintained activity. 
a) Avicel binding 
Periplasmic fractions obtained from B41 or pN23 cultures bound successfully to 
avicel. However, to recover the protein bound to the avicel further treatment 
was necessary. Sodium dodecyl sulphate (SDS) used to strip the xylanase from 
the avicel completely denatured the protein, so the SDS procedure only indicated 
the amount of protein present in the periplasmic fraction. Binding studies using 
varying amounts of avicel to bind to periplasmic fmction indicated a 1: 1 ratio of 
avicel to bind B41 periplasm and 3: 5 ratio for pN23. This was a quantitative 
result taken from analysis of the intensity of the banding patterns present in the 
SDS-page mini gels. Once the ideal amounts of avicel required for periplasm 
binding had been elucidated, a separate method for extracting the xylanase 
without denaturation was employed. 
As an extraction technique, this was unsatisfactory as little active xylanase was 
recovered from the avicel. SDS is an extremely powerful detergent and although 
it can strip avicel completely of bound protein, the protein structure is not 
maintained. 
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b) Guanidine extraction 
It was reasoned that the high concentration of guanidine hydrochloride (6M) 
used in this method of extraction would strip the xylanase protein from avicel 
without significant denaturation of the protein. The enzyme would therefore 
retain its catalytic activity and tertiary structure. Analysis of the SDS-page mini 
gels showed only faint banding patterns corresponding to any xylanase protein 
washed from the avicel by guanidine. As very little xylanase was effectively 
removed from avicel by this method, the cellulose columns extraction technique 
was used. 
c) Cellulose column extraction 
From analysis of the SDS-page mini gels, this method of xylanase extraction 
from periplasm proved least successful. Again, only faint banding patterns were 
observed on the gels, indicating that negligible amounts of protein were binding 
to the cellulose column. Further repetition of cellulose columns using NaCI 
100 mM to elute the protein also proved disappointing. 
(iv) Xylanase protein recov= 
It is clear from this work that the methods employed in the recovery of active 
xylanase protein were unable to provide sufficient quantities for further 
analysis. 
Xylanase is a large and consequently a structurally complex enzyme. Most 
laboratory techniques for protein extraction involve some degree of tertiary 
structure degradation and subsequent protein refolding after recovery. It would 
therefore be logical to assume that xylanase protein is unstable under these 
extraction conditions and cannot be recovered by these methods. It should also 
be noted that the E. coli used to produce the full form protein were subjected to 
accelerated synthetic rates. This may have lead to incomplete or incorrect 
protein transcription/translation within the host cell. 
The most likely avenue of further work in xylanase protein recovery is to 
concentrate on crystallisation of the protein and hence determine its crystal 
structure. 
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(v) Modelling of protein structure 
There are many methods available for evaluation of protein conformation. 
Solvent accessibility can be used to predict the probability of an amino acid 
being buried or exposed in a protein. 23 The degree of ideal crystal packing 
24 indicates the arrangement of residues in a protein. 
Distance geometry methods allow constraints to be placed on atoms and residues 
thus defining relative positions within protein structure. Knowledge-based 
prediction of structure is most commonly used. These methods involve 
correlation of amino acid properties and amino acid sequence. There are three 
algorithms that are most widely used. The first two rely on parameters obtained 
from analysis of fully elucidated sequences and corresponding 
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structures. 14-IS, 2S-26 The third method is based on stereochernical criteria. 
Minimum energy calculations (as in this work) allow the protein sequence to 
fold and adopt a minimum energy conformation. There are two problems with 
this approach. Firstly appropriate parameters defining energy contributions of 
individual atoms and residues must be unified. There are many software 
packages available, each with a separate forcefield and parameter set. The 
second problem involves negotiating multiple minima (by crossing saddle 
points) in energy minimisation. Several algorithms cannot push the energy 
minimisation through a local energy well and consequently the "global" 
minimum is never reached. What is needed is a unified forcefield and parameter 
set to define all possible atomic interactions. Energy calculations are being 
constantly refined, but minimisation schemes have so far failed to predict chain 
folding accurately. 28-29 This has been seen in this work using the limited turn 
information. 
Systematic searching of all possible conformations of sequential residues is 
another method of structure prediction. 30 Sections of protein (up to 6 residues) 
are subjected to conformational search and analysis. Each conformation is 
screened using the electrostatic energy, the exposed hydrophobic area and a 
solvent screening term. This is a computationally intensive approach with 
hundreds of possible structures generated from only a few selected torsions. 
Class prediction of protein structure is based on division of a known set of 
crystal Structures into four categories, cc, 0, oc+P and WO. These correspond to 
amino acid sequences of high a content, high 0 content, mixed (x and 0 content 
and disordered structures. 31 
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A more recent approach involves the use of neural networks which learn from 
existing structures how to predict the secondary structure of small sections of 
sequences. 32 The neural network approach only achieves predictive success 
rates of around 65%. 33 Introduction of tertiary structural information (such as 
NMR distance constraints) is necessary to improve prediction rate. 
Other recent predictive methods have been developed to predict structure based 
on hydrophobicity of individual amino acids. 34-3S These "antigenicity values" 
are currently amongst the most popular methods of prediction. 36 
Finally, there are expert systems. These are custornised computer programs 
specific to individual molecular systems. Each structure is minimised to a global 
minimum as quickly as possible, then database searching is used to compare 
homologous structures. Computer modelling is then used in conjunction with 
external data for each molecular system to provide a model for the protein 
structure. 3S 
Current methodologies for tertiary structure prediction from primary and 
secondary data do not enable us to predict a protein's conformation. 36 
The simple algorithms available for prediction of secondary structure from raw 
sequence data have degrees of accuracy varying from 40% to 70% successful 
prediction (note that 50% predictive success constitutes a random guess! )? 7 
Prospects for tertiary prediction are encouraging. There are three approaches in 
use for prediction of tertiary protein structure. 
The first involves the use of sequence homology where peptides of known three 
dimensional structure are compared with homologous sequences. The 
homologous sequence is then mapped onto the tertiary structure of the known 
structure and refined using minimisation. The second method uses secondary 
structure prediction of short sequences of amino acids. These short units are 
then assembled into a compact structure. 
These first two methods rely heavily on the data base of known crystal 
structures. 38-39 As the Brookhaven database contains relatively few well- 
resolved structures at present (around 200 solved to a resolution better than 2A) 
this method is dependant on the improvement of X-ray crystallography 
techniques and NMR spectroscopy and the increase in published structures. 
Once the database is sufficiently large and varied, predictive schemes will 
improve as a consequence. 
The third method is not reliant on this data. Empirical ab initio energy 
functions can be used to derive the tertiary structure at minimum energy 
potential. 
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Trial structures are evaluated and either rejected or accepted for further 
refinement. 
Research is continuing into the modelling of tertiary protein structure. 
Ultimately, the identification of any predictive motifs is limited by the protein 
structure database size. 12 Many more data will be needed before protein 
structure can be precisely predicted. However, with novel X-ray crystal 
structures constantly being resolved, it may not be long before the database size 
will be large enough to perfect predictive schemes. 
(vi) Importance of cjý! stal data 
The methodology of X-ray crystallography of proteins is a complex one and is 
not covered in this work. The reader should refer to a specific review available 
on this subject. 4041 It should be stressed, however, that perhaps the greatest 
hurdle in protein crystallography is the growth of sufficiently large, high quality 
crystals. 
11is process can be the rate-limiting step for many research groups. Primarily, 
large amounts of pure protein are required for crystallisation - typically gram 
amounts. This is where recombinant DNA technology can provide the raw 
protein (both full-form and mutant enzymes). 
Harvesting and purification of the raw protein is crucial to the success of such 
projects. Finally, even if all the previous criteria are fulfilled, the crystals must 
be grown. Ibis can take anywhere from a month, one to two years and 
sometimes not at all. 12 In difficult cases, it might be possible to grow protein 
crystals complexed with a substrate or suitable inhibitor (see Part 2). Once 
suitable crystals have been obtained, sophisticated hardware and computer 
software must be employed to collect and process the crystal data. 
(vii) Xylanase as a target for protein modffing 
In terms of both scientific interest and commercial application, this enzyme 
should still be actively considered for further work. Xylanase is thought to be in 
the structural class of proteins known as 8-fold WO-barrels. 36 Many proteins 
with little sequence homology adopt this conformation, indicating that amino 
acid composition and sequence does not necessarily dictate tertiary structure. 
Suggestions have been made that many m/0-barrel proteins evolved from a 
common ancestor. 42 Xylanase has no structurally-resolved related proteins, thus 
making it an ideal candidate for further study of the (x/P class of proteins. 
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Xylanase is also unique amongst the endoxylanases in that is has a markedly 
high amount of SER residues in its sequence. Little is yet known about the 
function of these serine-rich areas of sequence which are highly conserved. 5 
Further work must be pursued to determine the role these SER residues play in 
xylanase biological function. 
On a commercial level, xylanase may well have a future in transgenic livestock 
or as a silage innoculant. 43 Elucidation of structure and modelling of specific 
active site mutations will lead to enhancement of specific activity and increased 
knowledge of reaction mechanism. 
(viii) Future work 
Perhaps the best approach is to combine all available data from as many sources 
of information as possible. Protein class (either globular or linear) can be 
established using circular dichroism. 44 Flexible pattern matching and sequence 
motifs can be used to predict secondary loops and turns. Since this work was 
completed, the alpha carbon backbone of region B of xylanase has been 
reportedly elucidated by X-ray crystallography at the Reading Institute 
(unpublished). QUANTA/CHARMm has automatic sidechain placement 
functionality, whereby sidechain residues are fitted to protein backbone. Any 
NMR distance constraints are applied and the residues are subjected to simulated 
annealing. 71bis process minimises each sidechain group and performs local 
dynamics simulation. This allows the residues to occupy an possible areas of 
conformational space and adopt the lowest energy structure. 
(ix) Summary 
Current methodologies for modelling an unknown protein structure are limited 
by the amount of existing data from elucidated structures. With time, these 
limits will be surpassed as the crystal databases expand to encompass all the 
different classes of protein. This part of the research work was highly ambitious 
and tackled many of the issues that are faced by Protein Modelling groups. At 
this point in time, we are still dependent on the valuable data from the x-ray 
crystallographer in order to understand more about protein structure and 
function. It is my firm belief that in the next 20 years we will be able to have a 
significantly greater level of automation in the elucidation of novel protein 
structures. Computational instrumentation is still improving, and the computer- 
modeller has increasingly more and more powerful hardware and software at 
histher disposal. When one considers that the computer equipment used in this 
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work has an equivalent today eight times more powerful, then one is confident 
that more elegant and sophisticated algorithms will be developed. T'hese 
predictive tools will greatly aid the scientist in the pursuit of Nirvana - tertiary 
structure from primary amino acid sequence. 
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PART TWO 
THYMIDYLATE SYNTHASE AND NOVEL DRUG DESIGN 
2.1 INTRODUCTION 
(i) nymidylate S3mthase 
Thymidylate Synthase (TS) has been regarded as a key enzyme in cancer 
chemotherapy for well over a decade. 4S46 TS catalyses the reductive methylation of 2'- 
deoxyuridylate monophosphate (dUMP) to 2'-deoxythymidylate monophosphate 
(dTMP) with the accompanying conversion of 5,10-methylene tea-ahydrofolate (5,10- 
met THF) to 7,8-dihydrofolate (7,8 DHF). 47 
Blocking this dTMP synthesis results in "Thymineless death"ý849 where rapidly 
proliferating cells become starved of the DNA necessary for cellular division. Protein 
and RNA biosynthesis is unaffected by TS inhibition thus making this enzyme a 
seemingly attractive target for cancer treatment. 
Throughout the 1980's considerable effort was put into development of a potent 
antifolate, one of the most notable being NIO-Propargyl-5,8-dideazafolic acid 
(CB3717). SO-SS Phase I and phase H clinical studies were carried out using CB3717 
with varying degrees of success. s6-59 
Although CB3717 proved a very tight binding inhibitor of TS and overcame 
methotrexate resistance, the drug was found to display renal toxicity. This renal 
toxicity was due to poor aqueous solubility and human studies were discontinued. 
Recent studies have involved modification of the CB3717 to improve solubility while 
maintaining cytotoxity to cancer ceUs. 6"4 
(ii) Ilymidylate Synthase CIZEstal Structure 
The structure of Escherichia coli thymidylate synthase complexed with the substrate 
dUMP and an analogue of THF (CB3717) was solved and refimed at 1.97 angstroms 
by Robert M. Stroud and his group at the University of California in 1989.6s-66 This 
crystal structure was kindly made available for analysis. , 
TS exists as a dimer with a single active site in each subunit. Stroud crystallised TS in 
two forms; a "reduced" (major) form and "oxidised" (minor) form. The major form 
of TS contains dUMP covalently bound to cysteine in both dUMP sites and in the 
presence of CB3717 (see Figure 2.1 ). 
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Figure 2.1 
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One active site of the minor fon-n contains dUMP noncovalently bound and in the 
presence of CB3717 while the other active site contains only inorganic phosphate and 
CB3717. 
The active site of TS is a large cavity which binds CB3717 in two possible 
conformations. One is seen in the major form and one in the minor form (see Figure 
2.2). 
(iii) Computer modelling using QUANTA/CHARMm 
a) Overview 
The three-dimensional coordinates provided by Stroud acted as the starting point for all 
modelling work. 66 The programs CHARMrn (version 21.2) and QUANTA (version 
3.0) were used as supplied by Molecular Simulations. 68 
CHARMm is a software tool for modelling both structure and function of molecules. 
The program can perform many different computational tasks, but only the functions 
utilised in this work will be discussed in depth: 
b) Architecture of modeffing 
CHARMrn consists of FORTRAN source code which can manipulate data in two 
ways: either directly, input created by the user fed into the program via a command 
stream, or through the use of external files that are opened and closed with 
computational results written to another external file. 
Crystal Structures can be read directly into CHARMrn for analysis but where definitive 
Cartesian coordinates are not available, the information must be generated within 
CHARMrn using the standard parameter set. 
This parameter set defines the atomic masses, partial charges, bonds, angles, dihedral 
angles and improper torsional angles between atoms. From this parameter set, a 
residue topology file (RTF) is created with the correct molecular topology for each 
individual residue in the molecule. In the case of large molecules, in order to reduce 
computational time, an extended atom representation is used in the RTF. An extended 
representation specifies methyl, methylene and methine groups as single 'atoms'. The 
remaining aliphatic hydrogens are not simulated. 
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Figure 2.2 
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Only polar hydrogens are defined i. e. those hydrogen atoms bound to oxygen, 
nitrogen, a carbonyl carbon or an olefin carbon. 68 
Once all the RTF's have been created, the primary structure file (PSF) is generated and 
read into CHARMm. 
The PSF only contains molecular topology information and partial atomic charges. All 
other data such as bond angle or force constraints are read in from the binary version 
of parameter file. 
c) Atomic coordinate manipulation 
A complete set of Cartesian coordinates is always necessary if molecular energy 
computations are to be performed. Crystal structure analysis yields these coordinates 
but in cases where all the coordinates are not available, it is possible to generate the 
entire structure from internal coordinates (I. C. 's). I. C. 's are generated from the 
internal coordinate table which contains the reference geometries about which the bond, 
angle or dihedral angles are determined. If the positions of any three atoms are known, 
the position of a fourth atom can be defined from the ICs. The IC's consist of three 
values - an angle, a distance and a dihedral angle. The IC table contains five values 
corresponding to angle, distance and dihedral values. Given four atoms, AAC and D 
arranged as below: - 
D 
AB 
The IC table contains the A-C bond distance, the A-B-C bond angle, the A-B-C-D 
dihedral angle, the B-C-D bond angle and the C-D bond distance. 
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(iv) Computational Algorithms 
a) Overview 
In addition to building molecular structures CHARMrn provides algorithms for 
calculation of empirical energy in energy minimisation of structures, molecular 
dynamics and vibrational analysis. This work is concerned with the energy 
minimisation routines associated with TS and novel anffolate ligands. 
b) Energetics and force 
Provided that Cartesian coordinates, or parameter set and a PSF are available, the 
potential energy of any molecular structure can be calculated. The total energy of a 
molecule is described by the following equation where the total energy is the sum of 
the following terms: - 
ENERGY(E) = Eb + Eo + Eo + El + intemal 
E +E +E + extemal ei vdw hb 
Econs + Euser special 
This comprehensive empirical energy function is based on the Born-Oppenheimer 
approximation. 69 
c) Internal Energy Terms 
CHARMrn describes energy empirically, 70 in that the internal and external energy 
terms are a function only of the nuclear coordinates and not of the electronic positions. 
'Mis assumption 
states that electronic and nuclear components of nuclei motion are separable as 
electrons can adjust their positions instantaneously in response to movement of the 
nuclei. The internal energy terms are described as follows: - 
BondEnergy: E =Ek (r-r ) bb0 
where kb = force constant and ro = equilibrium bond length. 
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Bond Angle Energy: EO=jkO(0-00) 2 
where ko = force constant and 00 = equilibrium bond angle. 
DihedmlEnergy: E, =7, k, [I+cos(no-3)] 
where k0= force constant, ý= dihedral angle and n= periodicity 
Improper Energy: EI =YkL(1- 10) 
where k, = force constant, i0= equilibrium improper angle 
d) External Energy Terms 
Nonbonded interactions make up most of the computational time when potential energy 
is calculated. Any two atoms in a molecular structure have an interaction between them. 
For large molecules such as TS (over 5000 atoms), each atom win be affected by all the 
other atoms in the structure. The computational time needed to evaluate all these 
interactions is extremely long - fortunately CHARMm allows the user to specify a 
distance beyond which no interactions are calculated. This is called the switching 
function and is important in saving computational time when calculating potential 
energies. For example, a cut off distance of 1 1A (i. e. for each atom, only atoms within 
an 1 1A radius are involved in calculation of nonbonded interaction for that atom) 
ensures that 95% of the associated nonbonded energy is computed for that atom. The 
Electrostatic and Van der Waals interactions contribute nearly all the external 
(nonbonded) energy of a molecular system. 
e) Electrostatic Energy 
Electrostatic energy is due primarily to the interactions of polar and charged atoms. 
Polar atoms arise from non-uniform charge distribution of covalently bound atoms of 
different electronegativities. The total electrostatic energy results from the summation 
of attractive and repulsive partial or net charges and is greater than van der Waals 
energy. Electrostatic energy also acts at a longer range than van der Waals; forces. 
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Electrostatic Energy: EI=1: 1j 
e ij>i 41cEor.. Ij 
where qi qj = atomic charges, co = dielectric constant and r ij = interatomic distance 
CHARMrn approximates the positive and negative partial or net charge as point 
charges, centered at each individual atom. TIds is the monopole approximation, the 
energy between two point charges being dependent on the distance between them. 
f) van der Waals Energy 
van der Waals energy principally is due to the forces of electron shell repulsion and an 
attractive dispersion force between a pair of atoms. The attractive forces or London 
forces are the universal forces between atoms that hold non-polar molecules together in 
the liquid phase. Ibis force is due to the fluctuating dipolar moment of molecules, 
resulting in a net attractive force. 
( A.. B. - 
van der Waals Energy: E Ij vdw 
. 
jT i, j>j 
Ij r Ij 
where r ij = interatomic distance 
Balancing the attractive forces am short range repulsive forces which result from 
electron cloud overlap between molecules. The repulsive force is more sensitive to 
distance between molecules than the attractive force. Ibe resulting force is referred to 
as a 6-12 potential or the Lennard-Jones potential. 
To maximise the efficiency of nonbonded calculations (van der Waals and electrostatic 
interactions), CHARMm creates a list of all the pairs of interactions that are to be 
calculated. Careful modification of the nonbonded list can dramatically reduce the 
computational time required to perform minimisation routines. 
Atom pairs that are too far apart or directly connected (via bond or bond angle) are 
excluded from the nonbonded list. The nonbonded cutoff distance (CUTNB) used 
throughout this work is 12A, atom pairs that are further than 12A are not included in 
the nonbonded HSL 
The nonbonded list is constructed in two steps. Firstly, all residues that can interact are 
found and a minimum rectangular solid box about each separate residue is createdL All 
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potentially interacting pairs are then computed. Ile second stage in the nonbonded list 
generation searches all atoms in the residue pairs that interact to create the final list. 
For most calculations, a cutoff point of 12A makes very little difference to the energy 
of a large molecule, however there is always the possibility that overall long range 
interactions outside the 12A cutoff distance may not be negligible. Individual long 
range interactions are negligible as the van der Waals and electrostatic potentials 
beyond I IA are very small. 
In order to smooth out the change in energy beyond 12A - automatically zero, as no 
atoms outside this range are considered, CHARMm includes two functions to smooth 
out the energy around the cutoff distance. 
The switching function (VSWITCH) is applied to the van der Waals interaction and the 
shifting function (SHIFI) applied to the electrostatic function - the default applies the 
SWITCH function to both nonbonded terms. 
71be SFHFr function is more simple than the VSWITCH function - SHIFr modifies 
the potential energy and forces so that they disappear at a given cutoff distance 
(CUTOFNB). ne CUTOFNB value in this work is I IA. The function takes the 
following form: 
2rý rý IJ + IJ 
r 2 4 r C ut cl ut 
where rij = interatomic distance and rcut = cutoff distance 
The VSWITCH function requires two variables CrONNB and CTOFNB to define the 
switching function. CTONNB defines the distance at which the VSWITCH function 
is "on" and CTOFNB, the distance when the function is "off'. 
In this work CTONNB = 9A and CTOFNB = 11 A( as above). 
. 
(roff 
-r 
(roff 
+2r-3ron) 
r< ron: l ron <r< roff - (roff 
- ron 
), , 
roff < ro 
Ile update frequency of the nonbonded list is specified by INBFRQ - in this work the 
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nonbonded list is updated every 10 steps unless otherwise specified. 
g) Constraint Energy 
Atomic constraints fix atoms in space so that they do not move during minimisation of 
the molecular structure. Ile simplest form of constraint is to allow atoms no 
movement and all energy terms involving fixed atoms remain fixed. However, for most 
applications, it is desirable to allow atoms some freedom of movement whiIst 
minimisation is performed. 
In cases where the starting structure is well ordered and near to a conformational 
minimum, such as an X-ray crystal structure, a harmonic constraint is applied to the 
atoms. 
Econs =I ik I mass I 
(r 
i-r oi)exp 
where Econs = the constraint energy, ki and massi , the force constant and the mass 
of the atom i, ri the position of the atom and r0i , its reference position about which 
the atom is to be centred. 
Harmonic constraints on atoms allow a molecular structure to relax during 
minimisation while avoiding large displacement of atoms. 
(v) Minimisafion 
When potential energies and forces acting on the atoms in a molecular structure have 
been defined, it is possible to calculate the total potential of the structure. However, this 
is a calculation of a single fixed conformation and usually it is preferable to determine a 
"low energy" structure or a number of low energy structures of the molecule under 
investigation. Minimum energy conformations are obtained by minimisation. 
Minimisation is performed to relieve strain in conformations obtained experimentally 
and determine the conformational local energy minimum. In this work, local minima 
around the starting x-ray crystal structure are examined. Many minimisation 
techniques exist for finding low energy conformations. CHARMm. supports five 
different, iterative minimisation algorithms. Of these, three algorithms were used to 
minimise the TS crystal structure. 
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a) Steepest Descents ( SD ) 
This is the simplest non convergent first derivative method of minimisation. SD moves 
atoms directly down the energy gradient. A displacement opposite to the potential 
energy gradient is added to the Cartesian coordinates at each step. If a lower energy 
results, the step size is increased, otherwise it is decreased. This algorithm is robust 
and quickly improves poor starting geometries ( such as close contacts between atoms 
). However, SD suffers from poor convergence near the minimum and can often 
overshoot a local minimum. 
Generally, SD is useful for initial minimisation of large, well ordered structures ( such 
as X-ray crystal structures ) where small changes in atomic positions can relieve close 
contacts. SD can also minimise and relieve steric strain in small molecules with poorly 
defined structure.. SD stores no information on the previous directional movement of 
atoms, so cannot predict better movement directions. 
b) Powell (POWE) 
The second minimisation algorithm used in this work is the conjugate gradient Powell 
method minimiser. Ibis is an iterative method of minimisation and makes use of the 
previous change in energy ( as well as the current gradient ) after each minimisation 
step. 71be POWE method converges to a minimum energy faster than SD, requiring 
fewer evaluations of the energy and energy gradient to achieve the same reduction in 
energy . 
However, POWE does not update the non-bonded and hydrogen bonded interaction 
lists. Very poor starting conformations can cause numerical data overflows. POWE is 
a useful algorithm minimising low energy conformation structures, before employing 
the sophisticated Adopted Basis Set Newton-Raphson method 
c) Adopted Basis Set Newton Raphson (ABNR) 
ABNR is based on the second derivative minimisation method Newton Raphson 
( NR)71. NR is much more efficient in locating a minimum, although it has poor 
tolerance for bad starting structures. NR requires excessive computational storage -a 
3N x 3N second derivative matrix (where 3N dimensions correspond to the 3N degrees 
of freedom of the structure ) must be stored and inverted. 
Computational time is extremely long using NR and is therefore is restricted to 200 or 
fewer atom systems in CHARMm. For most large molecular systems ( 200 atoms or 
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more) ABNR is normally the preferred algorithm. ABNR performs energy 
minimisation using the NR algorithm. The positions and forces from each of the 
previous steps are stored and the second derivative matrix is constructed by fmite 
differences from the displacement and the first derivative vectors. SD steps are applied 
along the directions of zero or negative eigenvalues 
to avoid saddle points Any new directions are incorporated into the displacements 
subspace ( the basis set by using a SD step along the residual gradient vector 
calculated at each step. ABNR is two to three times faster than NR as the second 
derivative matrix is much smaller. 
(vi) Electrostafic Potential Surface 
Effective representation of important atomic and molecular properties (such as 
accessibility and electrostatic potential) is provided within QUANTA. An adaptation 
of the Connolly Molecular surface prograrn72 can be applied from the Calculate menu 
under Solvent Surfaces. A probe sphere of radius IAA (equivalent to a charged 
proton) is rolled over the surface of the molecule or atoms under consideration, 
resulting in a smooth surface of dots which represents the Electrostatic potential 
surface accessible to a water molecule, including internal cavities. Connolly surfaces are 
used to study the shape, depth and chemical characteristics of receptor sites of a 
molecular structure. 
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2.2 MATERIALS AND METHODS 
(i) Software 
The programs CHARMrn (Version 21.2 ) and QUANTA (Version 3.2.3 ) were 
used as supplied by Molecular Simulations without modification of source code. 
(ii) Hardware 
Computational drug design was performed using Silicon Graphics 4D/20 
Personal Iris workstations with 12 MB main memory and 380 MB disk storage 
capacity. 
(iii) 12= 
The source of the three-dimensional coordinates of Thymidylate Synthase was in 
the form of the crystal structure of Escherichla coli 71'hymidylate Synthase (TS) 
complexed with the substrate dUMP and CB3717 ( an analogue of the cofactor 
methylene tetrahydrofolate, ), solved by multiple isomorphous replacement and 
refined at 1.97A resolution. 6S, 67 
The parameter set PARM30. PRM that defined atomic masses, partial charges 
etc. was slightly modified to include several custornised parameters (see 
Appendix 2.1). 
Novel compounds designed as TS inhibitors were derived from the crystal 
structure of CB3717 in TS. 
(iv) Methods 
The original crystal data for each form of TS was obtained from 8 separate files. 
All headers were removed from each structure file and catenated together. 
The molecular structure files (MSFs) were generated using QUANTA's amino 
acid dictionary for proteins with polar hydrogens only (v 20.3 parameters), 
renamed, reordered and assigned to new segments within QUANTA as follows: 
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SEGMENT NAME 
is 
2S 
IH 
2H 
RESIDUE NUMBER 
I TO 264 
301 TO 564 
565 TO 566 
567 TO 568 
This order is common to all MSFs of TS in this work (see Appendix 2.2 for fun 
structure information). 
a) Comparison of the two TS forms 
TS was crystallised in two forms -a "reduced" (so called as it was recrystallised, 
in a greater amount of mercaptoethanol) and an "oxidised" form (see Figure 
2.3). 
ne monomers of each form were compared using the Protein Package within 
the Applications menu in QUANTA. The main chains of the monomer 
subunits were compared using Comparison and Superposition. 
b) Analysis of crystal structure 
Secondary structure was assigned to each TS form by using Calculate H bonds 
and Calculate secondary structure within the Protein package. 
The b -value parameter in the raw crystal data was assigned by colour in the TS 
structure - red corresponding to the high b -value and blue to a low b -value. 
Ile b- value is an indicator of the thermal mobility, a high value indicates 
large fluctuations of movement while a low value indicates small fluctuations. 
Polar hydrogens were added to the starting structure using the Add polar 
hydrogens within Molecular Editor 
c) Active site comparison 
From initial visual studies of the TS crystal structure, there appeared to be two 
distinct pockets that CB3717 could occupy. 
A common RTF for CB3717 was generated in the Molecular Editor of 
QUANTA. Each monomer of TS contained one active site, so there are four 
active sites in all, when both TS forms are considered. - 
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Figure 2.3 
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Both forms of TS were read into QUANTA and mapped onto the reduced form 
of TS active site that contained CB3717 and dUMP covalently bound - within 
Protein Package,, the oxidised form of TS was superimposed in two segments 
onto segment 1S of the reduced form of TS 
is A----ý 
ReducecI4 
Form 
2S reduced form 
1S oxidised form 
2S oxidised form 
Then a Comparison using LSQ keyboard (the least squares algorithm) 
mapped all the monomers of the TS protein onto each other. Note that the 
CB3717 and dUMP molecules were not directly superimposed into the 
"averaged" active site, but were allowed to move in each active site. 
d) Conformational preferences of CB3717 
In order to determine any conformational preferences, CB3717 (the antifolate) 
was removed from both the oxidised and reduced form of TS , then minimised 
in 
vacuo using the steepest descents algorithm (SD) . Once the r. m. s. deviation was 
consistently below 0.3kcal between two coordinate sets, this provided a good 
indication of the overall change in conformation of a molecule between 
minimisation steps. 
Then Adopted-basis set Newton Raphson (ABNR) was applied until r. m. s. 
deviation was below 0.1. Typically, an in vacuo minimisation of CB3717 
underwent 150 steps SD and 250 steps ABNR with a step size of 0.1. Any 
change in CB3717 conformation after minimisation was noted. 
e) THF and DHF conformations 
Methylene tetrahydrofolate (THF) and dihydrofolate (DRF) are the normal 
cofactors of TS. CB3717 was selected from both the major and minor forms of 
TS and converted into DHF and THF using the molecular editor. Atom types 
and charges were assigned using charge templates within QUANTA - (charge 
smoothing over all atoms) and the coordinates saved with all hydrogen atoms 
included in the structure. 
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f) Application of Patches 
In order to allow CHARMm to recognise the covalent bond between the two 
dUMP molecules and the cysteine residues in the major ("reduced") form of TS, 
a "patch" file was created. 17his was called MAJOATF and this patch specified 
the covalent S-H bond for residues IS: 146 to lH: 565 and 2S: 446 to 2H: 567 
(CYS to dUMP). 
(see Appendix 2.3 
g) Minimisation of TS containing CB3717, THF and DHF 
For docking of DHF and THF into TS, the RTF's corresponding to these 
structures were changed to include polar hydrogens within QUANTA's 
Molecular Editor. The newly created RTF's with polar hydrogen representation 
were called THF. RTF and DHF. RTF 
This was to determine preferred conformation of DHF and THF either within TS 
or in vacuo . Once minimisation of the substratelenzyme complex was 
completed, DHF and THF were removed from the structure and reminimised as 
before to check if a reasonable fit was attained. 
h) NIO substitution and N' ligand design 
Now that the behaviour of THF, DHF and CB3717 within TS and in vacuo had 
been determined, an investigation of the effect of the propargyl group (CP1, 
CP2, CP3 and H46) of CB3717 was undertaken. 
The propargyl group is responsible for the highest specificity of the 
NIO -substituted quinazoline based series of ligands for TS. 73-83 
i) Minimisation of one subunit of TS 
In order to significantly reduce the computational time required to minimise TS 
and associated bound novel ligands, half of the dimer crystal structure was 
minimised. 
The minor form of TS had one monomer fixed so that the constrained atoms did 
not move during minimisation. Segments 2S and 2H were subjected to a CONS 
FIX command in CHARMm. This fixed aH atoms in residues 301 to 564 and 
567 to 568. Four ARG residues (424 to 427) were not fixed as these residues 
formed part of the active site of the second subunit (see Figure 2.4). 
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Figure 2.4 
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Similarly the major form of TS had segments 1S and 1H fixed (residues 1 to 
264 and 565 to 566) apart from the four ARG residues 124 to 127). 
Each TS form was then subjected to 25 steps SD and 250 steps ABNR. 
Minimised coordinate were read out to "TS_ýHALF_MlN. CRD" and 
"TS-MDLHALIý_MIN. CRD" respectively. 
Bifurcated ligand design - the BEF series 
Bifurcated ligands based on the crystal structure of CB3717 were built as 
follows: 
The 1S segment of the minor from of TS was matched with the 2S segment of 
the major form using comparison in QUANTA's protein package. 
Residues 1H: 566 from the TS minor form and 2H: 568 from the major form were 
selected and saved to separate MSF's. In Molecular editor, the propargyl groups 
of each CB3717 were removed and the quinazoline ring system from 
2H: 568(major) added to NIO of the IH: 566 (minor) CB3717. This was called 
BIF1, the bifurcated ligand based on the CB3717 found in the minor form of TS 
in the 1S segment( see Figure 2.5). 
Similarly, BIF2 was created by removing the propargyl groups of both template 
CB3717 molecules and the quinazoline ring system 1H: 566(minor) added to NIO 
of 2H: 566(major) 
Atom numbers for both new bifurcated molecules were changed accordingly. 
All atoms were retyped and bond types correctly assigned. Atoms were charged 
using charge templates option in molecular editor. 
To relieve any steric strain or incorrect dihedral angle conformation around the 
NIO the two new ligands were separately minimised with a harmonic constraint 
force of 50 kcal/mol placed on all atoms in each new structure apart from C 11, 
C9, C6, C26 and N10 which were allowed to minimise, freely. 
With these constraints in place the BIF ligands underwent 25 steps SD and 250 x 
4 steps ABNR, while the harmonic constraint force was allowed to relax. Once 
harmonic constraints were removed, a further 25 steps SD and 250 x4 steps 
ABNR were performed to give final minimised structures of bifurcated ligand. 
The new BIF molecules were introduced into their respective active sites: BIFI 
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Figure 2.5 
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into the locus previously occupied by IH: 566 CB3717 of the minor TS form and 
BIF2 into lH: 568 of the major form. 
The BIF ligands were then fixed using the CONS FIX command and the 
enzyme allowed to minimise around them with 25 steps SD and 250 x4 steps 
ABNR. 
Finally, the BIF ligands were allowed to minimise freely within TS with 25 steps 
SD and 500 x2 ABNR. This gave a final, minimised TS structure containing 
BIFI in the minor form and BIF2 in the major form (see Figure 2.6 and 2.7). 
k) External energy interactions for each atom in the BIF and CB3717 series at 4, 
8 and 12A range 
Once minimisations were completed, a script file was set up to calculate van der 
Waals and electrostatic contributions (the nonbonded interactions) at a 4,8 and 
12A sphere around each ligand. Charges were reported back from CHARMni 
for each atom in the bound ligand. By using "awk" files (see Appendix 2.3) it 
was possible to determine the contributions made by specific functional groups 
and hence assess binding affinity of the whole ligand. Summated contributions 
of the quinazoline ring systems and glutamate tails sections of CB3717 were 
noted and compared to the contributions from atoms in the BIF molecules. 
1) Comparison of internal and external energy contributions 
The dihedral, angle, bond and improper angle values were calculated using 
CHARMm for each ligand. (BIFI, BIF2 and the major and minor CB3717 
ligands). These were the internal energy terms (as described in Chapter 2.1) and 
were summed and compared with the external energy contributions. Ilis 
indicated whether binding was affected more by ligand conformation or by 
atomic structure. 
m) Van der Waals and electrostatic summation - bumps and gaps 
Once individual atomic contributions to nonbonded interaction were collated, 
those atoms that had poor van der Waals and electrostatic contributions were 
substituted with other atoms to create new ligands. This was performed in the 
molecular editor by changing one atom type at a time in either B IF l or BIF2. 
Each structure was saved to a new filename and atoms retyped and recharged on 
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Figure 2.7 
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exit of the Molecular editor. In total there were 18 ligands generated from BIFI 
and BIF2 making a total of 20 novel structures that could bind into the active site 
of TS in both major and minor forms of the enzyme. 
The changes to BIF1 and BIF2 were also influenced by the assessment of close 
contacts within the active site. The close contacts were assessed using the 
neighbouring atoms tool in the main viewport of QUANTA. The dot surface 
generation program in QUANTA was also used to define the 3 dimensional 
space of the active site pocket and shape of the ligand. A dot surface (20 point 
density) was generated based on the van der Waals calculation of atomic size. 
The two dot surfaces (for the TS pocket and ligand) were attached to the 
structure using the manage graphical objects tool in QUANTA. This allowed 
visual inspection of the goodness 
of fit of each structure generated. 
Atoms in the ligand that visibly overlapped the active site pocket were selected 
and changed in the molecular editor. Areas that revealed "gaps" in the pocket 
were noted and in the cases of obvious gaps, an atom substitution was made in 
the ligand structure to fill the pocket more snugly. 
n) Solvation energies - comparison of interaction 
To approximate the behaviour of each of the ligands ( 20 BIF and CB 37 17 
parent structures) either complexed to TS or in solution the following approach 
was used. 
A 15A sphere of 420 water molecules was placed around each individual BEF 
ligand and minimised (see Figure 2.8) The final energy associated with the 
solvated ligand was noted. This value was compared to the equivalent solvation 
and subsequent minimisation of the two CB3717 ligands - again in 420 water 
molecules. Ibis solvation was carried out using the solvate option under the 
CHARMrn submenu of QUANTA. 
To approximate each ligand's preference for either remaining in solution or 
bound to TS, the solvated CB3717 energy values were subtracted from the 
energy values from the final minimisation of TS containing each CB3717 ligand. 
This energy difference corresponded to a positive value relating to the parent 
ligand's preference for remaining in solution. 
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Figure 2.8 
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Each BIF ligand was similarly assessed, with solvated energies compared to 
final energies of bound ligand in TS. If the positive value obtained from this 
calculation was lower than the corresponding CB3717 value, the new bifurcated 
ligand was deemed to have a reduced preference for remaining in solution i. e. a 
greater preference for binding to the TS molecule. 
m) Most promising ligands 
Those new bifurcated ligands which showed greatest affinity for the TS enzyme 
were subjected to further scrutiny. A Connolly electrostatic surface was 
generated for each ligand and corresponding active site pocket. Visual 
assessments of bumps and gaps were made ( see Figure 2.9 and 2.10), with 
emphasis on visualisation of electrostatically favourable interactions (e. g. a blue 
or negatively charged ligand surface close to a red or positively charged pocket 
surface). The Connolly surface was generated from the Calculate option in 
QUANTA, using a probe radius of 1AA and formal charge of +1. Electrostatic 
surfaces were rendered using a 20 point dot density with colouring of each 
surface ramped from red to blue (positive to negative). 
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2.3 RESULTS 
(i) TS Fonns - major and minor conformations 
The main chains (a carbon backbone and side chain residues) of the TS 
monomers are almost identical in structure. Mainchain comparison of each 
monomer gave an r. m. s. displacement of 0.535A and a maximum displacement 
of 4.121A. 
Ile entire structure of each monomer gave an r. m. s. displacement of 1.123A and 
a maximum displacement of 10.533A. The global structure of the monomer is 
highly conserved in both forms of TS . 6S 
The coordinate data obtained from Stroud is well-resolved and the residues in 
both TS forms are identical with the exception of one residue in each monomer - 
LYS 235 and LYS 535 in the major form dimer are replaced by ALA 235 and 
ALA 535 in the minor form dimer. 
(ii) Crystal Structure 
Assuming that TS crystal structure is an accurate representation of in vivo 
structure, it necessarily follows that computer modelling and drug design based 
on this structure is valid. 
B-values from raw data indicate that the crystal lattice is highly stable around the 
core of the dimer molecule. Typical core protein b-values are of the order of I to 
2. The surface of the crystal structure has a greater b-value range from I to 7. 
This is to be expected, as this is at the solvent interface in which the TS crystals 
were solved. 
The overall structure of the TS molecule bound to CB3717 is similar to a 
previously solved TS unbound structure of LCasei 84 or E. Coli. 85 The major 
and minor forms consist of 528 residues but the contents of each active site 
differs markedly. 
(iii) Active site 
Ile residues that define the boundaries of the TS binding sites am highly 
conserved. 65-66 
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TS exists as a dimer with a single active site in each subunit. The major from of 
TS contains dUMP covalently bound to cysteines IS: 146 and 2S: 446 in both 
active sites in the presence of CB3717 (CB3: S66 and CB3: S68). One active site 
of the minor form contains dUMP (residue IH: 565) noncovalently bound in the 
presence of CB3717 (CB3: 566) whilst the other contains only phosphate 
(2S: 567) and CB3717. 
The active site is a large cavity that allows CB3717 to bind in one conformation 
in the major form and a different one in the minor form. This second binding 
site6s has CB3717 with the quinazoline ring rotated 147* away from the position 
occupied in the major form binding site. 
Ile phosphate ion in the major fon-n is lodged between four arginine residue 
side-chains, two ARG from each monomer and a serine (SER). 
Analysis of CB3717 in the TS crystal structure reveals that in the major form 
(reduced) the glutamate tail is oriented in two different positions, approximately 
180* about the C14 carbon. The benzyl group of CB3717 shifts only slightly 
along the plane in the major and minor forms. 'Me major difference is the 147* 
shift of the quinazoline ring. 
The "minor" pocket containing the alternate CB3717 conformation undergoes 
little sidechain disturbance, which may indicate a stable second pocket in TS. 
The quinazoline rings of CB3717 in the minor form push dUMP out of the 
"major" pocket, while in the minor TS form, dUMP remains more planar, lining 
the pocket boundary. The pocket dimensions are approximately 7A x 10A x 
10A. This would indicate that the preferred conformation of CB3717 is the 
"minor" conformation when no dUMP is present. 
In the minor form where dUMP is present, the pocket in the major form is 
blocked by the dUMP, so CB3717 adopts the 147* shift, occupying the "minor" 
pocket. 
In the major form, covalently bound dUMP is drawn away from the pocket, 
giving CB3717 enough space to take up the "major" conformation. 
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(iv) Conformational preferences of CB3717 
From initial in vacuo minimisation of CB3717 there appears to be no 
conformational preference for either "major" or "minor" positions. However, 
within TS, the preferred conformation of CB3717 is the "minor" structure. Even 
when noncovalently bound dUMP is present in the pocket, CB3717 still prefers 
the "minor" conformation. In the major form of TS, when the CYS: 146 residue 
covalently binds to dUMP, conditions in the pocket that the "minor" CB3717 
occupy become unfavourable. The dUMP moves across to sterically block the 
"minor" pocket. The "major" pocket is preferred. So, when no dUMP is present, 
CB3717 prefers the "minor" conformation. When dUMP is present but is 
noncovalently bound, the "minor" conformation is still preferred. Finally, when 
dUMP is covalently bound , the preferred conformation is the "major" 
conformation. 
(v) Conformational preferences of DHF and THF 
Minimisation in vacuo of DHF and 5,10-THF gave conflicting results. DHF 
appears to have no preferential conformation while 5,10-THF prefers the 
"reduced" (major) conformation. 'Ibis basic minimisation procedure gave only a 
rough estimate of conformational preference - the final conformation of 5,10- 
THF may well have been governed by the atom constraints placed on 5,10-THF 
at C4A, C8A and C 11 around the 5-membered ring. 
(vi) Conformational preferences of DUE and THE in IS 
From comparison of minimised structures of TS (containing either DHF or 5,10- 
-THF substrates) compared to starting crystal structures, DHF and 5,10-THF 
seem to have no preference for which pocket they occupy. 
(vii) The cbnew series of ligands 
The N9 substituted series of ligands were found to be energetically unfavourable 
within the major and minor TS active sites. the NIO substituted CB371786 
ligands were pushed out of the pocket as the propargyl group on CIO was not in 
the most favourable orientation. Close contacts (bumps) were found between the 
HG of SER 2S: 444 and H38 of the cb3new ligand and HG of ASN 2S: 441 and 
H39 of cb3new. Reorientation of the propargyl group to point into the active site 
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cavity did not stop the whole ligand from being forced out of the active site 
(cb3new) in both major and minor TS forms. 
The ammonium group that then replaced the propargyl (cb4new) resulted in the 
ligand remaining within the active site. Extension of this ammonium group (by 
additions of CH2 units to the C 10 group) allowed the NH3+ to hydrogen bond to 
the inorganic phosphate (in the minor form of TS). This extended carbon chain 
from the CIO group proved to be highly flexible. Consequently many 
energetically unfavourable conformations were generated. These cbnew ligands 
were deemed unsuitable for further investigation. 
(viii) Monomer minimisations 
By placing a CONS FIX constraint on a monomeric subunit of each form of TS, 
the run-time of each minimisation was reduced by up to 30%. Typically a series 
of half enzyme minimisations now took 5 hours of C. P. U. time rather than in 
excess of 8. No gross change in structure was observed at the interface between 
monomeric subunits. The total energy of major and minor forms of TS was 
-6151kcal mol-I and -6113 kcal mol-I respectively. 
(ix) The BIF series of heands 
A comparison of the relative energy contributions of the new quinazoline ring 
system in the BIF ligands compared with the propargyl group in CB3717, 
revealed that the new quinazoline bifurcated portions contributed to a net 
decrease in energy of each enzyme system. Atom naming covention for BEFI, is 
shown below: 
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Comparison of Energy bif I-quinazoline -33.39 kcal /mol 
63717-ýminorj-propargyl -0.97 kcal/mol 
IC Energy Contributions 
bif2-quinazoline 
63-ýmajorý-propargyl 
BIF1 
CB3717 minor 
BIF2 
CB3717 major 
-19.76 kcal/mol 
-4.85 kcal/mol 
7.74 kcal/mol 
4.11 kcal/mol 
9.91 kcal/mol 
2.78 kcal/mol 
TOTAL ENERGY of TS MINOR FORM 
containing BIFI 
containing CB3717 
-6144.59 kcal /mol 
-6117.14 kcal /mol 
MAJOR FORM 
containing BEF2 
containing CB3717 
-6214.23 kcal /mol 
-6153.99 kcal /mol 
(x) Interactions at 4.8 and I 1A. 
Individual Van der Waals' and ElectrostatiC87 energies were calculated for each 
atom in BER and BIF2 ligands over a sphere radius of 4,8 and 1 IA. These 
energy contributions were compared to the parent CB3717 compound (see 
Appendix 2.4 for details). The atoms that gave poor contribution to overall 
energy were changed in subsequent BEF ligands. From the BIM and BIF2 
ligands, these were the atoms that were changed: N21, NI, N3, N23, C8, C23 
and C28. 
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LIGAND NUMBER PARENT ATOM NEW ATOM TYPE 
MINOR FORM TS 
BIF3 N21 C21 
BIF5 NI cl 
BIF7 N21 & Nl C21 & Cl 
BIF9 C28 N28 
BIFI I C8 N8 
BIF13 C28 & C8 N28 & N8 
BIF15 N23 C23 
BIF17 N3 C3 
BIF19 N23 & N3 C23 & C3 
MAJOR FORM TS 
BIF4 N21 C21 
BIF6 Nl cl 
BIF8 N21 & NI C21 & Cl 
BIF. 10 C8 N8 
BIF12 C28 N28 
BIF14 C8 & C28 N8 & N28 
BIF16 N3 C3 
BIF18 N23 C23 
BIF20 N23 & N3 C23 & C3 
(xi) Solvation energies and minimisation 
The BIF series ligands were minimised within TS and also within a 15A water 
sphere containing 420 TIP3 water molecules. From comparison of CB3717 
minimised within TS or in a sphere of 420 water molecules a comparison could 
be made between BIF ligands and CB3717. This comparison indicated the 
energy associated with each ligand for remaining in solution or bound to TS. 
From 20 novel compounds designed, studies indicated all but BIF2 had greater 
preference to be bound to TS rather than in solution when compared to their 
parent CB3717 ligand (see Figure 2.11 and 2.12). The most notable of these 
were BEF5, BIF7, BIF9, BIRO, BIF12 and BIF18. (see Appendix 2.4 and Figures 
2.13 to 2.16) 
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(xii) Connolly surface calculations 
Examination of electrostatic potential surface" for the BIF series of ligands 
showed that these new ligands fit snugly into the bifurcated pocket of TS with no 
overlapping electrostatic contacts. The Connolly surfaces also showed that there 
were no poor steric interactions within the TS pocket of both major and minor 
forms. 
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Figure 2.11 
80 
Figure 2.12 
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Figure 2.15 
84 
Figure 2.16 
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2.4 DISCUSSION 
(i) Molecular Mechanics and Drug D '_ 
Molecular mechanics is a classical method of expressing a molecular structure as 
a set of balls and springs, with series of potential energy functions expressing the 
molecular force field as a sum of these functions. 89 More elegant models 
describing these molecules include cross valence, polarization and nonbonded 
interactions. 
Each individual energy term has a preferential equilibrium position (e. g. bond 
length, bond angle, van der Waals etc. ) and force constants are used to associate 
energetic penalties with each individual deviation from the equilibrium. A 
"Force Field" is simply the complete set of analytical energy functions and their 
associated sets of numerical parameters (based on experimentally or 
theoretically calculated force constants). 
CHARMrn is one of the most extensively tested force fields, 90 - others include 
MM289 and AMBER. 91-92 CHARMm force fields are considered the standard 
for macromolecules90 and use the "united-atom" representation - all non- 
hydrogen bonding hydrogens are implicitly included by slightly increasing the 
effective size of the parent atom to which the hydrogens are bonded. 93 
In cases where the force field does not describe the parameters of certain 
functional groups, an estimation of bond, bond angle or dihedral angle is 
required (see Appendix 2.1). 
Once all the necessary parameters have been obtained, molecular mechanics 
energy minimisation can be performed. 
ii) HistQa of Computer-aided drug design (i 
Man has been fighting disease for centuries. Many varieties of plants and herbs 
have found their way (often by chance or observation) into the front line in 
combating disease and illness. More recently, observations of effective 
compounds has been backed up with scientific reasoning - active substances in 
plants and herbs (which have been traditionally considered to be of medical 
importance) have undergone in-depth investigation. 
At the start of this century, scientists began to follow up unexpected results of 
chemical investigations and biochemical experiments. Chemists began massive 
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screening programs of hundreds of derivatives of active compounds - empiricism 
ruled supreme! 
In the 1950's drugs were designed, based only on vague notions of physical 
properties and functional groups. Structure-activity relationships were based 
more on chance and guesswork than rational drug design. By the mid 1960's, 
more key or "lead" drugs were reaching hospitals - good drugs were being 
replaced by better ones, often from just a small structural change to the original 
compound. 
Advances in Physical chemistry and Biochemistry provided the foundation of 
knowledge on which a new quantitative approach to drug design was built. 
In 1962, the Organic chemist Corwin Hansch brought together the quantitative 
terms that mathematics was now able to describe - structure and activity 
combined with the computational power of the emerging (and constantly 
improving) computers. This new approach to drug design opened the doors to a 
new area of scientific research. 94 
The first X-ray diffraction photograph was displayed in 1912 - from this simple 
X-ray picture of an inorganic structure developed the protein crystallography and 
protein modelling that is today working hand in hand with computational 
chemistry and computer-aided drug design. 
From 1930 to 1980, equipment and techniques in X-ray crystallography steadily 
improved, especially with the introduction of automatic diffractometers and 
rapid data-processing with computers. In the 1980s, synchrotron radiation 
greatly enhanced protein crystal structure analysis. The high resolution and 
intensity available from synchrotron radiation allowed many more 
protein/inhibitor complexes to be resolved - even some protein/substrate 
complexes were elucidated. 
1965 saw the introduction of a novel tool for the x-ray crystallographer. A line 
-drawing cathode ray tube controlled by a small computer was used to display 
small proteins and protein folding. 
Within only 5 years, over 20 other graphical systems were in use, and as 
technology improved through the 1970's, interactive systems were developed. 
By the 1980's not only could structures be represented but properties: van der 
Waals surfaces could be represented by contour lines, as could electrostatic 
potentials. Colour and dot surface generation brought structures out from the 2 
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dimensional screen. It became possible to see active sites of proteins and to see 
interactions between residues. 
In 1982, Martin Karplus and his colleagues put forward a computer program to 
model complete macromolecular systems. This program could build structures 
(either from existing data or from scratch), energy minimise them and perform a 
range of tasks. These included molecular dynamics simulation and analysis of 
structural equilibrium and dynamic properties of molecules. 
Today, state-of-the-art molecular modelling systems provide extensive 
computational and graphics facilities for analysing known structures and 
interactions. 
It is now possible to gain accurate three-dimensional structural information on 
proteins and complexes formed between these proteins and inhibitors. 
(iii) Use and Limitations of Modelling 
Models are essential components of experimental and theoretical chemistry. 
Computer modelling draws together mathematical, conceptual, iconic and 
enactive modelling methods employed by the chemist. The mathematical model 
is described in the forcefield of the modelling program, the iconic model in the 
three-dimensional graphics displayed on the computer monitor, the enactive by 
the manipulations of structure made possible by the modelling program and the 
conceptual model is realised by the modeller as he/she sees the compound 
described by the previous models. Computer modelling acts as a stimulus to 
creative thinking. An experienced modeller can distinguish between "possible" 
and "improbable" compounds. This speeds up the selection process in the 
development of novel compounds and is a very important feature of computer 
modelling. Traditional benchmark chemistry is a slow and thorough process - 
computer modelling can help a chemist design novel compounds faster. 
One must take care not to fall into the trap of relying on computer modelling to 
provide the definitive answer. The data generated by a modelling program acts 
as a pointer to chemical interaction and does not always generate the same 
results that benchwork provides. Modelling currently facilitates the work of a 
scientist, whether that scientist is building a structural model based on NMR 
distance constraints, X-ray crystal data refinement or a de novo model using 
theory alone. 
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(v) Physiology of IS 
TS is not similar to other folate-based enzymes in its binding to substrate. " TS 
is an intracellular enzyme that is responsible for the synthesis of dTMP, a key 
building block in the production of DNA. Dihydrofolate reductase (DHFR) was 
a pervious target for drug design, but unlike TS, blocking of this enzyme by 
methotrexate resulted in purine synthesis and blocking of RNA production. Cells 
also became resistant to these drugs by simply raising the level of intracellular 
DHFR. 100-101 Many different classes of compound have an inhibitory effect on 
TS102-109 and polyglutamation of these drugs is known to increase inhibitory 
effect up to one hundred times. 110 If the two pockets in TS can be utilised 
simultaneously, then a suitable drug analogue would have tetrahydrofolate and 
dihydrofolate chemical characteristics. The amount of intracellular dUMP 
present would obviously affect the relative binding of these compounds 
(vi) Active site of TS 
It was reasoned that if inorganic phosphate was needed in 1 pocket of TS for 
catalytic activity, then a NH3+ moiety interacting with the inorganic phosphate 
would induce allosteric blocking of enzyme act 
' 
ivity. if the phosphate was an 
artefact (or not present under physiological conditions) then a carboxyl (COO-) 
group could be introduced to mimic the ARG residue binding to phosphate and 
resulting in competitive inhibition of THE 
(vii) Novel Ligands 
From the computer modelling in this study, the following ligands are put forward 
for future work: BIF5, BIF7, BEF9, BIFIO, BIF12 and BIF18. The structural data 
obtained from this study have been maintained on archived data tape and are 
available for analysis should provision be made for suitable experimental 
synthesis. Whether these compounds are indeed better inhibitors of TS in vivo 
will only be revealed after an adventurous organic chemist has produced them I 
To this end, I propose that BEF5 and BIF7 be put forward for synthesis as these 
are the best relative inhibitors of TS and are reasonably easy to synthesise. 
(viii) Future Work 
Should the crystal coordinates of human TS become available on the 
Brookhaven database, a full screen of existing compounds should be made. 
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Ligands with low binding affinity for TS shou 
' 
Id be compared to more active 
compounds. The use of computer modelling will greatly facilitate this process 
and lead to a greater understanding of biological activity of these antifolates. Site 
directed mutagenesis of TS will give an insight into the catalytic mechanisms of 
TS and the mode of inhibitor action. One of the BIF ligands at least should be 
put forward to enzyme assay and cell cytotoxicity studies, even if it proves 
inactive. 'Me knowledge gained from this exercise will certainly benefit future 
work in the development of novel TS inhibitors. 
(ix) Summary 
TS is still a protein very much under the attention of the scientific community. 
'Ibis work has shown that there is a large pocket within TS into which a 
bifurcated molecule can fit. Initial studies indicate that such a compound may 
have increased binding affinity for TS and hence be a more potent inhibitor of 
the enzyme. This work also indicates that TS may exist in two distinct forms, 
dependent on the levels of substrate present. It is not known if both active sites 
are simultaneously involved in synthesis of dTMP. I sincerely hope that this 
work will help another to develop a potent antifolate that will go at least part of 
the way to combating cancer -an illness for which there must be a solution. 
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Appendix 1.1 
Transformation of Religated Plasmids 
Cultures of JM83 containing pNM52 were grown overnight at 370C in an orbiting 
shaker by taking I ml. of stock culture of the strain and inoculating aseptically into 10 
ml of prewarmed L-broth (see Appendix 1.2) containing 10 W TETR . 
The following day 1 ml of the JM83 culture was pipetted into a sterilised 2 litre flask 
containing 200 ml of pre-wanned L-broth and 200 W TETR. 
The Cells were grown at 200 rpm until the optical density of the culture was 0.4 at 
550 nm. The Culture was cooled on ice for 10 minutes to prevent further growth. 
Approximately 2x 50 ml of the culture was removed and centrifuged at 4000 rpm for 4 
mins at 40C. 
After the supernatant was discarded, the cells were resuspended in half the volume 
(25 ml) of ice cold sterile 0.1 m M902 and recentrifuged at 4000 rpm for 4 mins at 
40C (Approximately 5000 x g). 
After the supernatant was decanted off, each cell culture pellet was resuspended in 
4 ml ice cold sterile 0.1 m CaC12: rhe Cells were maintained on ice for 2 hours, after 
which time they were competent and took up the B41 and pN23++ plasmids. 
10 pI of either pN23++ or B41 plasmid was added to 200 ml competent IM83 
(containing pNM52) cells and placed on ice for 30 minutes in eppendorfs. 
Transformants were placed in a 420C water bath for exactly 2 minutes and transferred 
to ice for a further 30 minutes to allow the cells to recover and express resistance. 
Appendix 1.2 
1. L-Broth preparation 
Compound g/litre 
Bactotryptone 10 
Bactoyeast 5 
NaCl 10 
For a working solution of 4 litres L-broth, slightly less than 2 litres of single distilled 
water were poured into a5 litre beaker. The above ingredients (x4) were added, and the 
pH raised to 7.5 (the optimum pH for E. coli growth) using 1M NaOH. 
The solution was made up to 4 litres, with single distilled water. The L-Broth was 
decanted into 500 ml duran bottles ( up to the 400 ml mark ). The bottles were 
autoclaved at 1200C for 15 minutes. 
2. Agar Plate preparation 
A 2% bacto agar medium was prepared by adding 8g of bacto agar to 400 ml of L- 
Broth duran bottles. The bottles were autoclaved at 1200C for 15 minutes. Following 
sterilisation, plates were poured immediately, allowed to set for 30 minutes and dried 
inverted in a 370C incubator for I hour. 
L-Agar Plates containing antibiotics 
The same procedure was followed as with Iagar plates, except that after sterilisation, 
the agar was cooled to 550C ( as antibiotics are thermolabile). The following antibiotic 
concentrations were added depending on the media required: 
Media Concentration add per 400 Final antibiotic 
ml L-Broth concentration 
L-Agar and Ampicillin 4 ml of 10 mg/ml stock 100 gg/ml 
ampicHin solution added 
L-Agar and Tetracycline 700 W of a 
1/1000 stock 15 gg/ml 
I tetracycline solution added 
Plates were poured as described previously. 
Appendix 13 
Cultures were kept on ice whenever possible. For 100 mIs volume of culture: the 
culture was cooled on ice for 10 minutes to prevent further growth. 
Ile cells were spun down (2x 50 ml ) at 800 rpm at 40C for 10 minutes. 
After supernatant was discarded, the cells were resuspended gently in 5 ml 20% 
sucrose in 10 mM tris buffer pH 8.0 (ice cold). To this mixture was then added 
0.25 ml EDTA (0.5m) and the cells were maintained on ice for 30 minutes. 
The cells were then recentrifuged at 8000 rpm at 40C for 10 minutes. The supernatant 
was decanted ( this was the "sucrose wash" - if needed, then this was transferred to 
eppendorfs). 
Ile cells were resuspended vigorously in 5 ml ice cold sterile water and maintained on 
ice for a further 30 minutes. 
Finally, the cells were recentrifuged at 8000 rpm at 40C for 10 minutes and supernatant 
decanted to eppendorfs (total volume approximately 5 ml ). Miis was the periplasmic 
protein fraction of the cell culture. 
Appendix 1.4 
For 1.3%w/v xylan stock: DNSA reagent: 
1.3g xylan made up to 100 ml 1% w/v DNSA 
0.2% w/v phenol, 
1% w/v NaOH 
(to activate DNSA just before use, DNSA reagent made up fresh for all assays. To 100 
ml of DNSA reagent was added Xylose stock 1 mg/ml in PC buffer I ml 5% w/v 
Sodium sulphate, and lOgI 20% w/v glucose) 
Standard curve Figure A 
Xylose Stock gg/ml E575 run 
Extinction 
0 0.000 
50 0.090 
100 0.170 
200 0.360 
300 0.550 
400 0.800 
500 0.900 
600 1.220 
700 1.350 
B41 plasmid Sucrose wash Periplasm 
0.150 0.975 
0.195 0.975 
0.210 1.245 
0.250 1.155 
Average extinction value: 0.201 1.088 
pN23 plasmid Sucrose wash Periplasm 
0.233 0.425 
0.275 0.805 
0.285 0.695 
0.225 0.470 
Average extinction value: 0.255 0.599 
Standard Curve Figure B 
Xylose Stock gg/ml E575nm Extinction 
0 
200 0.230 
300 0.380 
400 0.500 
500 0.600 
600 0.720 
700 0.860 
1000 1.240 
B41 plasmid Sucrose wash Periplasm 
0.140 0.810 
0.190 1.060 
0.190 1.040 
0.080 1.050 
Average extinction value: 0.150 0.990 
pN23 plasmid Sucrose wash Periplasm 
_ 0.150 0.580 
0.180 0.710 
0.100 0.790 
0.110 0.490 
Average extinction value: 1 0.135 0.643 
Standard curve Figure C 
Xylose Stock gg/ml E575nm Extinction 
0 0.000 
50 0.100 
100 0.170 
200 0.320 
300 0.500 
400 0.610 
500 0.810 
600 0.910 
700 1.080 
800 1.140 
B41 plasmid 0.000 (-0.130) 
B41 plasmid + IPTG 1.675 
pN23 plasmid 0.000 (-0.123) 
pN23 plasmid + IPTG 1.005 
Standard curve Figure D 
Xylose Stock 
4g/m, 
E575nm 
extinction 
0 0.000 
100 0.220 
200 0.420 
500 1.080 
800 1.650 
Time after IPTG 
induction (mins) 
B41 neat 
periplasm 
B41 (10-1) pN23 neat 
periplasm 
pN23 (10-1) 
E575nm E575nm E575nm E575nm 
90 0.245 0.167 0.178 0.250 
120 0.832 0.329 0.829 0.176 
270 1.006_ 0.666 1.931 0.553 
360 2.018 0.781 1.262 0.527 
960 1.758 0.938 1.987 0.859 
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Appendix 2.1 
Custom parameter set 
BOND 
c CR66 386.0 1.419 from C CR56 
CH2E CUY1 350.0 1.46 from CT CUYJ 
THETAS 
c C6R NT 70.0 120.0 from C C6R NP 
N6R C6R NT 70.0 120.0 from N6R C6R N5R 
H NT C6R 35.0 109.47 from H NT C 
CR66 c N6R 62.0 111.3 from CR56 C N6R 
CR66 C 0 86.0 128.8 from CR56 C0 
c CR66 CR66 116.0 119.2 from C CR56 CR56 
c CR66 C6R 70.0 120.0 from C6R CR66 C6R 
c CR66 C6RE 70.0 120.0 from C6R CR66 C6R 
cuyl CH2E NT 50.0 109.47 from CUYI CT NT 
CH2E cuyl cuyl 25.0 180.0 from CT CUY1 CUY1 
CH2E C N 58.0 120.0 from CT CN 
c C6R N 70.0 120.0 from C C6R NP 
C6RE C NP 70.0 117.5 from C6R C NP 
cuyl CH2E NP 50.0 109.47 from CUY1 CT NT 
C6R C6RE C 70.0 120.0 from C6R C6R C 
C6RE C CR66 65.0 120.0 from C6RE C6R CR66 
PHI 
x C6RE C x 3.1 2 180.0 from X C6RE C6RE X 
x CH2E CUY1 X 0.4 3 0.0 from X CT CUY1 X 
x C6RE CR66 X 3.1 2 180.0 from X C6R CR66 X 
x c CR66 X 3.1 2 180.0 from X C6R CR66 X 
Appendix 2.2 
Residue Topology Files 
PHOSPHATE and dUMP 
CB3717 
Propri eto ry and Confidential Property of Polygen Corporation 
TEMPLATE FOR CREATING CHARMm RTF file (from ChemNote) 
- m) replaced 
by first 4 characters of molecule name 
(% 
_r) replaced 
by RTF format of residue definition 
Build RTF for phs 
residue definition in RTF format built inline 
21 3 
MASS 1 H 1.00800 ! Hydrogen bonding hydrogen (neutral group) 
MASS 2 HC 1.00800 ! Hydrogen bonding hydrogen (charged group) 
MASS 3 HA 1.00800 ! Aliphatic or aromatic hydrogen 
MASS 4 HT 1.00800 ! TIPS3P water model hydrogen 
MASS 5 LP 0.0 ! ST2 lone pair 
MASS 6 MBE 9.01218 ! Beryllium 
MASS 7 B 10.81 ! Boron 
MASS 8 HO 1.00800 ! Hydrogen on an alcohol oxygen 
MASS 9 HMU 1.00800 ! Mu-bonded hydrogen for metals and boron-hydride, 
MASS 10 CT 12.01100 ! Aliphatic carbon (tetrahedral) 
MASS 11 CHIE 13.01900 ! Extended atom carbon with one hydrogen 
MASS 12 CH2E 14.02700 ! Extended atom carbon with two hydrogens 
MASS 13 CH3E 15.03500 ! Extended atom carbon with three hydrogens 
MASS 14 C 12.01100 ! Carbonyl or Guanidinium carbon 
MASS 15 CM 12.01100 ! Carbonmonoxide, or other triply bonded, carbon 
MASS 16 CUA1 12.01100 ! Carbon in double bond, first pair 
MASS 17 CUA2 12.01100 ! Carbon in double bond, second conjugated pair 
MASS 18 CUY1 12.01100 ! Carbon in triple bond, first pair 
MASS 19 CUY2 12.01100 ! Carbon in triple bond, second conjugated pair 
MASS 20 CUA3 12.01100 ! Carbon in double bond, third conjugated pair 
MASS 21 C5R 12.01100 ! Aromatic carbon in a five membered ring 
MASS 22 C6R 12.01100 ! Aromatic carbon in a six membered ring 
MASS 23 C5RE 13.01900 ! Extended aromatic carbon in five membered ring 
MASS 24 C6RE 13.01900 ! Extended aromatic carbon in six membered ring 
MASS 25 CR55 12.01100 ! Aromatic carbon-merged five membered rings 
MASS 26 CR56 12.01100 ! Aromatic carbon-merged five/six membered rings 
MASS 27 CR66 12.01100 ! Aromatic carbon-merged six membered rings 
MASS 28 C5RP 12.01100 ! for Aryl-Aryl bond between C5R rings 
MASS 29 C6RP 12.01100 ! for Aryl-Aryl bond between C6R rings 
MASS 30 N5RP 14.00670 ! for Ar-Ar bond between five membered rings 
MASS 31 N 14.00670 ! Nitrogen; planar-valence of 3, i. e. nitrile, et 
MASS 32 NP 14.00670 ! Nitrogen in peptide, amide, or related, group 
MASS 33 NX 14.00670 ! Proline nitrogen, or similar 
MASS 34 N5R 14.00670 ! Nitrogen in a five membered aromatic ring 
MASS 35 N6R 14.00670 ! Nitrogen in a six membered aromatic ring 
MASS 36 NT 14.00670 ! Nitrogen (tetrahedral), i. e. Amine, etc. 
MASS 37 NC 14.00670 ! Charged guanidinuim-type nitrogen 
MASS 38 N02 14.00670 ! Nitrogen in nitro, or related, group 
MASS 39 N6RP 14.00670 ! for Aryl-Aryl bond between six membered rings 
MASS 40 0 15.99940 ! Carbonyl oxygen for amides, or related structurý 
MASS 41 OA 15.99940 ! Carbonyl oxygen for aldehydes, or related struc 
MASS 42 OK 15.99940 ! Carbonyl oxygen for ketones, or related structu. 
MASS 43 OC 15.99940 ! Charged oxygen 
MASS 45 OT 15.99940 ! Hydroxyl oxygen (tetrahedral)/Ionizable acid o>ý: 
MASS 46 OW 15.99940 ! TIP3P water model oxygen 
MASS 47 OH2 15.99940 ! ST2 water model oxygen 
MASS 48 OM 15.99940 ! Carbo=onoxide, or other triply bonded, oxygen 
MASS 49 OS 15.99940 ! Ester oxygen 
MASS 50 OE 15.99940 ! Ether oxygen / Acetal oxygen 
MASS 51 OAC 15.99940 ! Carbonyl oxygen for acids 
MASS 52 05R 15.99940 ! Oxygen in five membered aromatic ring-radicals, 
MASS 53 06R 15.99940 ! Oxygen in aromatic ring - radicals etc. 
MASS 55 OSI 15.99940 ! Oxygen in Si-O-Si bond 
MASS 56 02M 15.99940 ! Oxygen in Si-O-Al or Al-O-Al bond 
MASS 57 OSH 0.00000 ! Massless 0 for zeolites, or related cage compou. 
MASS 60 PT 30.9738 ! Phosphorous, general; usually tetrahedral 
MASS 61 P03 30.9738 ! Phosphorous bonded to three oxygens 
MASS 62 P04 30.9738 ! Phosphorous bonded to four oxygens 
MASS 63 PUAl 30.9738 ! Phosphorous double bond 
MASS 64 P6R 30.9738 ! Phosphorous in aromatic 6-membered ring 
MASS 70 ST 32.06000 ! Sulphur, general; usually tetrahedral 
MASS 71 SHlE 33.06800 ! Extended atom sulphur with one hydrogen 
MASS 72 S5R 32.0600 ! Sulphur in a five membered aromatic ring 
MASS 73 S6R 32.0600 ! Sulphur in a six membered aromatic ring 
MASS 74 SE 32.060 ! Thioether sulphur 
MASS 75 SK 32.060 ! Thioketone sulphur 
MASS 76 Sol 32.0600 ! Sulphur bonded to one oxygen 
MASS 77 S02 32.0600 ! Sulphur bonded to two oxygens 
MASS 78 S03 32.0600 ! Sulphur bonded to three oxygens 
MASS 79 S04 32.0600 ! Sulphur bonded to four oxygens 
MASS 80 MLI 6.941 ! Lithium 
MASS 81 MNA 22.9898 ! Sodium 
MASS 82 MMG 24.305 ! Magnesiun 
MASS 83 MK 39.098 ! Potassium 
MASS 84 MCA 40.080 ! Calcium 
MASS 85 MMN 54.938 ! Manganese 
MASS 86 MFE 55.847 ! Iron 
MASS 87 MZN 65.38 ! Zinc 
MASS 88 MRB 85.4678 ! Rubidium 
MASS 89 MCS 132.9054 ! Cesium 
MASS 90 MSI 28.0855 ! Silicon 
MASS 91 MAL 26.9815 ! ALuminum 
MASS 92 XF 18.99840 ! Fluorine 
MASS 93 XCL 35.45300 ! Chlorine 
MASS 94 XBR 79.904 ! Bromine 
MASS 95 XI 126.9045 ! Iodine 
MASS 96 MCU 63.546 ! Copper 
MASS 97 MV 50.9415 ! Vanadium 
MASS 98 MCR 51.996 ! Chromium 
MASS 99 MCO 58.9332 ! Cobalt 
MASS 100 MNI 58.69 ! Nickel 
MASS 101 MAS 74.9216 ! Arsenic 
MASS 102 MSE 78.96 ! Selenium 
MASS 103 MSR 87.62 ! Strontium 
MASS 104 MY 88.9059 ! Yttrium 
MASS 105 MZR 91.22 ! Zirconium 
MASS 106 MNB 92.9064 ! Niobium 
MASS 107 MMO 95.94 ! molybdenum 
MASS 108 MRU 101.07 ! Ruthenium 
MASS 109 MRH 102.9055 ! Rhodium 
MASS 110 MPD 106.42 ! Palladium 
MASS ill MAG 107.868 ! Silver 
MASS 112 MCD 112.41 ! Cadmium 
MASS 113 MSN 118.69 ! Tin 
MASS 114 MSB 121.75 ! Antimony 
MASS 115 MBA 137.33 ! Barium 
MASS 116 MW 183.85 ! Tungsten 
MASS 117 MOS 190.2 ! Osmium 
MASS 118 MPT 195.08 ! Platinum 
MASS 119 MAU 196.08 ! Gold 
MASS 120 MHG 200.59 ! Mercury 
MASS 121 MPB 207.2 ! Lead 
MASS 122 MBI 208.9804 ! Bismuth 
MASS 123 MLA 138.9055 ! Lanthanum 
MASS 124 MCE 140.12 ! Cerium 
MASS 125 MPR 140.9077 ! Praseodymium 
MASS 126 MAC 227.0278 ! Actinium 
MASS 127 MTH 232.0381 ! Thorium 
MASS 128 MU 238.0289 ! Uranium 
MASS 129 MTE 127.60 ! Tellurium 
MASS 130 MPO 209.0 ! Polonium 
MASS 131 XAT 210.0 ! Astatine 
MASS 132 MTC 98.0 ! Technetium 
MASS 133 MSC 44.9559 ! Scandium 
MASS 134 MTI 47.88 ! Titanium 
MASS 135 MGA 69.72 ! Gallium 
MASS 136 MGE 72.59 ! Germanium 
MASS 137 MIN 114.82 ! Indium 
MASS 138 MHF 178.49 ! Hafnium 
MASS 139 MTA 180.9479 ! Tantalum 
MASS 140 MIR 192.22 ! Iridium 
MASS 141 MTL 204.383 ! Thallium 
MASS 142 MFR 223.0 ! Francium 
MASS 143 MRA 226.0254 ! Radium 
MASS 144 MND 144.24 ! Neodymium 
MASS 145 MPM 145.0 ! Promethium 
MASS 146 MSM 150.36 ! Samarium 
MASS 147 MEU 151.96 ! Europium 
MASS 148 MGD 157.25 ! Gadolinium 
MASS 149 MTB 158.9254 ! Terbium 
MASS 150 MDY 162.50 ! Dysprosium 
MASS 151 MHO 164.9304 ! Holmium 
MASS 152 MER 167.26 ! Erbium 
MASS 153 MTM 168.9342 ! Thulium 
MASS 154 MYB 173.04 ! Ytterbium 
MASS 155 MLU 174.967 ! Lutetium 
MASS 156 MPA 231.0359 ! Protactinium 
MASS 157 MNP 237.0482 ! Neptunium 
MASS 158 MPU 244.0 ! Plutonium 
MASS 159 MAM 243.0 ! Americium 
MASS 160 MCM 247.0 ! Curium 
MASS 161 MBK 247.0 ! Berkelium 
MASS 162 MCF 251.0 ! Californium 
MASS 163 MES 252.0 ! Einsteinium 
MASS 164 MFM 257.0 ! Fermium 
MASS 165 MMD 258.0 ! Medelevium 
MASS 166 MNO 259.0 ! Nobelium 
MASS 167 MLR 260.0 ! Lawrencium 
MASS 168 HE 4.00260 ! Helium 
MASS 169 NE 20.179 ! Neon 
MASS 170 AR 39.948 ! Argon 
MASS 171 KR 83.80 ! Krypton 
MASS 172 XE 131.29 ! Xenon 
MASS 173 RN 222.0 ! Radon 
MASS 174 MRF 261.0 ! Rutherfordium/Kurchatovium, 
MASS 175 MHA 262.0 ! Hahnium 
MASS 176 MRE 186.31 ! Rhenium, 
MASS 177 MSIU 28.08550 ! Silicon when as double bond 
MASS 180 NR56 14.00670 !N at fused bond between 5 and 6-membered aromat. 
MASS 181 NR66 14.00670 !N at fused bond between two 6-membered aromatic, 
MASS 182 NR55 14.00670 !N at fused bond between two 5-membered aromaticý 
MASS 183 NRI 14.00670 ! Protonated nitrogen in neutral histidine ring 
MASS 184 NR2 14.00670 ! Unprotonated nitrogen in neutral histidine ring 
MASS 185 NR3 14.00670 ! Nitrogens in charged histidine ring 
MASS 186 NC2 14.00670 ! for neutral guanidinium, group - Arg sidechain 
MASS 189 C5RQ 12.01100 ! for second Ar-Ar bond between C5RP rings (ortho, 
MASS 190 C3 12.01100 ! Carbonyl carbon in 3-membered aliphatic ring 
MASS 191 CT3 12.01100 !C in 3-membered aliphatic ring, usually tetraheý 
MASS 192 C4 12.01100 ! Carbonyl carbons in 4-membered aliphatic ring 
MASS 193 CT4 12.01100 !C in 4-membered aliphatic ring, usually tetrahe. 
MASS 194 C6RQ 12.01100 ! Carbon of C6RP type ortho to C6RP pair 
MASS 195 CQ66 12.01100 ! Third adjacent pair of CR66 types in fused ring 
MASS 196 CS66 12.01100 ! Second adjacent pair of CR66 types in fused rin, 
MASS 197 CPH1 12.01100 ! CG and CD2 carbons in histidine ring 
MASS 198 CPH2 12.01100 ! CE1 carbon in histidine ring 
MASS 199 CP3 12.01100 ! Carbon on nitrogen in proline ring 
AUTOGENERATE ANGLES DIHE 
DEFA FIRS NONE LAST NONE 
RESI phs -1.520 
GROUP 
ATOM P P04 1.36 
ATOM OP1 OC -0.72 
ATOM OP2 OC -0.72 
ATOM OP3 OC -0.72 
ATOM OP4 OC -0.72 
BOND P OP1 
BOND P OP2 
BOND P OP3 
BOND P OP4 
ACCE OP1 P 
ACCE OP2 P 
ACCE OP3 P 
ACCE ON P 
n. b. these taken from DNA. RTF's for Thimine 
taken on 3.10.91 
note much higher charge than old RTFIs 
END 
Proprietory and Confidential Property of Polygen Corporation 
TEMPLATE FOR CREATING CHARMm RTF file (from ChemNote) 
(% 
- m) replaced 
by first 4 characters of molecule name 
(%_r) replaced by RTF format of residue definition 
Build RTF for dum 
*'ýsidue definition in RTF format built inline r 
21 3 
MASS 1 H 1.00800 ! Hydrogen bonding hydrogen (neutral group) 
MASS 2 HC 1.00800 ! Hydrogen bonding hydrogen (charged group) 
MASS 3 HA 1.00800 ! Aliphatic or aromatic hydrogen 
MASS 4 HT 1.00800 ! TIPS3P water model hydrogen 
MASS 5 LP 0.0 ! ST2 lone pair 
MASS 6 MBE 9.01218 ! Beryllium 
MASS 7 B 10.81 ! Boron 
MASS 8 HO 1.00800 ! Hydrogen on an alcohol oxygen 
MASS 9 HMU 1.00800 ! Mu-bonded hydrogen for metals and boron-hydride. - 
MASS 10 CT 12.01100 ! Aliphatic carbon (tetrahedral) 
MASS 11 CHlE 13.01900 ! Extended atom carbon with one hydrogen 
MASS 12 CH2E 14.02700 ! Extended atom carbon with two hydrogens 
MASS 13 CH3E 15.03500 ! Extended atom carbon with three hydrogens 
MASS 14 C 12.01100 ! Carbonyl or Guanidinium carbon 
MASS 15 CM 12.01100 ! Carbonmonoxide, or other triply bonded, carbon 
MASS 16 CUAl 12.01100 ! Carbon in double bond, first pair 
MASS 17 CUA2 12.01100 ! Carbon in double bond, second conjugated pair 
MASS 18 CuYl 12.01100 ! Carbon in triple bond, first pair 
MASS 19 CUY2 12.01100 ! Carbon in triple bond, second conjugated pair 
MASS 20 CUA3 12.01100 ! Carbon in double bond, third conjugated pair 
MASS 21 C5R 12.01100 ! Aromatic carbon in a five membered ring 
MASS 22 C6R 12.01100 ! Aromatic carbon in a six membered ring 
MASS 23 C5RE 13.01900 ! Extended aromatic carbon in five membered ring 
MASS 24 C6RE 13.01900 ! Extended aromatic carbon in six membered ring 
MASS 25 CR55 12.01100 ! Aromatic carbon-merged five membered rings 
MASS 26 CR56 12.01100 ! Aromatic carbon-merged five/six membered rings 
MASS 27 CR66 12.01100 ! Aromatic carbon-merged six membered rings 
MASS 28 C5RP 12.01100 ! for Aryl-Aryl bond between C5R rings 
MASS 29 C6RP 12.01100 ! for Aryl-Aryl bond between C6R rings 
MASS 30 N5RP 14.00670 ! for Ar-Ar bond between five membered rings 
MASS 31 N 14.00670 ! Nitrogen; planar-valence of 3, i. e. nitrile, et 
MASS 32 NP 14.00670 ! Nitrogen in peptide, amide, or related, group 
MASS 33 NX 14.00670 ! Proline nitrogen, or similar 
MASS 34 N5R 14.00670 ! Nitrogen in a five membered aromatic ring 
MASS 35 N6R 14.00670 ! Nitrogen in a six membered aromatic ring 
MASS 36 NT 14.00670 ! Nitrogen (tetrahedral), i. e. Amine, etc. 
MASS 37 NC 14.00670 ! Charged guanidinuim-type nitrogen 
MASS 38 N02 14.00670 ! Nitrogen in nitro, or related, group 
MASS 39 N6RP 14.00670 ! for Aryl-Aryl bond between six membered rings 
MASS 40 0 15.99940 ! Carbonyl oxygen for amides, or related structur' 
MASS 41 OA 15.99940 ! Carbonyl oxygen for aldehydes, or related struc' 
MASS 42 OK 15.99940 ! Carbonyl oxygen for ketones, or related structu. 
MASS 43 OC 15.99940 ! Charged oxygen 
MASS 45 OT 15.99940 ! Hydroxyl oxygen (tetrahedral)/Ionizable acid ox. 
MASS 46 OW 15.99940 ! TIP3P water model oxygen 
MASS 47 OH2 15.99940 ! ST2 water model oxygen 
MASS 48 OM 15.99940 ! Carbonmonoxide, or other triply bonded, oxygen 
MASS 49 OS 15.99940 ! Ester oxygen 
MASS 50 OE 15.99940 ! Ether oxygen / Acetal oxygen 
MASS 51 OAC 15.99940 ! Carbonyl oxygen for acids 
MASS 52 05R 15.99940 ! Oxygen in five membered aromatic ring-radicals, 
MASS 53 06R 15.99940 ! Oxygen in aromatic ring - radicals etc. 
MASS 55 OSI 15.99940 ! Oxygen in Si-O-Si bond 
MASS 56 02M 15.99940 ! Oxygen in Si-O-Al or Al-O-Al bond 
MASS 57 OSH 0.00000 ! Massless 0 for zeolites, or related cage compouý 
MASS 60 PT 30.9738 ! Phosphorous, general; usually tetrahedral 
MASS 61 P03 30.9738 ! Phosphorous bonded to three oxygens 
MASS 62 P04 30.9738 ! Phosphorous bonded to four oxygens 
MASS 63 PUAl 30.9738 ! Phosphorous double bond 
MASS 64 P6R 30.9738 ! Phosphorous in aromatic 6-membered ring 
MASS 70 ST 32.06000 ! Sulphur, general; usually tetrahedral 
MASS 71 SHlE 33.06800 ! Extended atom sulphur with one hydrogen 
MASS 72 S5R 32.0600 ! Sulphur in a five membered aromatic ring 
MASS 73 S6R 32.0600 ! Sulphur in a six membered aromatic ring 
MASS 74 SE 32.060 ! Thioether sulphur 
MASS 75 SK 32.060 ! Thioketone sulphur 
MASS 76 Sol 32.0600 ! Sulphur bonded to one oxygen 
MASS 77 S02 32.0600 ! Sulphur bonded to two oxygens 
MASS 78 S03 32.0600 ! Sulphur bonded to three oxygens 
MASS 79 S04 32.0600 ! Sulphur bonded to four oxygens 
MASS 80 MLI 6.941 ! Lithium 
MASS 81 MNA 22.9898 ! Sodium 
MASS 82 MMG 24.305 ! Magnesiun 
MASS 83 MK 39.098 ! Potassium 
MASS 84 MCA 40.080 ! Calcium 
MASS 85 MMN 54.938 ! Manganese 
MASS 86 MFE 55.847 ! Iron 
MASS 87 MZN 65.38 ! Zinc 
MASS 88 MRB 85.4678 ! Rubidium. 
MASS 89 MCS 132.9054 ! Cesium 
MASS 90 MSI 28.0855 ! Silicon 
MASS 91 MAL 26.9815 ! ALuminum 
MASS 92 XF 18.99840 ! Fluorine 
MASS 93 XCL 35.45300 ! Chlorine 
MASS 94 XBR 79.904 ! Bromine 
MASS 95 XI 126.9045 ! Iodine 
MASS 96 MCU 63.546 ! Copper 
MASS 97 MV 50.9415 ! Vanadium 
MASS 98 MCR 51.996 ! Chromium 
MASS 99 MCO 58.9332 ! Cobalt 
MASS 100 MNI 58.69 ! Nickel 
MASS 101 MAS 74.9216 ! Arsenic 
MASS 102 MSE 78.96 ! Selenium 
MASS 103 MSR 87.62 ! Strontium 
MASS 104 MY 88.9059 ! Yttrium. 
MASS 105 MZR 91.22 ! Zirconium 
MASS 106 MNB 92.9064 ! Niobium, 
MASS 107 MMO 95.94 ! Molybdenum 
MASS 108 MRU 101.07 ! Ruthenium 
MASS 109 MRH 102.9055 ! Rhodium 
MASS 110 MPD 106.42 1 Palladium 
MASS 111 MAG 107.868 ! Silver 
MASS 112 MCD 112.41 ! Cadmium 
MASS 113 MSN 118.69, ! Tin 
MASS 114 MSB 121.75 ! Antimony 
MASS 115 MBA 137.33 ! Barium 
MASS 116 MW 183.85 ! Tungsten 
MASS 117 MOS 190.2 ! Osmium 
MASS 118 MPT 195.08 ! Platinum 
MASS 119 MAU 196.08 ! Gold 
MASS 120 MHG 200.59 ! Mercury 
MASS 121 MPB 207.2 ! Lead 
MASS 122 MBI 208.9804 ! Bismuth 
MASS 123 MLA 138.9055 ! Lanthanum 
MASS 124 MCE 140.12 ! Cerium 
MASS 125 MPR 140.9077 ! Praseodymium 
MASS 126 MAC 227.0278 Actinium 
MASS 127 MTH 232.0381 Thorium 
MASS 128 MU 238.0289 Uranium 
MASS 129 MTE 127.60 Tellurium 
MASS 130 MPO 209.0 Polonium 
MASS 131 XAT 210.0 Astatine 
MASS 132 MTC 98.0 Technetium 
MASS 133 MSC 44.9559 Scandium 
MASS 134 MTI 47.88 ! Titanium 
MASS 135 MGA 69.72 ! Gallium 
MASS 136 MGE 72.59 ! Germanium 
MASS 137 MIN 114.82 ! Indium 
MASS 138 MHF 178.49 ! Hafnium 
MASS 139 MTA 180.9479 ! Tantalum 
MASS 140 MIR 192.22 ! Iridium 
MASS 141 MTL 204.383 ! Thallium 
MASS 142 MFR 223.0 ! Francium 
MASS 143 MRA 226.0254 ! Radium 
MASS 144 MND 144.24 ! Neodymium 
MASS 145 MPM 145.0 ! Promethium 
MASS 146 MSM 150.36 ! Samarium 
MASS 147 MEU 151.96 ! Europium 
MASS 148 MGD 157.25 ! Gadolinium 
MASS 149 MTB 158.9254 ! Terbium 
MASS 150 MDY 162.50 ! Dysprosium 
MASS 151 MHO 164.9304 ! Holmium 
MASS 152 MER 167.26 ! Erbium 
MASS 153 MTM 168.9342 ! Thulium 
MASS 154 MYB 173.04 ! Ytterbium 
MASS 155 MLU 174.967 ! Lutetium 
MASS 156 MPA 231.0359 ! Protactinium 
MASS 157 MNP 237.0482 ! Neptunium 
MASS 158 MPU 244.0 ! Plutonium 
MASS 159 MAM 243.0 ! Americium 
MASS 160 MCM 247.0 ! Curium 
MASS 161 MBK 247.0 ! Berkelium 
MASS 162 MCF 251.0 ! Californium 
MASS 163 MES 252.0 ! Einsteinium 
MASS 164 MFM 257.0 ! Fermium 
MASS 165 MMD 258.0 ! Medelevium 
MASS 166 MNO 259.0 ! Nobelium 
MASS 167 MLR 260.0 ! Lawrencium 
MASS 168 HE 4.00260 ! Helium 
MASS 169 NE 20.179 ! Neon 
MASS 170 AR 39.948 ! Argon 
MASS 171 KR 83.80 ! Krypton 
MASS 172 XE 131.29 ! Xenon 
MASS 173 RN 222.0 ! Radon 
MASS 174 MRF 261.0 ! Rutherfordium/Kurchatovium 
MASS 175 MHA 262.0 ! Hahnium, 
MASS 176 MRE 186.31 ! Rhenium 
MASS 177 MSIU 28.08550 ! Silicon when as double bond 
MASS 180 NR56 14.00670 ! N at fused bond between 5 and 6-membered aromat 
MASS 181 NR66 14.00670 ! N at fused bond between two 6-membered aromatic 
MASS 182 NR55 14.00670 ! N at fused bond between two 5-membered aromatic 
MASS 183 NRl 14.00670 ! Protonated nitrogen in neutral histidine ring 
MASS 184 NR2 14.00670 ! Unprotonated nitrogen in neutral histidine ring 
MASS 185 NR3 14.00670 ! Nitrogens in charged histidine ring 
MASS 186 NC2 14.00670 ! for neutral guanidinium group - Arg sidechain 
MASS 189 C5RQ 12.01100 ! for second Ar-Ar bond between C5RP rings (ortho 
MASS 190 C3 12.01100 ! Carbonyl carbon in 3-membered aliphatic ring 
MASS 191 CT3 12.01100 ! C in 3-membered aliphatic ring, usually tetrahe 
MASS 192 C4 12.01100 ! Carbonyl carbons in 4-membered aliphatic ring 
MASS 193 CT4 12.01100 ! C in 4-membered aliphatic ring, usually tetrahe 
MASS 194 C6RQ 12.01100 ! Carbon of C6RP type ortho to C6RP pair 
MASS 195 CQ66 12.01100 ! Third adjacent pair of CR66 types in fused ring 
MASS 196 CS66 12.01100 ! Second adjacent pair of CR66 types in fused rin 
MASS 197 CPH1 12.01100 ! CG and CD2 carbons in histidine ring 
MASS 198 CPH2 12.01100 ! CE1 carbon in histidine ring 
MASS 199 CP3 12.01100 ! Carbon on nitrogen in proline ring 
AUTOGENERATE ANGLES DIHE 
DEFA FIRS NONE LAST NONE 
RESI DUM -1.000 
GROUP 
ATOM P P04 1.356 
ATOM OP1 OT -0.603 
ATOM OP2 OC -0.623 
ATOM OP3 OC -0.623 
ATOM OR5 OS -0.463 
ATOM CR5 CH2E 0.067 
ATOM CR4 CHlE 0.097 
ATOM CR3 CHlE -0.003 
ATOM OR3 OT -0.653 
ATOM CR2 CH2E 0.067 
ATOM CR1 CHIE 0.197 
ATOM OR1 OE -0.373 
ATOM Nl N6R -0.183 
ATOM C2 C 0.797 
ATOM 02 0 -0.553 
ATOM N3 NP -0.813 
ATOM C4 C 0.867 
ATOM 04 0 -0.553 
ATOM C5 C6RE -0.293 
ATOM C6 C6RE 0.257 
ATOM H21 H 0.397 
ATOM H24 HO 0.187 
ATOM H25 H 0.447 
BOND P OP1 
BOND OP1 H21 
BOND P OP2 
BOND P OP3 
BOND P OR5 
BOND OR5 CR5 
BOND CR5 CR4 
BOND CR4 CR3 
BOND CR3 OR3 
BOND OR3 H24 
BOND CR3 CR2 
BOND CR2 CR1 
BOND CR1 OR1 
BOND ORI CR4 
BOND CR1 Nl 
BOND Nl C2 
BOND C2 02 
BOND C2 N3 
BOND N3 C4 
BOND C4 04 
BOND C4 C5 
BOND C5 C6 
BOND C6 Nl 
BOND N3 H25 
IMPH C6 Nl C2 
IMPH Nl C2 N3 
IMPH C2 N3 C4 
IMPH N3 C4 C5 
IMPH C4 C5 C6 
IMPH C5 C6 Nl 
IMPH CR4 CR5 
IMPH CR3 CR4 
IMPH CR1 CR2 
IMPH Nl C2 C6 
IMPH C2 N3 Nl 
IMPH N3 C2 C4 
IMPH C4 C5 N3 
DONO H21 OP1 
DONO H24 OR3 
DONO H25 N3 
ACCE OP1 
ACCE OP2 P 
ACCE OP3 P 
ACCE OR5 
ACCE OR1 
ACCE OR3 
ACCE Nl 
ACCE 02 C2 
ACCE N3 
ACCE 04 C4 
N3 
C4 
C5 
C6 
Nl 
C2 
CR3 OR1 
OR3 CR2 
OR1 Nl 
CR1 
02 
H25 
04 
IC OP2 P OP1 H21 
Ic OP3 P OP1 H21 
IC OR5 P OP1 H21 
IC OP1 P OR5 CR5 
IC OP2 P OR5 CR5 
IC OP3 P OR5 CR5 
IC P OR5 CR5 CR4 
IC OR5 CR5 CR4 CR3 
IC OR5 CR5 CR4 OR1 
IC CR5 CR3 *CR4 OR1 
IC CR5 CR4 CR3 OR3 
1.69 108.84 -84.98 109.47 1.09 
1.65 107.56 154.72 109.47 1.09 
1.61 106.58 25.39 109.47 1.09 
1.51 106.58 78.38 125.71 1.41 
1.69 102.92 -167.17 125.71 1.41 
1.65 119.55 -43.67 125.71 1.41 
1.61 125.71 102.01 134.13 1.30 
1.41 134.13 148.15 112.42 1.50 
1.41 134.13 2.99 131.90 1.52 
1.30 112.42 153.43 108.06 1.52 
1.30 112.42 109.52 110.86 0.86 
IC OR1 CR4 CR3 OR3 1.52 108.06 -97.06 110.86 0.86 
IC CR5 CR4 CR3 CR2 1.30 112.42 -132.26 105.06 1.56 
IC CR4 OR3 *CR3 CR2 1.50 110.86 -115.48 109.53 1.56 
IC CR4 CR3 OR3 H24 1.50 110.86 157.43 109.47 1.09 
IC CR2 CR3 OR3 H24 1.56 109.53 41.95 109.47 1.09 
IC CR4 CR3 CR2 CR1 1.50 105.06 -29.99 103.88 1.45 
IC OR3 CR3 CR2 CR1 0.86 109.53 89.13 103.88 1.45 
IC CR3 CR2 CR1 OR1 1.56 103.88 27.85 109.82 1.54 
IC CR3 CR2 CR1 Nl 1.56 103.88 177.44 114.65 1.55 
IC CR2 OR1 *CR1 Nl 1.45 109.82 -145.04 126.58 1.55 
IC CR2 CR1 OR1 CR4 1.45 109.82 -15.08 104.13 1.52 
IC Nl CR1 ORI CR4 1.55 126.58 -160.12 104.13 1.52 
IC CR1 OR1 CR4 CR5 1.54 104.13 141.46 131.90 1.30 
IC CR1 OR1 CR4 CR3 1.54 104.13 -4.79 108.06 1.50 
IC CR2 CR1 Nl C2 1.45 114.65 68.26 121.20 1.53 
IC OR1 CRI Nl C2 1.54 126.58 -148.12 121.20 1.53 
IC CR2 CR1 NI C6 1.45 114.65 -111.69 120.72 1.39 
IC CR1 C2 *Nl C6 1.55 121.20 179.96 118.08 1.39 
IC CR1 Nl C2 02 1.55 121.20 -3.46 132.99 1.11 
Ic C6 NI C2 02 1.39 118.08 176.50 132.99 1.11 
IC CR1 Nl C2 N3 1.55 121.20 175.44 109.39 1.44 
IC Nl 02 *C2 N3 1.53 132.99 -178.83 117.61 1.44 
IC Nl C2 N3 C4 1.53 109.39 4.51 130.33 1.45 
IC 02 C2 N3 C4 1.11 117.61 -176.39 130.33 1.45 
IC Nl C2 N3 H25 1.53 109.39 -175.47 114.84 1.09 
IC C2 C4 *N3 H25 1.44 130.33 179.98 114.83 1.09 
IC C2 N3 C4 04 1.44 130.33 177.71 125.69 1.27 
IC H25 N3 C4 04 1.09 114.83 -2.31 125.69 1.27 
IC C2 N3 C4 C5 1.44 130.33 -2.01 117.07 1.47 
IC N3 04 *C4 C5 1.45 125.69 179.72 117.23 1.47 
IC N3 C4 C5 C6 1.45 117.07 -0.57 112.55 1.38 
IC 04 C4 C5 C6 1.27 117.23 179.69 112.55 1.38 
IC C4 C5 C6 Nl 1.47 112.55 -0.19 132.40 1.39 
IC C5 C6 Nl CR1 1.38 132.40 -176.95 120.72 1.55 
IC C5 C6 Nl C2 1.38 132.40 3.09 118.08 1.53 
END 
Pýýprietory and Confidential Property of Polygen Corporation 
T. 
iý. 
PLATE FOR CREATING CHARMm RTF file (from ChemNote) 
(%_jn) replaced by first 4 characters of molecule name 
(%_r) replaced by RTF format of residue definition 
Build RTF for CB3 
* ýýs idue definition in RTF format built inline 
21 3 
MASS 1 H 1.00800 ! Hydrogen bonding hydrogen (neutral group) 
MASS 2 HC 1.00800 ! Hydrogen bonding hydrogen (charged group) 
MASS 3 HA 1.00800 ! Aliphatic or aromatic hydrogen 
MASS 4 HT 1.00800 ! TIPS3P water model hydrogen 
MASS 5 LP 0.0 ! ST2 lone pair 
MASS 6 MBE 9.01218 ! Beryllium 
MASS 7 B 10.81 ! Boron 
MASS 8 HO 1.00800 ! Hydrogen on an alcohol oxygen 
MASS 9 HMU 1.00800 ! Mu-bonded hydrogen for metals and boron-hydride, ' 
MASS 10 CT 12.01100 ! Aliphatic carbon (tetrahedral) 
MASS 11 CHlE 13.01900 ! Extended atom carbon with one hydrogen 
MASS 12 CH2E 14.02700 ! Extended atom carbon with two hydrogens 
MASS 13 CH3E 15.03500 ! Extended atom carbon with three hydrogens 
MASS 14 C 12.01100 ! Carbonyl or Guanidinium carbon 
MASS 15 CM 12.01100 ! Carbonmonoxide, or other triply bonded, carbon 
MASS 16 CUA1 12.01100 ! Carbon in double bond, first pair 
MASS 17 CUA2 12.01100 ! Carbon in double bond, second conjugated pair 
MASS 18 CuYl 12.01100 ! Carbon in triple bond, first pair 
MASS 19 CUY2 12.01100 ! Carbon in triple bond, second conjugated pair 
MASS 20 CUA3 12.01100 ! Carbon in double bond, third conjugated pair 
MASS 21 C5R 12.01100 ! Aromatic carbon in a five membered ring 
MASS 22 C6R 12.01100 ! Aromatic carbon in a six membered ring 
MASS 23 C5RE 13.01900 ! Extended aromatic carbon in five membered ring 
MASS 24 C6RE 13.01900 ! Extended aromatic carbon in six membered ring 
MASS 25 CR55 12.01100 ! Aromatic carbon-merged five membered rings 
MASS 26 CR56 12.01100 ! Aromatic carbon-merged five/six membered rings 
MASS 27 CR66 12.01100 ! Aromatic carbon-merged six membered rings 
MASS 28 C5RP 12.01100 ! for Aryl-Aryl bond between C5R rings 
MASS 29 C6RP 12.01100 ! for Aryl-Aryl bond between C6R rings 
MASS 30 N5RP 14.00670 ! for Ar-Ar bond between five membered rings 
MASS 31 N 14.00670 ! Nitrogen; planar-valence of 3, i. e. nitrile, et 
MASS 32 NP 14.00670 ! Nitrogen in peptide, amide, or related, group 
MASS 33 NX 14.00670 ! Proline nitrogen, or similar 
MASS 34 N5R 14.00670 ! Nitrogen in a five membered aromatic ring 
MASS 35 N6R 14.00670 ! Nitrogen in a six membered aromatic ring 
MASS 36 NT 14.00670 ! Nitrogen (tetrahedral), i. e. Amine, etc. 
MASS 37 NC 14.00670 ! Charged guanidinuim-type nitrogen 
MASS 38 N02 14.00670 ! Nitrogen in nitro, or related, group 
MASS 39 N6RP 14.00670 ! for Aryl-Aryl bond between six membered rings 
MASS 40 0 15.99940 ! Carbonyl oxygen for amides, or related structur 
MASS 41 OA 15.99940 ! Carbonyl oxygen for aldehydes, or related strut 
MASS 42 OK 15.99940 ! Carbonyl oxygen for ketones, or related structu 
MASS 43 OC 15.99940 ! Charged oxygen 
" MASS 45 OT 15.99940 ! Hydroxyl oxygen (tetrahedral)/Ionizable acid ox, 
MASS 46 OW 15.99940 ! TIP3P water model oxygen 
MASS 47 OH2 15.99940 
MASS 48 OM 15.99940 
MASS 49 OS 15.99940 
MASS 50 OE 15.99940 
MASS 51 OAC 15.99940 
MASS 52 05R 15.99940 
MASS 53 06R 15.99940 
MASS 55 OSI 15.99940 
MASS 56 02M 15.99940 
MASS 57 OSH 0.00000 
MASS 60 PT 30.9738 
MASS 61 P03 30.9738 
MASS 62 P04 30.9738 
MASS 63 PUAl 30.9738 
MASS 64 P6R 30.9738 
MASS 70 ST 32.06000 
MASS 71 SHlE 33.06800 
MASS 72 S5R 32.0600 
MASS 73 S6R 32.0600 
MASS 74 SE 32.060 
MASS 75 SK 32.060 
MASS 76 Sol 32.0600 
MASS 77 S02 32.0600 
MASS 78 S03 32.0600 
MASS 79 S04 32.0600 
MASS 80 MLI 6.941 
MASS 81 MNA 22.9898 
MASS 82 MMG 24.305 
MASS 83 MK 39.098 
MASS 84 MCA 40.080 
MASS 85 MMN 54.938 
MASS 86 MFE 55.847 
MASS 87 MZN 65.38 
MASS 88 MRB 85.4678 
MASS 89 MCS 132.9054 
MASS 90 msi 28.0855 
MASS 91 MAL 26.9815 
MASS 92 XF 18.99840 
MASS 93 XCL 35.45300 
MASS 94 XBR 79.904 
MASS 95 XI 126.9045 
MASS 96 MCU 63.546 
MASS 97 MV 50.9415 
MASS 98 MCR 51.996 
MASS 99 mco 58.9332 
MASS 100 MNI 58.69 
MASS 101 MAS 74.9216 
MASS 102 MSE 78.96 
MASS 103 MSR 87.62 
MASS 104 MY 88.9059 
MASS 105 MZR 91.22 
MASS 106 MNB 92.9064 
MASS 107 MMO 95.94 
MASS 108 MRU 101.07 
MASS 109 MRH 102.9055 
MASS 110 MPD 106.42 
MASS ill MAG 107.868 
MASS 112 MCD 112.41 
ST2 water model oxygen 
Carbonmonoxide, or other triply bonded, oxygen 
Ester oxygen 
Ether oxygen / Acetal oxygen 
Carbonyl oxygen for acids 
Oxygen in five membered aromatic ring-radicals, 
Oxygen in aromatic ring - radicals etc. 
Oxygen in Si-O-Si bond 
Oxygen in Si-O-Al or Al-O-Al bond 
Massless 0 for zeolites, or related cage compou, 
Phosphorous, general; usually tetrahedral 
Phosphorous bonded to three oxygens 
Phosphorous bonded to four oxygens 
Phosphorous double bond 
Phosphorous in aromatic 6-membered ring 
Sulphur, general; usually tetrahedral 
Extended atom sulphur with one hydrogen 
Sulphur in a five membered aromatic ring 
Sulphur in a six membered aromatic ring 
Thioether sulphur 
Thioketone sulphur 
Sulphur bonded to one oxygen 
Sulphur bonded to two oxygens 
Sulphur bonded to three oxygens 
Sulphur bonded to four oxygens 
Lithium 
Sodium 
Magnesiun 
Potassium 
Calcium 
Manganese 
Iron 
Zinc 
Rubidium. 
Cesium 
Silicon 
ALuminum. 
Fluorine 
Chlorine 
Bromine 
Iodine 
Copper 
Vanadium 
Chromium 
Cobalt 
Nickel 
Arsenic 
Selenium 
Strontium 
Yttrium 
Zirconium 
Niobium 
Molybdenum 
Ruthenium 
Rhodium 
Palladium 
Silver 
Cadmium 
MASS 113 MSN 118.69 ! Tin 
MASS 114 MSB 121.75 ! Antimony 
MASS 115 MBA 137.33 ! Barium 
MASS 116 MW 183.85 ! Tungsten 
MASS 117 MOS 190.2 ! Osmium 
MASS 118 MPT 195.08 ! Platinum 
MASS 119 MAU 196.08 ! Gold 
MASS 120 MHG 200.59 ! Mercury 
MASS 121 MPB 207.2 ! Lead 
MASS 122 MBI 208.9804 ! Bismuth 
MASS 123 MLA 138.9055 ! Lanthanum 
MASS 124 MCE 140.12 ! Cerium 
MASS 125 MPR 140.9077 ! Praseodymium 
MASS 126 MAC 227.0278 ! Actinium 
MASS 127 MTH 232.0381 ! Thorium 
MASS 128 MU 238.0289 ! Uranium 
MASS 129 MTE 127.60 ! Tellurium 
MASS 130 MPO 209.0 ! Polonium 
MASS 131 XAT 210.0 ! Astatine 
MASS 132 MTC 98.0 ! Technetium 
MASS 133 MSC 44.9559 ! Scandium 
MASS 134 MTI 47.88 ! Titanium 
MASS 135 MGA 69.72 ! Gallium 
MASS 136 MGE 72.59 ! Germanium 
MASS 137 MIN 114.82 ! Indium 
MASS 138 MHF 178.49 ! Hafnium 
MASS 139 MTA 180.9479 ! Tantalum 
MASS 140 MIR 192.22 ! Iridium 
MASS 141 MTL 204.383 ! Thallium 
MASS 142 MFR 223.0 ! Francium 
MASS 143 MRA 226.0254 ! Radium 
MASS 144 MND 144.24 ! Neodymium 
MASS 145 MPM 145.0 ! Promethium 
MASS 146 MSM 150.36 ! Samarium 
MASS 147 MEU 151.96 ! Europium 
MASS 148 MGD 157.25 ! Gadolinium 
MASS 149 MTB 158.9254 ! Terbium 
MASS 150 MDY 162.50 ! Dysprosium 
MASS 151 MHO 164.9304 ! Holmium 
MASS 152 MER 167.26 ! Erbium 
MASS 153 MTM 168.9342 ! Thulium 
MASS 154 MYB 173.04 ! Ytterbium 
MASS 155 MLU 174.967 ! Lutetium 
MASS 156 MPA 231.0359 ! Protactinium 
MASS 157 MNP 237.0482 ! Neptunium 
MASS 158 MPU 244.0 ! Plutonium 
MASS 159 MAM 243.0 ! Americium 
MASS 160 MCM 247.0 ! Curium 
MASS 161 MBK 247.0 ! Berkelium 
MASS 162 MCF 251.0 ! Californium 
MASS 163 MES 252.0 ! Einsteinium 
MASS 164 MFM 257.0 ! Fermium 
MASS 165 MMD 258.0 ! Medelevium 
MASS 166 MNO 259.0 ! Nobelium 
MASS 167 MLR 260.0 ! Lawrencium 
MASS 168 HE 4.00260 ! Helium 
MASS 169 NE 20.179 ! Neon 
MASS 170 AR 39.948 ! Argon 
MASS 171 KR 83.80 ! Krypton 
MASS 172 XE 131.29 ! Xenon 
MASS 173 RN 222.0 ! Radon 
MASS 174 MRF 261.0 ! Rutherfordium/Kurchatovium 
MASS 175 MHA 262.0 ! Hahnium. 
MASS 176 MRE 186.31 ! Rhenium. 
MASS 177 MSIU 28.08550 ! Silicon when as double bond 
MASS 180 NR56 14.00670 !N at fused bond between 5 and 6-membered aromat 
MASS 181 NR66 14.00670 !N at fused bond between two 6-membered aromatic, 
MASS 182 NR55 14.00670 !N at fused bond between two 5-membered aromatic 
MASS 183 NR1 14.00670 ! Protonated nitrogen in neutral histidine ring 
MASS 184 NR2 14.00670 ! Unprotonated nitrogen in neutral histidine ring 
MASS 185 NR3 14.00670 ! Nitrogens in charged histidine ring 
MASS 186 NC2 14.00670 ! for neutral guanidinium group - Arg sidechain 
MASS 189 C5RQ 12.01100 ! for second Ar-Ar bond between C5RP rings (ortho 
MASS 190 C3 12.01100 ! Carbonyl carbon in 3-membered aliphatic ring 
MASS 191 CT3 12.01100 !C in 3-membered aliphatic ring, usually tetrahe, 
MASS 192 C4 12.01100 ! Carbonyl carbons in 4-membered aliphatic ring 
MASS 193 CT4 12.01100 !C in 4-membered aliphatic ring, usually tetrahe 
MASS 194 C6RQ 12.01100 ! Carbon of C6RP type ortho to C6RP pair 
MASS 195 CQ66 12.01100 ! Third adjacent pair of CR66 types in fused ring 
MASS 196 CS66 12.01100 ! Second adjacent pair of CR66 types in fused rin,,. 
MASS 197 CPH1 12.01100 ! CG and CD2 carbons in histidine ring 
MASS 198 CPH2 12.01100 ! CEI carbon in histidine ring 
MASS 199 CP3 12.01100 ! Carbon on nitrogen in proline ring 
AUTOGENERATE ANGLES DIHE 
DEFA FIRS NONE LAST NONE 
RESI CB3 -2.000 
GROUP 
ATOM Nl N6R -0.740 
ATOM C2 C6R 0.900 
ATOM NA2 NP -0.750 
ATOM N3 N6R -0.560 
ATOM C4 C 0.580 
ATOM OA4 0 -0.519 
ATOM C4A CR66 -0.069 
ATOM C5 C6RE 0.031 
ATOM C6 C6R 0.031 
ATOM C7 C6RE 0.031 
ATOM C8 C6RE 0.031 
ATOM C8A CR66 -0.069 
ATOM C9 CH2E 0.031 
ATOM N10 NP -0.369 
ATOM CPI CH2E 0.031 
ATOM CP2 cuyl -0.269 
ATOM CP3 cuyl -0.259 
ATOM Cll C6R 0.231 
ATOM C12 C6RE 0.031 
ATOM C13 C6RE 0.031 
ATOM C14 C6R 0.131 
ATOM C15 C6RE 0.031 
ATOM C16 C6RE 0.031 
ATOM CC0.580 
ATOM 00 -0.519 
ATOM N NP -0.319 
ATOM CA CHlE 0.131 
ATOM CT C 0.171 
ATOM 01 OC -0.540 
ATOM 02 OC -0.540 
ATOM CB CH2E 0.031 
ATOM CG CH2E 0.031 
ATOM CD C 0.171 
ATOM OE1 OC -0.539 
ATOM OE2 OC -0.540 
ATOM H36 H 0.281 
ATOM H37 H 0.331 
ATOM H38 H 0.361 
ATOM H39 H 0.361 
BOND Nl C2 
BOND C2 NA2 
BOND NA2 H38 
BOND NA2 H39 
BOND C2 N3 
BOND N3 C4 
BOND C4 OA4 
BOND C4 C4A parameter for bond distance not found 
BOND C4A C5 
BOND C5 C6 
BOND C6 C7 
BOND C7 C8 
BOND C8 C8A 
BOND C8A Nl 
BOND C8A C4A 
BOND C6 C9 
BOND C9 N10 
BOND N10 CP1 
BOND CPl CP2 parameter for bond distance not found 
BOND CP2 CP3 
BOND NIO CII 
BOND Cll C12 
BOND C12 C13 
BOND C13 C14 
BOND C14 C15 
BOND C15 C16 
BOND C16 Cll 
BOND C14 C 
BOND C0 
BOND CN 
BOND N CA 
BOND CA CT 
BOND CT 01 
BOND CT 02 
BOND CA CB 
BOND CB CG 
BOND CG CD 
BOND CD OE1 
BOND CD OE2 
BOND N H36 
BOND N3 H37 
IMPH C8A Nl C2 N3 
IMPH Nl C2 N3 C4 
IMPH C2 N3 C4 C4A 
IMPH N3 C4 C4A C8A 
IMPH C8A C4A C5 C6 
IMPH C4A C5 C6 C7 
IMPH C5 C6 C7 C8 
IMPH C6 C7 C8 C8A 
IMPH C7 C8 C8A C4A 
IMPH C4A C8A Nl C2 
IMPH Nl C8A C4A C4 
IMPH C16 C11 C12 C13 
IMPH C11 C12 C13 C14 
IMPH C12 C13 C14 C15 
IMPH C13 C14 C15 C16 
IMPH C14 C15 C16 C11 
IMPH C15 C16 C11 C12 
IMPH C2 N3 Nl NA2 
IMPH NA2 H39 C2 H38 
IMPH N3 C2 C4 H37 
IMPH C4 C4A N3 OA4 
IMPH C4A C5 C8A C4 
IMPH C6 C5 C7 C9 
IMPH C8A C4A C8 NI 
IMPH N10 Cpl CII C9 
IMPH C11 C12 C16 N10 
IMPH C14 C13 C15 C 
IMPH CN C14 0 
IMPH NC CA H36 
IMPH CA'N CT CB 
IMPH CT 01 02 CA 
IMPH CD OE1 OE2 CG 
DONO H38 NA2 
DONO H39 NA2 
DONO H37 N3 
DONO H36 N 
ACCE Nl 
ACCE NA2 
ACCE N3 
ACCE OA4 C4 
ACCE N10 
ACCE 0C 
ACCE N 
ACCE 01 CT 
ACCE 02 CT 
ACCE OE1 CD 
ACCE OE2 CD 
IC C8A Nl C2 NA2 1.44 123.91 -179.54 114.88 1.47 
IC C8A Nl C2 N3 1.44 123.91 -1.60 119.99 1.47 
IC Nl NA2 *C2 N3 1.15 114.88 -177.82 125.09 1.47 
IC Nl C2 NA2 H39 1.15 114.88 -77.32 119.96 1.09 
IC N3 C2 NA2 H39 1.47 125.09 104.85 119.96 1.09 
Ic Nl C2 NA2 H38 1.15 114.88 102.61 120.00 1.09 
IC C2 H38 *NA2 H39 1.47 120.00 179.93 120.04 1.09 
IC Nl C2 N3 C4 1.15 119.99 1.57 117.56 1.23 
Ic NA2 C2 N3 C4 1.47 125.09 179.28 117.56 1.23 
IC NI C2 N3 H37 1.15 119.99 -178.40 121.21 1.09 
Ic C2 C4 *N3 H37 1.47 117.56 179.97 121.23 1.09 
IC C2 N3 C4 OA4 1.47 117.56 -178.93 117.03 1.22 
IC H37 N3 C4 OA4 1.09 121.23 1.03 117.03 1.22 
Ic C2 N3 C4 C4A 1.47 117.56 0.95 125.09 1.31 
IC N3 OA4 *C4 C4A 1.23 117.03 -179.89 117.89 1.31 
IC N3 C4 C4A C5 1.23 125.09 177.92 120.53 1.35 
IC OA4 C4 C4A C5 1.22 117.89 -2.19 120.53 1.35 
Ic N3 C4 C4A C8A 1.23 125.09 -3.20 118.76 1.38 
Ic C4 C5 *C4A C8A 1.31 120.53 -178.85 120.70 1.38 
Ic C4 C4A C5 C6 1.31 120.53 -174.12 116.95 1.36 
Ic C8A C4A C5 C6 1.38 120.70 7.02 116.95 1.36 
Ic C4A C5 C6 C7 1.35 116.95 -8.52 121.61 1.42 
Ic C4A C5 C6 C9 1.35 116.95 -178.42 126.74 1.48 
Ic C5 C7 *C6 C9 1.36 121.61 171.35 111.00 1.48 
Ic C5 C6 C7 C8 1.36 121.61 4.91 119.39 1.30 
Ic C9 C6 C7 C8 1.48 111.00 176.26 119.39 1.30 
Ic C6 C7 C8 C8A 1.42 119.39 0.47 119.97 1.36 
Ic C7 C8 C8A Nl 1.30 119.97 173.89 124.40 1.44 
Ic C7 C8 C8A C4A 1.30 119.97 -1.90 120.88 1.38 
IC Nl C4A *C8A C8 1.44 114.60 176.18 120.88 1.36 
Ic C4A C8A Nl C2 1.38 114.60 -0.60 123.91 1.15 
Ic C8 C8A Nl C2 1.36 124.40 -176.63 123.91 1.15 
IC Nl C8A C4A C4 1.44 114.60 2.94 118.76 1.31 
Ic C8 C8A C4A C4 1.36 120.88 179.12 118.76 1.31 
IC Nl C8A C4A C5 1.44 114.60 -178.18 120.70 1.35 
Ic C5 C6 C9 N10 1.36 126.74 135.23 105.09 1.58 
Ic C7 C6 C9 N10 1.42 111.00 -35.56 105.09 1.58 
Ic C6 C9 N10 CP1 1.48 105.09 -8.64 116.04 1.50 
Ic C6 C9 N10 Cll 1.48 105.09 132.99 109.46 1.46 
Ic C9 cpl *NlO Cll 1.58 116.04 -136.83 121.20 1.46 
Ic C9 N10 CP1 CP2 1.58 116.04 -74.58 114.97 1.55 
IC Cll N10 CPI CP2 1.46 121.20 148.59 114.97 1.55 
IC N10 CP1 CP2 CP3 1.50 114.97 -5.28 176.11 1.30 
Ic C9 N10 Cll C12 1.58 109.46 132.79 124.69 1.37 
Ic CP1 N10 Cll C12 1.50 121.20 -87.90 124.69 1.37 
IC C9 N10 Cll C16 1.58 109.46 -44.23 113.13 1.39 
IC N10 C12 *Cll C16 1.46 124.69 176.77 122.11 1.39 
IC N10 C11 C12 C13 1.46 124.69 -178.01 121.08 1.42 
Ic C16 C11 C12 C13 1.39 122.11 -1.24 121.08 1.42 
Ic C11 C12 C13 C14 1.37 121.08 0.62 116.84 1.34 
Ic C12 C13 C14 C15 1.42 116.84 0.19 123.59 1.40 
Ic C12 C13 C14 C 1.42 116.84 179.52 122.88 1.56 
Ic C13 C15 *C14 C 1.34 123.59 -179.39 113.53 1.56 
IC C13 C14 C15 C16 1.34 123.59 -0.40 119.43 1.41 
Ic C C14 C15 C16 1.56 113.53 -179.78 119.43 1.41 
IC C14 C15 C16 C11 1.40 119.43 -0.19 116.95 1.39 
IC C15 C16 C11 N10 1.41 116.95 178.10 113.13 1.46 
IC C15 C16 C11 C12 1.41 116.95 0.99 122.11 1.37 
Ic C13 C14 C01.34 122.88 48.86 120.34 1.22 
Ic C15 C14 C01.40 113.53 -131.75 120.34 1.22 
IC C13 C14 CN1.34 122.88 -168.32 111.81 1.34 
Ic C14 0 *C N 1.56 120.34 -141.06 116.79 1.34 
IC C14 CN CA 1.56 111.81 -144.28 138.04 1.45 
IC 0CN CA 1.22 116.79 -0.04 138.04 1.45 
IC C14 CN H36 1.56 111.81 35.83 110.97 1.09 
IC C CA *N H36 1.34 138.04 179.88 110.98 1.09 
IC CN CA CT 1.34 138.04 166.65 108.30 1.57 
IC H36 N CA CT 1.09 110.98 -13.46 108.30 1.57 
IC CN CA CB 1.34 138.04 42.95 113.02 1.56 
IC N CT *CA CB 1.45 108.30 124.77 111.23 1.56 
IC N CA CT 01 1.45 108.30 -11.13 128.27 1.32 
IC CB CA CT 01 1.56 111.23 113.64 128.27 1.32 
IC N CA CT 02 1.45 108.30 115.83 118.88 1.26 
IC CA 01 *CT 02 
IC N CA CB CG 
IC CT CA CB CG 
IC CA CB CG CD 
IC CB CG CD OE1 
IC CB CG CD OE2 
IC CG OE1 *CD OE2 
1.57 128.27 -135.23 96.56 1.26 
1.45 1 13.02 15.12 111.03 1.52 
1.57 111.23 -106.95 111.03 1.52 
1.56 111.03 153.31 105.72 1.57 
1.52 105.72 -79.91 116.38 1.41 
1.52 105.72 53.53 118.09 1.27 
1.5 7 116.3 8 -137.19 109.52 1.27 
END 
Appendix 2.3 
patch data and awk rites 
Propriet ory a nd Confidential Property of Polygen Corporation 
TEMPLATE FOR CREATING C HARMm RTF file (from ChemNote) 
(% 
-m 
) rep laced by f irst 4 characters of molecule name 
(%-r ) rep laced by R TF format of residue definition 
Build RTF for CB3 
* ýýsidue defi nition in RTF format built inline 
21 3 
MASS 1 H 1.00800 ! Hydrogen bonding hydrogen (neutral group) 
MASS 2 HC 1.00800 ! Hydrogen bonding hydrogen (charged group) 
MASS 3 HA 1.00800 ! Aliphatic or aromatic hydrogen 
MASS 4 HT 1.00800 ! TIPS3P water model hydrogen 
MASS 5 LP 0.0 ! ST2 lone pair 
MASS 6 MBE 9.01218 ! Beryllium 
MASS 7 B 10.81 ! Boron 
MASS 8 HO 1.00800 ! Hydrogen on an alcohol oxygen 
MASS 9 HMU 1.00800 ! Mu-bonded hydrogen for metals and boron-hydride, 
MASS 10 CT 12.01100 ! Aliphatic carbon (tetrahedral) 
MASS 11 CHlE 13.01900 ! Extended atom carbon with one hydrogen 
MASS 12 CH2E 14.02700 ! Extended atom carbon with two hydrogens 
MASS 13 CH3E 15.03500 ! Extended atom carbon with three hydrogens 
MASS 14 C 12.01100 ! Carbonyl or Guanidinium carbon 
MASS 15 CM 12.01100 ! Carbonmonoxide, or other triply bonded, carbon 
MASS 16 CUAl 12.01100 ! Carbon in double bond, first pair 
MASS 17 CUA2 12.01100 ! Carbon in double bond, second conjugated pair 
MASS 18 CUYI 12.01100 ! Carbon in triple bond, first pair 
MASS 19 CUY2 12.01100 ! Carbon in triple bond, second conjugated pair 
MASS 20 CUA3 12.01100 ! Carbon in double bond, third conjugated pair 
MASS 21 C5R 12.01100 ! Aromatic carbon in a five membered ring 
MASS 22 C6R 12.01100 ! Aromatic carbon in a six membered ring 
MASS 23 C5RE 13.01900 ! Extended aromatic carbon in five membered ring 
MASS 24 C6RE 13.01900 ! Extended aromatic carbon in six membered ring 
MASS 25 CR55 12.01100 ! Aromatic carbon-merged five membered rings 
MASS 26 CR56 12.01100 ! Aromatic carbon-merged five/six membered rings 
MASS 27 CR66 12.01100 ! Aromatic carbon-merged six membered rings 
MASS 28 C5RP 12.01100 ! for Aryl-Aryl bond between C5R rings 
MASS 29 C6RP 12.01100 ! for Aryl-Aryl bond between C6R rings 
MASS 30 N5RP 14.00670 ! for Ar-Ar bond between five membered rings 
MASS 31 N 14.00670 ! Nitrogen; planar-valence of 3, i. e. nitrile, et 
MASS 32 NP 14.00670 ! Nitrogen in peptide, amide, or related, group 
MASS 33 NX 14.00670 ! Proline nitrogen, or similar 
MASS 34 N5R 14.00670 ! Nitrogen in a five membered aromatic ring 
MASS 35 N6R 14.00670 ! Nitrogen in a six membered aromatic ring 
MASS 36 NT 14.00670 ! Nitrogen (tetrahedral), i. e. Amine, etc. 
MASS 37 NC 14.00670 ! Charged guanidinuim-type nitrogen 
MASS 38 N02 14.00670 ! Nitrogen in nitro, or related, group 
MASS 39 N6RP 14.00670 ! for Aryl-Aryl bond between six membered rings 
MASS 40 0 15.99940 ! Carbonyl oxygen for amides, or related structur 
MASS 41 OA 15.99940 ! Carbonyl oxygen for aldehydes, or related struc 
MASS 42 OK 15.99940 ! Carbonyl oxygen for ketones, or related structu 
MASS 43 OC 15.99940 ! Charged oxygen 
MASS 45 OT 15.99940 ! Hydroxyl oxygen (tetrahedral)/Ionizable acid O>c 
MASS 46 OW 15.99940 ! TIP3P water model oxygen 
MASS 47 OH2 15.99940 ! ST2 water model oxygen 
MASS 48 OM 15.99940 ! Carbonmonoxide, or other triply bonded, oxygen 
MASS 49 OS 15.99940 ! Ester oxygen 
MASS 50 OE 15.99940 ! Ether oxygen / Acetal oxygen 
MASS 51 OAC 15.99940 ! Carbonyl oxygen for acids 
MASS 52 05R 15.99940 ! Oxygen in five membered aromatic ring-radicals 
MASS 53 06R 15.99940 , ! Oxygen in aromatic ring - radicals etc. 
MASS 55 OSI 15.99940 ! Oxygen in Si-O-Si bond 
MASS 56 02M 15.99940 ! Oxygen in Si-O-Al or Al-O-Al bond 
MASS 57 OSH 0.00000 ! Massless 0 for zeolites, or related cage compou 
MASS 60 PT 30.9738 ! Phosphorous, general; usually tetrahedral 
MASS 61 P03 30.9738 ! Phosphorous bonded to three oxygens 
MASS 62 P04 30.9738 ! Phosphorous bonded to four oxygens 
MASS 63 PUAl 30.9738 ! Phosphorous double bond 
MASS 64 P6R 30.9738 ! Phosphorous in aromatic 6-membered ring 
MASS 70 ST 32.06000 ! Sulphur, general; usually tetrahedral 
MASS 71 SHlE 33.06800 ! Extended atom sulphur with one hydrogen 
MASS 72 S5R 32.0600 ! Sulphur in a five membered aromatic ring 
MASS 73 S6R 32.0600 ! Sulphur in a six membered aromatic ring 
MASS 74 SE 32.060 ! Thioether sulphur 
MASS 75 SK 32.060 ! Thioketone sulphur 
MASS 76 Sol 32.0600 ! Sulphur bonded to one oxygen 
MASS 77 S02 32.0600 ! Sulphur bonded to two oxygens 
MASS 78 S03 32.0600 ! Sulphur bonded to three oxygens 
MASS 79 S04 32.0600 ! Sulphur bonded to four oxygens 
MASS 80 MLI 6.941 ! Lithium 
MASS 81 MNA 22.9898 ! Sodium 
MASS 82 MMG 24.305 ! Magnesiun 
MASS 83 MK 39.098 ! Potassium 
MASS 84 MCA 40.080 ! Calcium 
MASS 85 MMN 54.938 ! Manganese 
MASS 86 MFE 55.847 ! Iron 
MASS 87 MZN 65.38 ! Zinc 
MASS 88 MRB 85.4678 ! Rubidium 
MASS 89 MCS 132.9054 ! Cesium 
MASS 90 MSI 28.0855 ! Silicon 
MASS 91 MAL 26.9815 ! ALuminum 
MASS 92 XF 18.99840 ! Fluorine 
MASS 93 XCL 35.45300 ! Chlorine 
MASS 94 XBR 79.904 ! Bromine 
MASS 95 XI 126.9045 ! Iodine 
MASS 96 MCU 63.546 ! Copper 
MASS 97 MV 50.9415 ! Vanadium 
MASS 98 MCR 51.996 ! Chromium 
MASS 99 MCO 58.9332 ! Cobalt 
MASS 100 MNI 58.69 ! Nickel 
MASS 101 MAS 74.9216 ! Arsenic 
MASS 102 MSE 78.96 ! Selenium 
MASS 103 MSR 87.62 ! Strontium 
MASS 104 MY 88.9059 ! Yttrium 
MASS 105 MZR 91.22 ! zirconium 
MASS 106 MNB 92.9064 ! Niobium 
MASS 107 MMO 95.94 ! Molybdenum 
MASS 108 MRU 101.07 ! Ruthenium 
MASS 109 MRH 102.9055 ! Rhodium 
MASS 110 MPD 106.42 ! Palladium 
MASS 111 MAG 107.868 ! Silver 
MASS 112 MCD 112.41 ! Cadmium 
MASS 113 MSN 118.69 ! Tin 
MASS 114 MSB 121.75 ! Antimony 
MASS 115 MBA 137.33 ! Barium 
MASS 116 MW 183.85 ! Tungsten 
MASS 117 MOS 190.2 ! Osmium 
MASS 118 MPT 195.08 ! Platinum 
MASS 119 MAU 196.08 ! Gold 
MASS 120 MHG 200.59 ! Mercury 
MASS 121 MPB 207.2 ! Lead 
MASS 122 MBI 208.9804 ! Bismuth 
MASS 123 MLA 138.9055 ! Lanthanum 
MASS 124 MCE 140.12 ! Cerium 
MASS 125 MPR 140.9077 ! Praseodymium 
MASS 126 MAC 227.0278 ! Actinium 
MASS 127 MTH 232.0381 ! Thorium 
MASS 128 MU 238.0289 ! Uranium 
MASS 129 MTE 127.60 ! Tellurium 
MASS 130 MPO 209.0 ! Polonium 
MASS 131 XAT 210.0 ! Astatine 
MASS 132 MTC 98.0 ! Technetium 
MASS 133 MSC 44.9559 ! Scandium 
MASS 134 MTI 47.88 ! Titanium 
MASS 135 MGA 69.72 ! Gallium 
MASS 136 MGE 72.59 ! Germanium 
MASS 137 MIN 114.82 ! Indium 
MASS 138 MHF 178.49 ! Hafnium 
MASS 139 MTA 180.9479 ! Tantalum 
MASS 140 MIR 192.22 ! Iridium 
MASS 141 MTL 204.383 ! Thallium 
MASS 142 MFR 223.0 ! Francium 
MASS 143 MRA 226.0254 ! Radium 
MASS 144 MND 144.24 ! Neodymium 
MASS 145 MPM 145.0 ! Promethium 
MASS 146 MSM 150.36 ! Samarium 
MASS 147 MEU 151.96 ! Europium 
MASS 148 MGD 157.25 ! Gadolinium 
MASS 149 MTB 158.9254 ! Terbium 
MASS 150 MDY 162.50 ! Dysprosium 
MASS 151 MHO 164.9304 ! Holmium 
MASS 152 MER 167.26 ! Erbium 
MASS 153 MTM 168.9342 ! Thulium 
MASS 154 MYB 173.04 ! Ytterbium 
MASS 155 MLU 174.967 ! Lutetium 
MASS 156 MPA 231.0359 ! Protactinium 
MASS 157 MNP 237.0482 ! Neptunium 
MASS 158 MPU 244.0 ! Plutonium 
MASS 159 MAM 243.0 ! Americium 
MASS 160 MCM 247.0 ! Curium 
MASS 161 MBK 247.0 ! Berkelium 
MASS 162 MCF 251.0 ! Californium 
MASS 163 MES 252.0 ! Einsteinium 
MASS 164 MFM 257.0 ! Fermium 
MASS 165 MMD 258.0 ! Medelevium 
MASS 166 MNO 259.0 ! Nobelium 
MASS 167 MLR 260. '0 ! Lawrencium 
MASS 168 HE 4.00260 ! Helium 
MASS 169 NE 20.179 ! Neon 
MASS 170 AR 39.948 ! Argon 
MASS 171 KR 83.80 ! Krypton 
MASS 172 XE 131.29 ! Xenon 
bmss 173 RN 222.0 ! Radon 
MASS 174 MRF 261.0 ! Rutherfordium/Kurchatovium. 
MASS 175 MHA 262.0 ! Hahnium 
MASS 176 MRE 186.31 ! Rhenium. 
MASS 177 MSIU 28.08550 ! Silicon when as double bond 
MASS 180 NR56 14.00670 !N at fused bond between 5 and 6-membered aromat 
MASS 181 NR66 14.00670 !N at fused bond between two 6-membered aromatic 
MASS 182 NR55 14.00670 !N at fused bond between two 5-membered aromatic 
MASS 183 NR1 14.00670 ! Protonated nitrogen in neutral histidine ring 
MASS 184 NR2 14.00670 ! Unprotonated nitrogen in neutral histidine ring 
MASS 185 NR3 14.00670 ! Nitrogens in charged histidine ring 
MASS 186 NC2 14.00670 ! for neutral guanidinium. group - Arg sidechain 
MASS 189 C5RQ 12.01100 ! for second Ar-Ar bond between C5RP rings (ortho 
MASS 190 C3 12.01100 ! Carbonyl carbon in 3-membered aliphatic ring 
MASS 191 CT3 12.01100 !C in 3-membered aliphatic ring, usually tetrahe 
MASS 192 C4 12.01100 ! Carbonyl carbons in 4-membered aliphatic ring 
MASS 193 CT4 12.01100 !C in 4-membered aliphatic ring, usually tetrahe 
MASS 194 C6RQ 12.01100 ! Carbon of C6RP type ortho to C6RP pair 
MASS 195 CQ66 12.01100 ! Third adjacent pair of CR66 types in fused ring 
MASS 196 CS66 12.01100 ! Second adjacent pair of CR66 types in fused rin 
MASS 197 CPH1 12.01100 ! CG and CD2 carbons in histidine ring 
MASS 198 CPH2 12.01100 ! CEI carbon in histidine ring 
MASS 199 CP3 12.01100 ! Carbon on nitrogen in proline ring 
AUTOGENERATE ANGLES DIHE 
DEFA FIRS NONE LAST NONE 
PRES MAJO -0.33 
! Patch for dump to CYS This may not actually work but who knows? 
GROUP 
ATOM 1SG SE -0.12 
GROUP 
ATOM 2Nl NP -0.20 
ATOM 2C6 CHlE -0.10 
ATOM 2C5 CH2E +0.12 
BOND 1SG 2C6 
ANGL 2Nl 2C6 1SG 
DIHE 2CR1 2Nl 2C6 1SG 
DIHE 2C2 2Nl 2C6 1SG 
DIHE 2C4 2C5 2C6 1SG 
DIHE 2Nl 2C6 1SG 1CB 
DIHE 2C5 2C6 1SG ICB 
DIHE 2C6 1SG 1CB ICA 
ic 2CR1 2Nl 2C6 1SG 
ic 2C2 2Nl 2C6 1SG 
ic 2C4 2C5 2C6 ISG 
ic 2Nl 2C6 1SG ICB 
ic 2C5 2C6 1SG 1CB 
ic 2C6 1SG 1CB ICA 
2C6 ISG 1CB 2C5 2C6 1SG 
0.0 0.0 180.0 0.0 0.0 
0.0 0.0 180.0 0.0 0.0 
0.0 0.0 180.0 0.0 0.0 
0.0 0.0 180.0 0.0 0.0 
0.0 0.0 180.0 0.0 0.0 
0.0 0.0 180.0 0.0 0.0 
END 
#! /bin/sh 
nawk I 
(if ($4 - /", (N2AIH33IH34IH35IC22IN23IN21IC24104AICA41CA8lC28IC25IC26IC27IC2 
(if (NF == 12) 
(sum += $11; sum2 += $12) 
(if (NF 
(sum += $10; sum2 += $11) 
(if ($4 
{if (NF == 12) 
(sum5 += $11; sum6 += $12) 
(if (NF 
{sum5 += $10; sum6 += $11) 
(if ($4 !- /", (N2AIH33IH34IH35IC22IN23IN21IC24104AICA41CA8lC28IC25IC26IC271C 
{if (NF == 12) 
{Sum3 += $11; sum4 += $12) 
) 
(if (NF == 11) 
[sum3 += $10; sum4 
(if ($4 - /^(011021CT)$/) 
I 
(if (NF == 12) 
(sum7 += $11; sum8 += $12) 
I 
[if (NF == 11) 
(sum7 += $10; sum8 += $11) 
(if ($4 - /^(01)$/) 
1 
(if (NF == 12) 
(sum15 += $11; sum16 += $12) 
I 
(if (NF == 11) 
(sum15 += $10; sum16 += $11} 
(if ($4 - /^(02)$/) 
(if (NF == 12) 
{suml7 += $11; sum18 += $12) 
(if (NF == 11) 
(sum17 += $10; sum18 += $11) 
{if ($4 - /^(OE1)$/) 
{if (NF == 12) 
(sum19 += $11; sum20 += $12) 
} 
(if (NF == 11) 
(sum19 += $10; sum20 += $11) 
(if ($4 - /^(OE2)$/) 
[if (NF == 12) 
{sum2l += $11; sum22 += $12) 
I 
(if (NF == 11) 
(sum2l += $10; sum22 += $11) 
{if ($4 - /^(OE11OE21CDICGICB)$/) 
(if (NF == 12) 
{sum9 += $11; sumlO += $12) 
) 
{if (NF == 11) 
(SUM9 += $10; sumlo += $11) 
(if ($4 - /^(ClIIC12IC13IC14IC151C16)$/) 
(if (NF == 12) 
(sumll += $11; sum12 += $12) 
} 
(if (NF == 11) 
{sumll += $10; sum12 += $11} 
(if ($4 - /^(CIOINIH)$/) 
(if (NF == 12) 
(sum13 += $11; sum14 += $12) 
) 
{if (NF == 11) 
(sum13 += $10; sum14 += $11) 
END (print uFILE = 1$11"; 
print "TOTAL VDW of bif sum; 
print "TOTAL ELEC of bif sum2; 
print "TOTAL VDW of quin sum5; 
print "TOTAL ELEC of quin = H, sum6; 
print "TOTAL nonbonded of both sides sum5 + sum6 sum + sum2; 
print NTOTAL VDW of main sum3; 
print "TOTAL ELEC of main sum4; 
print "TOTAL nonbonded of main = 11, sum3 + sum4; 
print *TOTAL VDW sum + sum3; 
print "TOTAL ELEC sum2 + sum4; 
print "TOTAL VDW of short acid sum7; 
print "TOTAL ELEC of short acid sum8; 
print "TOTAL VDW of 01 = sum15; 
print "TOTAL ELEC of 01 sum16; 
print "TOTAL VDW of 02 = suml7; 
print "TOTAL ELEC of 02 N, sum18; 
print "TOTAL VDW of long a cid sum9; 
print "TOTAL ELEC of long acid sumlO; 
print "TOTAL VDW of OE1 = sum19; 
print "TOTAL ELEC of OE1 sum20; 
print "TOTAL VDW of OE2 = sum2l; 
print "TOTAL ELEC of OE2 sum22; 
print NTOTAL VDW of ring sumll; 
print "TOTAL ELEC of ring sum12; 
print "TOTAL VDW of amide sum13; 
print "TOTAL ELEC of amide suml4; 
print "TOTAL nonbonded sum2 + sum4 + sum + sum3), $1 
nawk 
{if ($4 - /^(NA2lH39IH38IH37IC2lN3 [NlIC41OA4lC4AIC8AIC8lC5lC6lC7lC9)$/) 
{if (NF == 12) 
(sum += $11; sum2 += $12) 
(if (NF == 11) 
{sum += $10; sum2 += $11) 
{if ($4 - /"(N2AIH33IH34IH35IC22IN23IN21IC24104AICA41CA8lC28IC25IC26IC27IC2 
(if (NF == 12) 
(sum5 += $11; sum6 += $12) 
{if (NF 
(sum5 += $10; sum6 += $11} 
(if ($4 !- /", (NA2lH39IH38IH37IC2lN3lNllC41OA4lC4AIC8AIC8lC5lC6lC7lC9)$/) 
{if (NF == 12) 
{sum3 += $11; sum4 += $12) 
{if (NF == 11) 
(sum3 += $10; sum4 += $11) 
(if ($4 - /^(01102[CT)$/) 
{if (NF == 12) 
(sum7 += $11; suM8 += $12) 
(if (NF == 11) 
(sum7 += $10; sum8 += $111 
(if ($4 
{if (NF == 12) 
(sum15 += $11; sum16 += $12) 
(if (NF == 11) 
(sum15 += $10; sum16 += $11) 
(if ($4 - /^(02)$/) 
(if (NF == 12) 
[suml7 += $11; sum18 += $12) 
Uf (NF == 11) 
(sum17 += $10; sum18 += $11) 
(if ($4 - /^(OE1)$/) 
(if (NF == 12) 
(sum19 += $11; sum20 += $12) 
{if (NF == 11) 
(sum19 += $10; sum20 += $11) 
(if ($4 - /^(OE2)$/) 
Uf (NF == 12) 
{sum2l += $11; sum22 += $12) 
(if (NF == 11) 
[sum2l += $10; sum22 += $11) 
(if ($4 - /^(OE11OE21CDICGICB)$/) 
(if (NF == 12) 
[SUM9 += $11; sumlO += $12) 
{if (NF == 11) 
(SUM9 += $10; sumlo += $11) 
(if ($4 - /^(CllIC12IC13IC14IC151C16)$/) 
{ 
} 
(if (NF == 12) 
(sumll += $11; sum12 += $12) 
(if (NF == 11) 
(sumll += $10; sum12 += $11) 
(if ($4 - /^(CIOINIH)$/) 
I 
{if (NF == 12) 
{suml3 += $11; sum14 += $12} 
(if (NF == 11) 
(sum13 += $10; sum14 += $11) 
END (print "FILE = 1$2"'; 
print "TOTAL VDW of bif sum; 
print "TOTAL ELEC of bif sum2; 
print "TOTAL VDW of quin sum5; 
print "TOTAL ELEC of quin sum6; 
print "TOTAL nonbonded of both sides sum5 + sum6 + sum + sum2; 
print "TOTAL VDW of main sum3; 
print "TOTAL ELEC of main sum4; 
print "TOTAL nonbonded of main = 11, sum3 + sum4; 
print "TOTAL VDW ", sum + sum3; 
print uTOTAL ELEC 11, sum2 + sum4; 
print "TOTAL VDW of short acid sum7; 
print "TOTAL ELEC of short acid sum8; 
print "TOTAL VDW of 01 = suml5; 
print "TOTAL ELEC of 01 suml6; 
print "TOTAL VDW of 02 = suml7; 
print "TOTAL ELEC of 02 suml8; 
print "TOTAL VDW of long a cid sum9; 
print "TOTAL ELEC of long acid sumlO; 
print "TOTAL VDW of OE1 = suml9; 
print "TOTAL ELEC of OE1 sum20; 
print "TOTAL VDW of OE2 = sum2l; 
print "TOTAL ELEC of OE2 sum22; 
print "TOTAL VDW of ring sumll; 
print "TOTAL ELEC of ring suml2; 
print "TOTAL VDW of amide suml3; 
print "TOTAL ELEC of amide sum14; 
print "TOTAL nonbonded = 11 , sum2 + sum4 + sum + sum3), $2 
nawk ' 
{if ($4 
{if (NF == 12) 
{sum += $11; sum2 += $12) 
) 
(if (NF == 11) 
(sum += $10; sum2 += $11) 
) 
) 
) 
(if ($4 - /^(NA2lH39IH38IH37IC2lN3lNllC41OA4lC4AIC8AIC8lC5lC6lC7lC9)$/) 
(if (NF == 12) 
[sum5 += $11; sum6 += $12) 
fif (NF == 11) 
[sum5 += $10; SUM6 += $11) 
(if ($4 !- /^(CP11CP21CP3)$/) 
{if (NF == 12) 
[sum3 += $11; sum4 += $12) 
(if (NF 
[sum3 += $10; sum4 += $11) 
(if ($4 - /^(011021CT)$/) 
{if (NF == 12) 
{sum7 += $11; sum8 += $121 
{if (NF == 11) 
(sum7 += $10; sum8 += $11} 
(if ($4 - /^(01)$/) 
(if (NF == 12) 
(sum15 += $11; sum16 += $12} 
(if (NF == 11) 
{suml5 += $10; sum16 += $11) 
(if ($4 - /^(02)$/) 
(if (NF == 12) 
(sum17 += $11; sum18 += $12) 
(if (NF 
(sum17 += $10; sum18 += $11) 
(if ($4 - /^(OE1)$/) 
{if (NF == 12) 
(SUM19 += $11; SUM20 += $12) 
(if (NF == 11) 
(sum19 += $10; sum20 += $11) 
(if ($4 - /^(OE2)$/) 
(if (NF == 12) 
(sum2l += $11; sum22 += $12) 
I 
{if 
[if (NF == 11) 
fsum2l += $10; sum22 += $11) 
/^(OE11OE21CDICGICB)$/) 
(if (NF == 12) 
{sum9 += $11; sumlO += $12) 
} 
(if 
I 
fif OF == 11) 
fs=9 += $10; s=10 += $11) 
($4 - /^(CllIC12IC13IC14IC151C16)$/) 
(if (NF == 12) 
(Sumll += $11; sum12 += $12) 
} 
(if 
(if (NF == 11) 
(sumll += $10; sum12 
($4 - /^(CIOINIH)$/) 
{if (NF == 12) 
{suml3 += $11; sum14 += $12) 
} 
END 
(if (NF == 11) 
{suml3 += $10; sum14 += $11) 
(print "FILE = '$3"'; 
print "TOTAL VDW of prop sum; 
print "TOTAL ELEC of prop sum2; 
print "TOTAL VDW of quin sum5; 
print "TOTAL ELEC of quin sum6; 
print "TOTAL nonbonded of both sides sum5 + sum6 + sum + sum2; 
print "TOTAL VDW of main sum3; 
print "TOTAL ELEC of main sum4; 
print "TOTAL nonbonded of main = 11, sum3 + sum4; 
print "TOTAL VDW sum + sum3; 
print "TOTAL ELEC sum2 + sum4; 
print "TOTAL VDW of short acid = 11, sum7; 
print "TOTAL ELEC of short acid = 11, sum8; 
print "TOTAL VDW of 01 = suml5; 
print "TOTAL ELEC of 01 suml6; 
print "TOTAL VDW of 02 = suml7; 
print "TOTAL ELEC of 02 = ", sum18; 
print "TOTAL VDW of long acid sum9; 
print "TOTAL ELEC of long acid sum10; 
print uTOTAL VDW of OEI = sum19; 
print "TOTAL ELEC of OE1 sum20; 
print "TOTAL VDW of OE2 = sum2l; 
print "TOTAL ELEC of OE2 sum22; 
print "TOTAL VDW of ring sumll; 
print "TOTAL ELEC of ring sum12; 
print "TOTAL VDW of amide sum13; 
print "TOTAL ELEC of amide sum14; 
print "TOTAL nonbonded = ", sum2 + sum4 + sum + sum3), $3 
nawk ' 
(if ($4 - /^(CP11CP21CP3)$/) 
I 
(if (NF == 12) 
(sum += $11; sum2 += $12) 
{if (NF 
(sum += $10; sum2 += $11) 
(if ($4 _ /A (NA2lH39IH38IH37IC2lN3lNllC41OA4lC4AIC8AIC8lC5lC6lC7lC9)$/) 
(if (NF == 12) 
[sum5 += $11; sum6 += $12) 
{if (NF 
(sum5 += $10; sum6 += $11) 
(if ($4 !- /ý(CP1jCP2jCP3)$/) 
(if (NF == 12) 
[sum3 += $11; sum4 += $12) 
{if (NF 
[sum3 += $10; sum4 += $11) 
(if ($4 _ /A(01 1021CT)$/) 
{if (NF == 12) 
[sum7 += $11; sum8 += $12) 
(if (NF == 11) 
(sum7 += $10; sum8 += $11) 
(if ($4 _ /A(01)$/) 
(if (NF == 12) 
(sum15 += $11; sum16 += $12) 
(if (NF == 11) 
(sum15 += $10; sum16 += $11) 
(if ($4 - /^(02)$/) 
(if (NF == 12) 
{suml7 += $11; sum18 += $12) 
(if (NF == 11) 
(sum17 += $10; sum18 += $11) 
(if ($4 - /^(OE1)$/) 
{if (NF == 12) 
(sum19 += $11; sum20 += $12) 
(if (NF == 11) 
(sum19 += $10; sum20 += $11) 
{if ($4 - /^(OE2)$/) 
{if (NF == 12) 
{sum2l += $11; sum22 += $12) 
(if (NF == 11) 
[sum2l += $10; sum22 += $11) 
{if ($4 - /^(OE11OE21CDICGICB)$/) 
(if (NF == 12) 
(SUM9 += $11; SUM10 += $12) 
{if (NF == 11) 
(SUM9 += $10; sumlo += $11) 
(if ($4 - /^(CllIC12IC13IC14IC151C16)$/) 
(if (NF == 12) 
(sumll += $11; sum12 += $12} 
(if (NF == 11) 
(sumll += $10; sum12 += $11} 
(if ($4 - /^(CIOINIH)$/) 
(if (NF == 12) 
) 
(sum13 += $11; sum14 += $12) 
(if (NF == 11) 
(SuM13 += $10; sum14 += $11) 
END {print "FILE 
. 
print "TOTAL VDW of prop = sum; 
print "TOTAL ELEC of prop sum2; 
print "TOTAL VDW of quin = sum5; 
print "TOTAL ELEC of quin sum6; 
print "TOTAL nonbonded of both sides sum5 + sum6 + sum + sum2; 
print "TOTAL VDW of main = sum3; 
print "TOTAL ELEC of main sum4; 
print "TOTAL nonbonded of main = 11, sum3 + sum4; 
print "TOTAL VDW sum + sum3; 
print "TOTAL ELEC sum2 + sum4; 
print "TOTAL VDW of short acid sum7; 
print "TOTAL ELEC of short acid sum8; 
print "TOTAL VDW of 01 = sum15; 
print "TOTAL ELEC of 01 sum16; 
print "TOTAL VDW of 02 = sum17; 
print "TOTAL ELEC of 02 sum18; 
print "TOTAL VDW of long a cid sum9; 
print "TOTAL ELEC of long acid sumlO; 
print "TOTAL VDW of OE1 = suml9; 
print "TOTAL ELEC of OE1 sum20; 
print "TOTAL VDW of OE2 = sum2l; 
print "TOTAL ELEC of OE2 sum22; 
print "TOTAL VDW of ring sumll; 
print "TOTAL ELEC of ring = sum12; 
print "TOTAL VDW of amide = sum13; 
print "TOTAL ELEC of amide sum14; 
print "TOTAL nonbonded = 11 , sum2 + sum4 + sum + sum3)1 $4 
Appendix 2.4 
solvation energies and input riles 
MINOR TS E kcal/mol MAJOR TS E kcal/mol 
CB3717 TS + ligand -6113.03 CB3717 TS + ligand -6151.21 
H20+ ligand -6628.62 
H20+ ligand -6618.23 
AEnergy -515.59 AEnergy . 467.02 
H20 only -6352.93 
H20 only -6394.04 
BIF1 TS + ligand -6136.85 BEF2 TS + ligand -6127.05 H20+ ligand -6613.77 H20+ ligand -6605.50 
AEnergy -476.92 Mnergy -478.45 
H20 only -6347.63 
H20 only -6348.96 
AAE -38.67 AAE 11.43 
BIF3 TS + ligand -6109.14 BIF4 TS + ligand -6131.47 H20+ ligand -6573-33 
H20+ ligand -6577.30 
AEnergy -464.19 AEnergy -445.83 
H20 only -6346.02 
H20 only -6329.25 
AAE -51.40 AAE -21.19 
BIF5 TS + ligand -6122.46 BIF6 TS + ligand -6111.41 H20+ ligand -6535.69 H20+ ligand -6560.46 
AEnergy -414.23 AEnergy -449.05 
H20 only -6342.39 
H20 only -6333.36 
AAE -101.36 AAE -17.97 
BIF7 TS + ligand -6115-25 BIF8 TS + ligand -6124-65 H20+ ligand -6520.20 
H20+ ligand -6575.71 
AEnergy -405.75 AEnergy -451.06 
H'20 only -6342.94 H. 20 only -6333.25 
AAE -109.84 AAE -15.96 
BIF9 TS + ligand -6114.83 BIF10 TS + ligand -6140.55 H20+ ligand -6550.45 
H20+ ligand -6564.85 
AEnergy -435.61 AEnergy -424.30 
H20 only -6341.59 
H20 only -6250.86 
AAE -79.98 AAE -42.72 
BIF1 I TS + ligand -6103.57 BIF12 TS + ligand -6141-63 H20+ ligand -6560.13 
H20+ ligand -6505.89 
AEnergy -456.56 AEnergy -364.26 
H20 only -6354.63 H20 only -6556.65 
AAE -59.03 AAE -102.76 
BIF13 TS + ligand -6110.62 BIF14 TS + ligand -6145-32 
H20+ ligand -6562.25 
H20+ ligand -6600-84 
AEnergy -451.63 AEnergy -455.52 H20 only -6331.56 H20 only -6338.98 
AAE -63.96 E -11.50 
BIF15 TS + ligand -6117.24 BIF16 TS + ligand -6125.58 H20+ ligand -6556.09 
H20+ ligand -6560.82 AEnergy -438.84 AEnergy . 435.50 H20 only -6340.65 
H20 only -6350.72 AAE -76.75 AAE -31.52 
BIF17 TS + ligand -6100.71 BIF18 TS + ligand -6147.70 H20+ ligand -6558.39 
H20+ ligand -6572.22 AEnergy -457.68 AEnergy -424.52 H20 only -6351.04 
H20 only -6345.47 AAE -57.91 AAE . 42.50 
BIF19 TS + ligand -6073.26 BEF20 TS + ligand -6103.88 H20+ ligand -6528.56 
H20+ ligand -6545.30 AEnergy -455.30 AEnergy -441.42 H20 only -6356.12 
H20 only -6351.34 AAE -60.29 AAE -25.60 
Script file produced by QUANTA 
; *CH. ýMm 
startup file for QUANTA 
Redirect the CHARMM output 
open write unit 7 Card name bifl4_in_final. LOG line 
outu 7 
bomlev -2 
bann 
open read unit 11 file name $CIDý_DATA/AMINO. BIN 
read rtf unit 11 file 
open read unit 12 card name $CHM-DATA/PATCHA. RTF 
read rtf unit 12 card appe 
oDen read unit 02 file name PARM. BIN 
read para unit 02 file 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"DUM. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"CB3. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"MAJO. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"BI14. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
read sequ quanta 
Read sequence using special 
1 
BI14 I 
generate BI14 setup 
read sequ quanta 
Read sequence using 
QUANTA option 
special QUANTA option 
264 
MET 1 LYS 2 GLN 3 TYR 4 LEU 5 GLU 6 
LEU 7 MET 8 GLN 9 LYS 10 VAL 11 LEU 12 
ASP 13 GLU 14 GLY 15 THR 16 GLN 17 LYS 18 
ASN 19 ASP 20 ARG 21 THR 22 GLY 23 THR 24 
GLY 25 THR 26 LEU 27 SER 28 ILE 29 PHE 30 
GLY 31 HSD 32 GLN 33 MET 34 ARG 35 PHE 36 
ASN 37 LEU 38 GLN 39 ASP 40 GLY 41 PHE 42 
PRO 43 LEU 44 VAL 45 THR 46 THR 47 LYS 48 
ARG 49 CYS 50 HIS 51 LEU 52 ARG 53 SER 54 
ILE 55 ILE 56 HSD 57 GLU 58 LEU 59 LEU 60 
TRP 61 PHE 62 LEU 63 GLN 64 GLY 65 ASP 66 
THR 67 ASN 68 ILE 69 ALA 70 TYR 71 LEU 72 
HSD 73 GLU 74 ASN 75 ASN 76 VAL 77 THR 78 
ILE 79 TRP 80 ASP 81 GLU 82 TRP 83 ALA 84 
ASP 85 GLU 86 ASN 87 GLY 88 ASP 89 LEU 90 
GLY 91 PRO 92 VAL 93 TYR 94 GLY 95 LYS 96 
GLN 97 TRP 98 ARG 99 ALA 100 TRP 101 PRO 102 
THR 103 PRO 104 ASP 105 GLY 106 ARG 107 HIS 108 
ILE 109 ASP 110 GLN 111 ILE 112 THR 113 THR 114 
VAL 115 LEU 116 ASN 117 GLN 118 LEU 119 LYS 120 
ASN 121 ASP 122 PRO 123 ASP 124 SER 125 ARG 126 
ARG 127 ILE 128 ILE 129 VAL 130 SER 131 ALA 132 
TRP 133 ASN 134 VAL 135 GLY 136 GLU 137 LEU 138 
ASP 139 LYS 140 MET 141 ALA 142 LEU 143 ALA 144 
PRO 145 CYS 146 HSD 147 ALA 148 PHE 149 PHE 150 
GLN 151 PHE 152 TYR 153 VAL 154 ALA 155 ASP 156 
GLY 157 LYS 158 LEU 159 SER 160 CYS 161 GLN 162 
LEU 163 TYR 164 GLN 165 ARG 166 SER 167 CYS 168 
ASP 169 VAL 170 PHE 171 LEU 172 GLY 173 LEU 174 
PRO 175 PHE 176 ASN 177 ILE 178 ALA 179 SER 180 
TYR 181 ALA 182 LEU 183 LEU 184 VAL 185 HIS 186 
MET 187 MET 188 ALA 189 GLN 190 GLN 191 CYS 192 
ASP 193 LEU 194 GLU 195 VAL 196 GLY 197 ASP 198 
PHE 199 VAL 200 TRP 201 THR 202 GLY 203 GLY 204 
ASP 205 THR 206 HSD 207 LEU 208 TYR 209 SER 210 
ASN 211 HSD 212 MET 213 ASP 214 GLN 215 THR 216 
HSD 217 LEU 218 GLN 219 LEU 220 SER 221 ARG 222 
GLU 223 PRO 224 ARG 225 PRO 226 LEU 227 PRO 228 
LYS 229 LEU 230 ILE 231 ILE 232 LYS 233 ARG 234 
LYS 235 PRO 236 GLU 237 SER 238 ILE 239 PHE 240 
ASP 241 TYR 242 ARG 243 PHE 244 GLU 245 ASP 246 
PHE 247 GLU 248 ILE 249 GLU 250 GLY 251 TYR 252 
ASP 253 PRO 254 HSD 255 PRO 256 GLY 257 ILE 258 
LYS 259 ALA 260 PRO 261 VAL 262 ALA 263 ILE 264 
generate 1S se tup 
read sequ quanta 
Rea d sequence using special QUANTA option 
264 
MET 301 LYS 302 GLN 303 TYR 304 LEU 305 GLU 306 
LEU 307 MET 308 GLN 309 LYS 310 VAL 311 LEU 312 
ASP 313 GLU 314 GLY 315 THR 316 GLN 317 LYS 318 
ASN 319 ASP 320 ARG 321 THR 322 GLY 323 THR 324 
GLY 325 THR 326 LEU 327 SER 328 ILE 329 PHE 330 
GLY 331 HSD 332 GLN 333 MET 334 ARG 335 PHE 336 
ASN 337 LEU 338 GLN 339 ASP 340 GLY 341 PHE 342 
PRO 343 LEU 344 VAL 345 THR 346 THR 347 LYS 348 
ARG 349 CYS 350 HIS 351 LEU 352 ARG 353 SER 354 
ILE 355 ILE 356 HSD 357 GLU 358 LEU 359 LEU 360 
TRP 361 PHE 362 LEU 363 GLN 364 GLY 365 ASP 366 
THR 367 ASN 368 ILE 369 ALA 370 TYR 371 LEU 372 
HSD 373 GLU 374 ASN 375 ASN 376 VAL 377 THR 378 
ILE 379 TRP 380 ASP 381 GLU 382 TRP 383 ALA 384 
ASP 385 GLU 386 ASN 387 GLY 388 ASP 389 LEU 390 
GLY 391 PRO 392 VAL 393 TYR 394 GLY 395 LYS 396 
GLN 397 TRP 398 ARG 399' ALA 400 TRP 401 PRO 402 
THR 403 PRO 404 
ILE 409 ASP 410 
VAL 415 LEU 416 
ASN 421 ASP 422 
ARG 427 ILE 428 
TRP 433 ASN 434 
ASP 439 LYS 440 
PRO 445 CYS 446 
GLN 451 PHE 452 
GLY 457 LYS 458 
LEU 463 TYR 464 
ASP 469 VAL 470 
PRO 475 PHE 476 
TYR 481 ALA 482 
MET 487 MET 488 
ASP 493 LEU 494 
PHE 499 VAL 500 
ASP 505 THR 506 
ASN 511 HSD 512 
HSD 517 LEU 518 
GLU 523 PRO 524 
LYS 529 LEU 530 
LYS 535 PRO 536 
ASP 541 TYR 542 
PHE 547 GLU 548 
ASP 553 PRO 554 
LYS 559 ALA 560 
generate 2S se tup 
read sequ quanta 
Rea d sequence using 
2 
DUM 565 CB3 566 
generate 1H se tup 
read sequ quanta 
Rea d sequence using 
1 
DUM 567 
generate 2H setup 
ASP 405 GLY 406 ARG 407 HIS 408 
GLN 411 ILE 412 THR 413 THR 414 
ASN 417 GLN 418 LEU 419 LYS 420 
PRO 423 ASP 424 SER 425 ARG 426 
ILE 429 VAL 430 SER 431 ALA 432 
VAL 435 GLY 436 GLU 437 LEU 438 
MET 441 ALA 442 LEU 443 ALA 444 
HSD 447 ALA 448 PHE 449 PHE 450 
TYR 453 VAL 454 ALA 455 ASP 456 
LEU 459 SER 460 CYS 461 GLN 462 
GLN 465 ARG 466 SER 467 CYS 468 
PHE 471 LEU 472 GLY 473 LEU 474 
ASN 477 ILE 478 ALA 479 SER 480 
LEU 483 LEU 484 VAL 485 HIS 486 
ALA 489 GLN 490 GLN 491 CYS 492 
GLU 495 VAL 496 GLY 497 ASP 498 
TRP 501 THR 502 GLY 503 GLY 504 
HSD 507 LEU 508 TYR 509 SER 510 
MET 513 ASP 514 GLN 515 THR 516 
GLN 519 LEU 520 SER 521 ARG 522 
ARG 525 PRO 526 LEU 527 PRO 528 
ILE 531 ILE 532 LYS 533 ARG 534 
GLU 537 SER 538 ILE 539 PHE 540 
ARG 543 PHE 544 GLU 545 ASP 546 
ILE 549 GLU 550 GLY 551 TYR 552 
HSD 555 PRO 556 GLY 557 ILE 558 
PRO 561 VAL 562 ALA 563 ILE 564 
special QUANTA option 
special QUANTA option 
I QUANTA coordinates included in script file 
open read unit 10 card name bifl4_in-ts. crd 
read coor unit 10 card 
close unit 10 
cons fix sele (segid ls or. segid lh) and. not. (resid 124 : 128) end 
print coor sele (segid ls or. segid lh) and. not. (resid 124 : 128) end 
I Energy script for CHARMm 
I 
FAST 
SHAKE OFF 
SKIPE NONE 
MINI SD - 
NSTE 25 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 - 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
MINI ABNR - 
NSTE 500 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
MINI ABNR - 
NSTE 500 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
open write unit 10 card name bifl4-final_jnin. crd 
write coor unit 10 card 
close unit 10 
Script file produced by QUANTA 
CHARMm startup file for QUANTA 
Redirect the CHARMM output 
open write unit 7 Card name bifl5_in_final. LOG line 
outu 7 
bomlev -2 
bann 
open read unit 11 file name $CIW_DATA/AMINO. BIN 
read rtf unit 11 file 
open read unit 12 card name $CHM_DATA/PATCHA. RTF 
read rtf unit 12 card appe 
open read unit 02 file name PARM. BIN 
read para unit 02 file 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"DUM. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
'ICB3. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"PHS. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
! Script for reading RTF 
DELE ATOM SELECT ALL END 
OPEN READ UNIT 77 CARD NAME 
"BI15. RTF" 
READ RTF CARD UNIT 77 APPEND 
CLOSE UNIT 77 
read sequ quanta 
Read sequence using special 
1 
BI15 1 
generate BI15 setup 
read sequ quanta 
Read sequence using 
QUANTA option 
special QUANTA option 
264 
MET 1 LYS 2 GLN 3 TYR 4 LEU 5 GLU 6 
LEU 7 MET 8 GLN 9 LYS 10 VAL 11 LEU 12 
ASP 13 GLU 14 GLY 15 THR 16 GLN 17 LYS 18 
ASN 19 ASP 20 ARG 21 THR 22 GLY 23 THR 24 
GLY 25 THR 26 LEU 27 SER 28 ILE 29 PHE 30 
GLY 31 HSD 32 GLN 33 MET 34 ARG 35 PHE 36 
ASN 37 LEU 38 GLN 39 ASP 40 GLY 41 PHE 42 
PRO 43 LEU 44 VAL 45 THR 46 THR 47 LYS 48 
ARG 49 CYS 50 HIS 51 LEU 52 ARG 53 SER 54 
ILE 55 ILE 56 HSD 57 GLU 58 LEU 59 LEU 60 
TRP 61 PHE 62 LEU 63 GLN 64 GLY 65 ASP 66 
THR 67 ASN 68 ILE 69 ALA 70 TYR 71 LEU 72 
HSD 73 GLU 74 ASN 75 ASN 76 VAL 77 THR 78 
ILE 79 TRP 80 ASP 81 GLU 82 TRP 83 ALA 84 
ASP 85 GLU 86 ASN 87 GLY 88 ASP 89 LEU 90 
GLY 91 PRO 92 VAL 93 TYR 94 GLY 95 LYS 96 
GLN 97 TRP 98 ARG 99 ALA 100 TRP 101 PRO 102 
THR 103 PRO 104 ASP 105 GLY 106 ARG 107 HIS 108 
ILE 109 ASP 110 GLN 111 ILE 112 THR 113 THR 114 
VAL 115 LEU 116 ASN 117 GLN 118 LEU 119 LYS 120 
ASN 121 ASP 122 PRO 123 ASP 124 SER 125 ARG 126 
ARG 127 ILE 128 ILE 129 VAL 130 SER 131 ALA 132 
TRP 133 ASN 134 VAL 135 GLY 136 GLU 137 LEU 138 
ASP 139 LYS 140 MET 141 ALA 142 LEU 143 ALA 144 
PRO 145 CYS 146 HSD 147 ALA 148 PHE 149 PHE 150 
GLN 151 PHE 152 TYR 153 VAL 154 ALA 155 ASP 156 
GLY 157 LYS 158 LEU 159 SER 160 CYS 161 GLN 162 
LEU 163 TYR 164 GLN 165 ARG 166 SER 167 CYS 168 
ASP 169 VAL 170 PHE 171 LEU 172 GLY 173 LEU 174 
PRO 175 PHE 176 ASN 177 ILE 178 ALA 179 SER 180 
TYR 181 ALA 182 LEU 183 LEU 184 VAL 185 HIS 186 
MET 187 MET 188 ALA 189 GLN 190 GLN 191 CYS 192 
ASP 193 LEU 194 GLU 195 VAL 196 GLY 197 ASP 198 
PHE 199 VAL 200 TRP 201 THR 202 GLY 203 GLY 204 
ASP 205 THR 206 HSD 207 LEU 208 TYR 209 SER 210 
ASN 211 HSD 212 MET 213 ASP 214 GLN 215 THR 216 
HSD 217 LEU 218 GLN 219 LEU 220 SER 221 ARG 222 
GLU 223 PRO 224 ARG 225 PRO 226 LEU 227 PRO 228 
LYS 229 LEU 230 ILE 231 ILE 232 LYS 233 ARG 234 
ALA 235 PRO 236 GLU 237 SER 238 ILE 239 PHE 240 
ASP 241 TYR 242 ARG 243 PHE 244 GLU 245 ASP 246 
PHE 247 GLU 248 ILE 249 GLU 250 GLY 251 TYR 252 
ASP 253 PRO 254 HSD 255 PRO 256 GLY 257 ILE 258 
LYS 259 ALA 260 PRO 261 VAL 262 ALA 263 ILE 264 
gener ate 1S se tup 
read sequ quanta 
Rea d sequence using special QUANTA option 
264 
MET 301 LYS 302 GLN 303 TYR 304 LEU 305 GLU 306 
LEU 307 MET 308 GLN 309 LYS 310 VAL 311 LEU 312 
ASP 313 GLU 314 GLY 315 THR 316 GLN 317 LYS 318 
ASN 319 ASP 320 ARG 321 THR 322 GLY 323 THR 324 
GLY 325 THR 326 LEU 327 SER 328 ILE 329 PHE 330 
GLY 331 HSD 332 GLN 333 MET 334 ARG 335 PHE 336 
ASN 337 LEU 338 GLN 339 ASP 340 GLY 341 PHE 342 
PRO 343 LEU 344 VAL 345 THR 346 THR 347 LYS 348 
ARG 349 CYS 350 HIS 351 LEU 352 ARG 353 SER 354 
ILE 355 ILE 356 HSD 357 GLU 358 LEU 359 LEU 360 
TRP 361 PHE 362 LEU 363 GLN 364 GLY 365 ASP 366 
THR 367 ASN 368 ILE 369 ALA 370 TYR 371 LEU 372 
HSD 373 GLU 374 ASN 375 ASN 376 VAL 377 THR 378 
ILE 379 TRP 380 ASP 381 GLU 382 TRP 383 ALA 384 
ASP 385 GLU 386 ASN 387 GLY 388 ASP 389 LEU 390 
GLY 391 PRO 392 VAL 393 TYR 394 GLY 395 LYS 396 
GLN 397 TRP 398 ARG 399 ALA 400 TRP 401 PRO 402 
THR 403 PRO 404 ASP 405 GLY 406 ARG 407 HIS 408 
ILE 409 ASP 410 GLN 411 ILE 412 THR 413 THR 414 
VAL 415 LEU 416 ASN 417 GLN 418 LEU 419 LYS 420 
ASN 421 ASP 422 PRO 423 ASP 424 SER 425 ARG 426 
ARG 427 ILE 428 ILE 429 VAL 430 SER 431 ALA 432 
TRP 433 ASN 434 VAL 435 GLY 436 GLU 437 LEU 438 
ASP 439 LYS 440 MET 441 ALA 442 LEU 443 ALA 444 
PRO 445 CYS 446 HSD 447 ALA 448 PHE 449 PHE 450 
GLN 451 PHE 452 TYR 453 VAL 454 ALA 455 ASP 456 
GLY 457 LYS 458 LEU 459 SER 460 CYS 461 GLN 462 
LEU 463 TYR 464 GLN 465 ARG 466 SER 467 CYS 468 
ASP 469 VAL 470 PHE 471 LEU 472 GLY 473 LEU 474 
PRO 475 PHE 476 ASN 477 ILE 478 ALA 479 SER 480 
TYR 481 ALA 482 LEU 483 LEU 484 VAL 485 HIS 486 
MET 487 MET 488 ALA 489 GLN 490 GLN 491 CYS 492 
ASP 493 LEU 494 GLU 495 VAL 496 GLY 497 ASP 498 
PHE 499 VAL 500 TRP 501 THR 502 GLY 503 GLY 504 
ASP 505 THR 506 HSD 507 LEU 508 TYR 509 SER 510 
ASN 511 HSD 512 MET 513 ASP 514 GLN 515 THR 516 
HSD 517 LEU 518 GLN 519 LEU 520 SER 521 ARG 522 
GLU 523 PRO 524 ARG 525 PRO 526 LEU 527 PRO 528 
LYS 529 LEU 530 ILE 531 ILE 532 LYS 533 ARG 534 
ALA 535 PRO 536 GLU 537 SER 538 ILE 539 PHE 540 
ASP 541 TYR 542 ARG 543 PHE 544 GLU 545 ASP 546 
PHE 547 GLU 548 ILE 549 GLU 550 GLY 551 TYR 552 
ASP 553 PRO 554 HSD 555 PRO 556 GLY 557 ILE 558 
LYS 559 ALA 560 PRO 561 VAL 562 ALA 563 ILE 564 
gener ate 2S se tup 
read sequ quanta 
Rea d se quence using special QUANTA option 
DUM 565 
gener ate 1H setup 
read sequ quanta 
Rea d se quence using special QUANTA option 
2 
PHS 567 CB3 568 
gener ate 2H se tup 
QUANTA coordinates included in script file 
open read unit 10 card name bifl5-in_ts. crd 
read coor unit 10 card 
close unit 10 
cons fix sele (segid 2s or. segid 2h) and. not. (resid 424 : 428) end 
print coor sele (segid 2s or. segid 2h) and. not. (resid 424 : 428) end 
Energy script for CHARMm 
Energy script for CHARMm 
FAST 
SHAKE OFF 
SKIPE NONE 
MINI SD - 
NSTE 25 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 - 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
MINI ABNR - 
NSTE 500 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
MINI ABNR - 
NSTE 500 NPRI 5 TOLG 0.000000 STEP 0.020000 TOLS 0.000000 TOLENR 0.001000 
INBFRQ 10 CUTNB 12.000000 CTONNB 9.000000 CTOFNB 11.000000 - 
VSWITCH SHIFT RDIE EPS 1.000000 - 
IHBFRQ 0- 
IMGFRQ 10 CUTIM 12.000000 
open write unit 10 card name bifl5_final-min. crd 
write coor unit 10 card 
close unit 10 
